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Abstract 
 
 
Cellular senescence is an end point of a signal transduction programme leading 
to irreversible cell cycle arrest accompanied by characteristic alterations to cell 
morphology, biochemical properties and gene expression profile. This phenotype 
can be triggered by a variety of stimuli including telomere shortening, DNA 
damage or activated oncogenes. Senescence is now recognised as a tumour 
suppressor mechanism mediated by p53 and pRB pathways which act to prevent 
the proliferation of cells that are at risk of tumourigenic transformation. 
RUNX1 is a transcription factor essential for definitive hematopoiesis and is 
frequently targeted in human leukaemias by chromosomal rearrangements. 
RUNX1 has been also demonstrated to act as a dominant oncogene in mice and 
the ectopic expression of RUNX1 in murine embryonic fibroblasts has been shown 
to cause senescence. 
The central aim of this study was to investigate the mechanism of senescence 
induction by RUNX1 and its fusion derived leukaemogenic oncoproteins in 
primary fibroblasts.   
My work showed that RUNX1 induces a strong senescence-like response in murine 
and human primary fibroblasts that requires intact DNA binding, CBFβ 
interaction and C-terminal transcriptional activation/repression domains.  
However, surprising differences were found between the major RUNX1 fusion 
oncoprotein derivatives.  The N-terminal fusion protein TEL-RUNX1 fails to 
induce senescence despite retention of a virtually full-length RUNX1 moiety, 
while the senescence-inducing potential is exaggerated in the truncated C-
terminal fusion protein RUNX1-ETO (AML1-ETO). The potential to drive 
senescence is retained by the deletion mutant RUNX1-ETO∆469 which lacks  
critical corepressor binding sites suggesting that the repression of target genes 
may be a primary mechanism implicated in RUNX1-ETO induced senescence.  
Interestingly, CBFβ-MYH11 fusion oncoprotein that affects RUNX1 indirectly by 
targeting CBFβ can also induce senescence when ectopically expressed in human 
primary cells. The RUNX1 and RUNX1-ETO induced senescent phenotypes differ 
from archetypal H-RasV12 as arrest occurs without a preliminary phase of 
proliferation and the arrested cells lack prominent foci of DNA strand breaks and 
chromatin condensation.  Notably however, RUNX1 and RUNX1-ETO display 
xiv 
differences in their potency and the extent of engagement of p53 and Rb 
effector pathways.  RUNX1-ETO is highly dependent on p53 function and unlike 
RUNX1 drives senescence in cells lacking intact p16Ink4a.  RUNX1-ETO appears to 
exert its unique effects through potent induction of reactive oxygen species and 
p38MAPK phosphorylation.  These findings illustrate the heterogeneous 
manifestations of senescence-like growth arrest and elucidate the distinctive 
biology and oncogenic properties of RUNX1 and its fusion derivatives.
15 
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1 Introduction 
1.1 Characteristics of RUNX transcription factors 
The RUNX (Runt-related transcription factor) genes encode the DNA-binding α-
chain partners of the CBF (core binding factor) complexes that play crucial 
lineage-specific roles in cell proliferation and differentiation. The Runx proteins 
form heterodimers with a non-DNA-binding partner, CBFβ that is encoded by a 
single gene in mammals and lacks intrinsic DNA binding activity but profoundly 
enhances the affinity of its α-chain partner for DNA and confers stability on the 
complex(Blyth et al 2005; Ito 2004; Ogawa et al 1993a; Ogawa et al 1993b; Wang 
et al 1993). 
The Drosophila regulatory gene runt, which functions in establishing 
segmentation patterns during embryogenesis as well as in sex determination and 
neurogenesis, was the first member of RUNX family to be identified twenty years 
ago (Duffy et al 1991; Duffy and Gergen 1991; Gergen and Butler 1988). Other 
invertebrate species with well-characterized RUNX transcription factors include 
the nematode Caenorhabditis elegans and the sea urchin Strongylocentrotus 
purpuratus (Nam et al 2002; Robertson et al 2002). Some lower organisms have 
only a single RUNX gene but in vertebrates multiplication of RUNX genes through 
gene duplication has occurred (Rennert et al 2003). Three highly conserved 
human and mouse RUNX genes: RUNX1, RUNX2 and RUNX3 were identified and 
localized on human chromosomes 21, 6 and 1 and on mouse chromosomes 16, 17 
and 4, respectively (Avraham et al 1995; Bae et al 1994; Calabi et al 1995; 
Levanon et al 1994). The three mammalian RUNX genes share extensive 
homology, which is also found in paralogous genes, CLIC and DSCR, that are 
adjacent to RUNX loci (Eggers et al 2002; Levanon et al 2001; Levanon et al 
2003b) (Figure 1.1). All three mammalian RUNX genes are transcriptionally 
regulated by two independent promoter regions, P1 (distal) and P2 (proximal) 
that encode isoforms with distinct amino-terminal sequences (Levanon and 
Groner 2004) (Figure 1.1).  
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Figure 1.1 Genomic organization of the human RUNX genes 
The two promoters P1 and P2 and initiator ATGs are indicated. 5’UTR are in 
yellow and orange and 3’UTR are in blue. Common exons are shown in similar 
colour and conserved neighbouring genes (CLIC and DSCR) are depicted 
The most highly conserved feature of the RUNX proteins is the 128-amino-acid 
Runt domain that functions in DNA binding, protein-protein interactions, ATP 
binding and which also contributes to nuclear localisation (Crute et al 1996; 
Kagoshima et al 1993; Kanno et al 1998a). The runt domain lies in the N-terminal 
half of the protein. Structural analysis has revealed that this domain forms an S-
type immunoglobulin fold which has also been identified in the 3-dimensional 
structure of the DNA binding domains of transcription factors such as p53, NF-κB, 
NFAT, STAT, and the T-box proteins (Figure 1.2) (Berardi et al 1999; Nagata et al 
1999). Outside the runt domain there is less sequence similarity between family 
members, although the similarity in amino acid composition is evident. The 
carboxy-terminal regions of RUNX proteins tend to be rich in proline, serine and 
threonine (PST) and regions of homology can be noticed in the functionally 
defined transactivation/inhibitory domains, nuclear-matrix-attachment signal 
and in the C-terminal VWRPY motif that functions as a recruitment motif for the 
Groucho/TLE family of corepressors (Aronson et al 1997; Levanon et al 1994; 
Zeng et al 1997). The RUNX proteins bind directly to target genes and activate or 
repress transcription depending on the context (Otto et al 2003; Speck and 
RUNX1 
RUNX2 
RUNX3 
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Gilliland 2002). The DNA-binding affinity of RUNX alpha chains is increased 
substantially via co-interaction with the non-DNA-binding β-chain cofactor which 
binds to the runt domain (Ogawa et al 1993a; Ogawa et al 1993b; Wang et al 
1993) and could be also potentially regulated by other cofactors and by 
chromatin structure.  
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Structure of the RUNX1 Runt domain-CBFβ-DNA complex 
DNA is shown in red and yellow. CBFβ is shown in magenta and the RUNX1 Runt 
domain in cyan. Runt domain loops in the major groove are coloured blue (C-
terminal loop) and red (βA’-B loop), whereas the loop contacting the minor 
groove is shown in green (βE’-F loop) (Zhang et al 2003c) 
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The RUNX proteins are key regulators of major developmental pathways and 
their expression is tightly regulated, leading to highly specific spatio-temporal 
expression patterns which when disrupted lead to various defects. RUNX1 is 
required for definitive haematopoiesis and is frequently mutated in human 
leukaemia (Speck and Gilliland 2002). RUNX2 is essential for osteogenesis and its 
haploinsufficiency is associated with cleidocranial dysplasia in humans (Komori 
et al 1997; Otto et al 2002). More recently, RUNX3 was shown to control some 
aspects of neurogenesis and thymopoiesis as well as play a role in the control of 
cell proliferation and apoptosis in the gastric epithelium (Inoue et al 2003; 
Levanon et al 2002; Levanon et al 2003a; Taniuchi et al 2002; Woolf et al 2003). 
RUNX3 is also frequently methylated in human gastric cancers (Li et al 2002). A 
growing body of evidence implicates RUNX genes as tumour suppressors in some 
cancers, where inactivating mutations, gene deletions or hypermethylation 
occur. On the other hand transcriptional activation of all three RUNX genes by 
retroviral insertional mutagenesis in lymphoma-prone CD2-MYC transgenic mice 
has revealed their dominant oncogenic potential. A common result of these 
insertions was found to be the overexpression of structurally intact RUNX gene 
products (Blyth et al 2001; Stewart et al 1996; Stewart et al 1997; Stewart et al 
2002; Wotton et al 2002).  
1.2 Nomenclature of RUNX proteins 
To avoid unnecessary confusion, an ad-hoc nomenclature committee on Runt-
domain proteins, has proposed the unified terms RUNX1, RUNX2, RUNX3 (the 
homologous genes in mouse are Runx1, Runx2, Runx3, respectively) that refer to 
transcriptional factors which had previously been described by multiple terms 
(van Wijnen et al 2004). RUNX1 has previously been designated by different 
names: AML1 (acute myeloid leukemia 1), PEBP2αB (polyoma virus enhancer-
binding protein 2αB) and CBFA2 (core-binding factor α2). RUNX2 could be found 
under names such as: AML3, PEBP2αA, CBFA1. Finally RUNX3 was known in the 
literature as: AML2, PEBP2αC, CBFA3. 
Kamil K. Wolyniec, 2008   Chapter 1,20  
1.3 Transcriptional regulation by RUNX1 
There are three major isoforms of the RUNX1 protein that are produced by 
alternative splicing: AML1c (RUNX1-P1), AML1b (RUNX1-P2) and AML1a that have 
been reported so far (Meyers et al 1993; Miyoshi et al 1991; Miyoshi et al 1995) 
(Figure 1.3). AML1b (453 amino acid) and AML1c (480 amino acid) contain the 
runt homology domain as well as a proline-, serine- and threonine-rich (PST) 
region which is a putative transcriptional activation domain (Bae et al 1994). The 
difference in length between AML1b and AML1c arises from the use of two 
different promoters: AML1b is transcribed from proximal-P2 (MRIPV) promoter 
whereas AML1c is transcribed from distal-P1 (MASDS) promoter. The shorter 250 
amino acid AML1a protein lacks the C-terminus including transactivation domain 
(PST region) but has a unique nine amino acids at its C-terminal end due to 
alternative splicing and can act as a competitive inhibitor of RUNX1 (Miyoshi et 
al 1991; Niitsu et al 1997; Tanaka et al 1995). For example it was reported that 
overexpression of AML1a blocks differentiation and promotes proliferation of 
murine myeloid cell line, whereas RUNX1 has the opposite effect of promoting 
differentiation and arresting proliferation (Tanaka et al 1995). RUNX1 binds to 
consensus sequence (PyGPyGGT, where Py is a pyrimidine) termed PEBP1 site, 
that was originally identified in polyomaviral and retroviral core enhancer 
elements (Kamachi et al 1990; Wang and Speck 1992).  
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Figure 1.3 Structure of AML1a, AML1b and AML1c 
RHD is the Runt homology domain, VWRPY indicates the C-terminal Groucho 
binding motif of RUNX1 family members, P1 –distal promoter, P2 –proximal 
promoter 
1.3.1 Transcriptional activation 
Most of the genes that have been shown to be activated by RUNX1 are involved 
in haematopoiesis i.e. T-cell and B-cell antigen receptor subunits (Erman et al 
1998; Prosser et al 1992; Redondo et al 1992; Wang et al 1993), interleukin 3 
(Uchida et al 1997), granulocyte-macrophage colony-stimulating factor (Hohaus 
et al 1995; Takahashi et al 1995), neutrophil elastase (Nuchprayoon et al 1994), 
myeloperoxidase (Britos-Bray and Friedman 1997; Nuchprayoon et al 1994) and 
granzyme B (Wargnier et al 1995). Because RUNX1 binding sites are necessary 
but not sufficient for transcriptional activation, this has led to the hypothesis 
that RUNX1 is an orchestrator of assembly of transcriptional activation 
complexes (Figure 1.4). The mechanism proposed for activation by the 
RUNX1/CBFβ complex is that it recruits coactivators such as p300/CBP 
(p300/CREB-binding protein), yes-associated protein (YAP) and ALY (Bruhn et al 
1997; Kitabayashi et al 1998; Yagi et al 1999). These coactivators do not bind 
DNA directly, but stimulate transcription by acetylating histones and/or 
recruiting the RNA polymerase II transcription-initiating complex. However, the 
RUNX1/CBFβ complex is regarded as a relatively inefficient transcriptional 
activator and requires synergistic cooperation with other transcription factors. In 
this regard RUNX1 binding sites are frequently adjacent to binding sites of of 
Myb, Ets, AP-1 and C/EBP factors and RUNX1 cooperates with these transcription 
factors to activate transcription (Frank et al 1995; Hernandez-Munain and 
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RUNX1-CBFβ 
p300 
C/EBP 
ETS 
MYB 
ALY 
DNA 
Krangel 1994; Mao et al 1999; Petrovick et al 1998; Sun et al 1995; Zhang et al 
1996).  
 
 
 
 
 
 
 
 
Figure 1.4 RUNX1 as an organizer of trancriptional activation 
RUNX1-CBFβ complex binds to the consensus sequence and interacts with 
coactivators (p300, C/EBP, ETS, MYB, ALY, AP-1) to initiate transcriptional 
activation  
1.3.2 Transcriptional repression 
Paradoxically, RUNX1 can also be a context-dependent transcriptional repressor, 
although this function of RUNX1 remains largely enigmatic. The CD4 gene is 
probably the best characterised example of RUNX1 mediated transcriptional 
repression that occurs during T lymphocyte development. RUNX1 binds the 
silencer and represses CD4 transcription in immature thymocytes (Taniuchi et al 
2002). The other mechanism has been recently proposed whereby RUNX1 binds 
positive transcription elongation factor b (P-TEFb) and represses transcriptional 
elongation by RNA polymerase II (Jiang et al 2005). Another example is the 
transcriptional repression of p21WAF1 promoter in NIH3T3 and HEL cells (human 
erythroleukaemic cell line) (Lutterbach et al 2000). Interestingly, RUNX1 
mediated repression of p21WAF1 in these cells was independent of the Groucho 
interaction motif but required two C-terminal domains of RUNX1 (amino acids 
208-237 and amino acids 290-387). One of these domains (amino acids 208-237) 
is adjacent to the runt domain and is required for interaction with the mSin3A 
and mSin3B corepressor proteins. However, the association with mSin3 was 
shown to be necessary but not sufficient for potent repression, since the other 
mutant (amino acids 290-387) that is still able to bind mSin3, was not found to 
be an efficient repressor (Lutterbach et al 2000). It is plausible that there could 
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be several different mechanisms of gene repression by RUNX1. In general, it has 
been proposed that the repressive property of RUNX1 is attributed to the 
recruitment of transcriptional corepressors such as histone deacetylases 
(HDACs), transducing-like enhancer of split (TLE), nuclear receptor corepressor 
(nCoR), mSin3 and SUV39H1 (Figure 1.5) (Aronson et al 1997; Chakraborty et al 
2003; Durst and Hiebert 2004; Lutterbach et al 2000; Reed-Inderbitzin et al 
2006).  
 
 
  
 
 
 
 
 
Figure 1.5 RUNX1 as an organizer of transcriptional repression 
RUNX1-CBFβ complex binds to the consensus sequence and interacts with 
corepressors (HDACs, nCoR, mSin3, SUV39H1, TLE) to initiate transcriptional 
repression  
 
If RUNX1 is capable of both transcription repression and activation it is of 
particular interest to understand the mechanism that converts RUNX1 from an 
activator to a repressor of transcription. Although an extensive survey in various 
cell types has not as yet been reported there is some evidence that repression 
by RUNX1 could be cell type and tissue specific. It has been shown that although 
RUNX1 represses p21WAF1 in NIH3T3 cells and HEL human erythroleukaemia cells 
it actually activates its promoter in K562 human myeloid cell line (Lutterbach et 
al 2000). It seems that the factors determining the outcome of transcription 
(repression or transactivation) of a target gene involve promoter-specific 
features such as the proximity of binding sites for co-activators or co-repressors 
as well as availability of such cofactors in the nucleus. In addition, 
postranslational modifications such as phosphorylation (Tanaka et al 1996) or 
acetylation (Yamaguchi et al 2004) may contribute to the regulation of RUNX1 
activity. The proposed model hypothesizes that binding of RUNX1 to activating 
factors such as p300 promotes expression whereas loss of p300 interaction and 
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subsequent binding to mSin3 proteins or Groucho family members leads to 
repression. 
1.4 Role of RUNX1 in haematopoiesis 
1.4.1 Foetal haematopoiesis 
It was suggested that RUNX1 may be a master regulator of haematopoiesis when 
it became clear that there is a large number of chromosomal translocations 
targeting RUNX1 that are associated with leukaemias (Blyth et al 2005). 
However, the evidence supporting the crucial role of RUNX1 in developmental 
haematopoiesis came from the analysis of the phenotype of RUNX1 null mice. 
These animals are chararacterized by normal morphogenesis and yolk-sac 
derived primitive erythropoesis, however they lack definitive haematopoietic 
progenitors in the yolk sac and foetal liver (Okuda et al 1996; Wang et al 1996a). 
Foetal liver cells from RUNX1 null embryo are unable to differentiate into any of 
haematopoietic lineages although this is not due to a defect in the foetal liver 
microenvironment (Okuda et al 1996; Wang et al 1996a). RUNX1 is also essential 
for the generation of functional haematopoietic stem cells (HSCs) and immature 
progenitors (Cai et al 2000). RUNX1 deficient mice die due to haemorrhaging 
(Okuda et al 1996; Wang et al 1996a). The dosage of RUNX1 during foetal 
haematopoiesis is critical. RUNX1 heterozygous embryos show earlier appearance 
of HSCs in the yolk sac on embryonic day 10 and a premature extinction of HSC 
in the aorta-gonad-mesonephros (AGM) (Cai et al 2000) while RUNX1+/- animals 
have reduced numbers of myeloid and erythroid progenitors (Wang et al 1996a). 
Interestingly RUNX1-/- and CBFβ-/- embryos have significantly overlapping 
phenotypes implying that the physiological effects of these two proteins are 
executed by RUNX1/CBFβ complexes, however other independent roles cannot 
be ruled out (Niki et al 1997; Sasaki et al 1996; Wang et al 1996b). 
1.4.2 Adult haematopoiesis 
The role of RUNX1 in adult haematopoiesis has been assessed in inducible gene 
targeting systems (conditional KO model, by f=floxed/Cre method) in the 
progeny of RUNX1f/- mice crossed to Mx-Cre transgenic mice (Ichikawa et al 
2004). Examination of bone marrow in adult animals revealed that  
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haematopoietic progenitors remained intact in contrast with dramatic effects in 
the fetus. Moreover, RUNX1 deletion provides a proliferative adavantage to 
haematopoietic progenitors, as evidenced by an increased Lin-c-Kit+Sca1+CD34- 
population in bone marrow and increased colony formation in vitro (Ichikawa et 
al 2004). However, RUNX1 has been implicated in adult megakaryocytic 
maturation and T-lymphocyte and B-lymphocyte differentiation. An analogous 
approach involving thymocyte-specific deletion of the RUNX1 gene has been 
undertaken to investigate the effects of RUNX1 in T-cell development. The 
progeny of RUNX1fl/fl mice crossed with Lck-Cre showed incomplete suppression 
of CD4 molecule in CD4-CD8- double negative (DN) thymocytes, and incomplete 
up-regulation of CD8 molecule in CD4+CD8+ double positive (DP) thymocytes 
(Taniuchi et al 2002). This represents a further case whereby RUNX1 is engaged 
in both gene activation (CD8) and gene repression (CD4). It was also shown in  
other studies that a hemizygous level of RUNX1 allows inefficient transition from 
DP thymocytes to more mature CD4+CD8- or CD4-CD8+ single-positive thymocytes 
(SP) (Hayashi et al 2000). Conversely, in RUNX1 over-expressing mice, an 
increase in the population of CD4-CD8+ thymocytes was observed (Hayashi et al 
2001). 
1.5 RUNX1 and leukaemia 
1.5.1 Loss-of-function 
The first implication that RUNX1 loss of function may play important role in 
leukaemogenesis was provided by the discovery that RUNX1 is involved in two 
common chromosomal translocations t(8;21) in acute myeloid leukaemia (AML) 
(Erickson et al 1992; Miyoshi et al 1991; Nisson et al 1992) and t(12;21) in 
pediatric B-cell precursor acute lymphoblastic leukaemia (B-ALL) (Golub et al 
1995; Romana et al 1995). RUNX1 chimeric proteins arising from translocations 
have been reported to have dominant negative activity with respect to the wild-
type gene product. Both RUNX1-ETO and TEL-RUNX1 have been demonstrated to 
recruit corepressors and actively repress transcription of RUNX1 target genes 
(Frank et al 1995; Gelmetti et al 1998; Hiebert et al 1996; Meyers et al 1995; 
Uchida et al 1999). Further evidence for antagonistic function of the fusion 
proteins was provided by the phenotype of RUNX1-ETO knock-in mice which 
Kamil K. Wolyniec, 2008   Chapter 1,26  
resembled RUNX1-knockouts (Okuda et al 1998; Yergeau et al 1997). Finally, in a 
retrospective study, sporadic point muations of RUNX1 were frequently found in 
myeloblastic leukaemia patients (Osato et al 1999) and subsequent studies found 
a high incidence of point mutations in the Runt domain of RUNX1 in three types 
of leukaemia: AML M0 subtype, MDS-AML, and secondary therapy related 
MDS/AML. Interestingly AML M0 mutations were predominantly biallelic 
suggesting selection for loss of function (Osato 2004; Preudhomme et al 2000). 
Moreover, monoallelic mutations underlie the hereditary condition familial 
platelet disorder (FPD), which predisposes to AML (Osato 2004; Song et al 1999). 
Despite the fact that loss of a second allele has not been observed in AML 
derived from FPD families so far, transdominant inhibition of the normal product 
could be considered as an alternative explanation. These observations highlight 
at least to some extent the concept of RUNX1 as a tumour suppressor where 
lower RUNX1 activity appears to correlate with a higher risk of developing 
leukaemia. Therefore, loss-of-function of RUNX1 is considered to be a common 
underlying mechanism for RUNX1-related leukaemias. However, a growing body 
of evidence suggests that RUNX1 alteration per se does not readily drive 
leukaemia and that additional genetic changes, ‘second hits’ are required for 
full-blown malignancy. Activation of the RAS pathway is one of the most 
common cooperating lesions in RUNX1 associated leukaemias. The RAS gene 
family and its upstream receptor tyrosine kinases such as c-Kit and FLT3 are 
frequently mutated in these types of leukaemias (Christiansen et al 2005; 
Goemans et al 2005; Speck and Gilliland 2002; Yamashita et al 2005). 
Interestingly, it has been recently shown that RUNX1 insufficiency in 
hematopoetic stem cells suppresses oncogenic N-RAS-induced effects such as 
apoptosis, senescence and differentiation (Motoda et al 2007). Therefore it 
seems that in this context RUNX1 is a part of a fail-safe mechanism that 
constrains neoplastic transformation. 
1.5.2 Gain-of-function 
On the other hand, strong evidence supporting the notion that RUNX1 act as a 
dominant oncogene came from in vivo mouse model insertional mutagenesis 
studies. RUNX1 together with other members of the family was identified as a 
common integration side in Mo-MuLV accelerated tumours in the CD2-MYC 
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transgenic model of lymphoma susceptible mice. This viral integration resulted 
in overexpression of intact RUNX genes (Blyth et al 2001; Stewart et al 1996; 
Stewart et al 1997; Stewart et al 2002; Wotton et al 2002). In addition, more 
than a decade ago it was reported that ectopic expression of RUNX1 P2 in 3T3 
fibroblasts promotes transformation (Kurokawa et al 1996). Surprisingly, similar 
subsequent studies where RUNX1 P1 was used instead did not confirm this 
observation (Frank et al 1999). Recently, however, it has been shown in our 
laboratory that in p53 null MEFs, RUNX1 P1 has apparent pro-oncogenic effect on 
cells, including cytoskeletal reorganisation, reduced contact inhibition at 
confluence and accelerated tumour expansion in vivo (Wotton et al 2004). 
Moreover, the RUNX1 locus is also involved in genetic amplification in a number 
of cases in B-ALL and there are some speculations that increased dosage of 
RUNX1 in Down’s syndrome patients predisposes them to acute megakaryocytic 
leukaemia (AMKL) (Osato and Ito 2005; Speck and Gilliland 2002). 
1.6 Chromosomal translocations that involve CBF 
CBFs are common target of gene rearrangements that are linked to human 
leukaemias. More than 30 different chromosomal translocations have been 
described that involve either RUNX1 or CBFβ. Of these the most common are 
t(8;21), inv(16) and t(12; 21). These translocations generate chimeric fusion 
oncoproteins that share common repressive functions with respect to wild type 
RUNX1 (Figure 1.6) (Blyth et al 2005). 
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Figure 1.6 Schematic representation of three major fusion oncoproteins 
arising from chromosomal rearrangements targeting CBF and RUNX1 
1.6.1 RUNX1-ETO in t(8; 21) 
The t(8;21) translocation was the first to be discovered and is the most frequent 
translocation found in AML, accounting for 10-20% cases (Miyoshi et al 1991). The 
RUNX1-ETO chimeric protein (752 amino acids) is produced by the fusion of the 
N-terminal portion of the RUNX1 protein, including the Runt domain, with the 
heterologous partner protein, ETO (also known as MTG8 or CBFA2T1) that lacks 
the first 30 amino acid residues. ETO is an ubiquitously expressed nuclear 
protein engaged in transcriptional repression through interaction with 
corepressors such as the N-CoR complex, mSin3A and HDACs (Lutterbach et al 
1998). Two molecular characteristics of the RUNX1-ETO fusion protein provide 
clues to its leukaemogenic potential. First, RUNX1-ETO retains the DNA binding 
Runt domain and heterodimerises with CBFβ and therefore binds to specific DNA 
sequences with high affinity. In fact, heterodimerisation with CBFβ is more 
stable with RUNX1-ETO than with wild-type RUNX1 (Tanaka et al 1998). Second, 
the adjacent ETO partner efficiently recruits multiple transcriptional repressor 
complexes (Gelmetti et al 1998). The resulting strong DNA-binding constitutive 
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repressor molecule can cause perturbations in gene expression which may trigger 
the transformation of haematopoietic cells. For instance, RUNX1-ETO represses 
such critical transcription factors as PU.1, C/EBPα, NF-1 (Burel et al 2001; 
Vangala et al 2003; Westendorf et al 1998; Yang et al 2005). Interestingly, in 
some cases RUNX1-ETO has been reported to enhance the expression of genes 
such as C/EBPε, c-Jun or anti-apoptotic Bcl-2 (Elsasser et al 2003; Klampfer et al 
1996; Shimizu et al 2000). The ability of RUNX1-ETO to affect normal RUNX1 
function was first shown in transient transfection assays, which demonstrated 
that RUNX1-ETO can function as a dominant negative regulator of RUNX1 
mediated transcriptional activation (Frank et al 1995; Meyers et al 1995). 
Consistent with a negative effect on RUNX1 function, RUNX1-ETO has been 
shown to block the differentiation of myeloid progenitor cell lines and the ability 
of RUNX1 to activate myeloid specific promoters (Kitabayashi et al 1998; 
Westendorf et al 1998). Evidence for in vivo dominant negative activity of the 
fusion protein was provided by RUNX1-ETO knock-in experiments, which showed 
that mice heterozygous for RUNX1-ETO had a similar phenotype as RUNX1 knock-
out mice (Okuda et al 1998; Yergeau et al 1997). Further attempts to express 
the fusion gene in adult mice using a tetracycline-inducible system, a 
conditional RUNX1-ETO knock in system, or a myeloid-specific promoter, all 
failed to induce spontaneous leukaemia (Higuchi et al 2002; Rhoades et al 2000; 
Yuan et al 2001), although RUNX1-ETO expression consistently enhanced the 
proliferation of HSCs and increased progenitor cell self-renewal capacity. In 
another study where stem cells were transduced with RUNX1-ETO and 
transplanted into lethally irradiated recipient animals, the stem cell 
compartment expanded dramatically (de Guzman et al 2002). Similarly direct 
targeting of RUNX1-ETO expression to stem cells by using the SCA-1 promoter 
enhanced myeloid progenitor expansion (Fenske et al 2004). These experiments 
suggest that AML-ETO can promote the expansion of a susceptible compartment 
that ultimately would acquire additional ‘hits’ leading to disease. Therefore it 
has become obvious that the RUNX1-ETO fusion protein does not cause 
leukaemia alone and requires additional cooperating events to induce 
leukaemogenesis in mice. RUNX1-ETO was analysed in the context of cooperating 
mutations in animals expressing RUNX1-ETO which were mutagenised with the 
alkylating agent N-ethyl-N-nitrosourea (ENU). In two independent systems, these 
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mice developed myeloid leukaemia at frequencies greater than ENU-treated WT 
mice (Yuan et al 2001; Higuchi et al 2002). In addition, retroviral transduction 
and haematopoietic cell transplantation experiments with p21WAF1-deficient cells 
showed that RUNX1-ETO is able to promote leukaemogenesis in the absence of 
p21WAF1 (Peterson et al 2007). Moreover, retroviral expression of a truncated 
form of RUNX1-ETO with a deleted C-terminal NcoR/SMRT-interacting region in 
bone marrow cells resulted in rapid onset of leukaemia in transplant recipient 
mice (Yan et al 2004) RUNX1-ETO was also shown to transform NIH3T3 cells 
through activation of AP-1 (Frank et al 1999). Paradoxically, RUNX1-ETO has an 
inhibitory effect on cell proliferation (Burel et al 2001) and overexpression of 
RUNX1-ETO reduces expression of target genes, including cyclin D3 and CDK4 
(Bernardin-Fried et al 2004; Burel et al 2001; Lou et al 2000). The cellular 
consequence is impairment in the transition from G1 to S phase and slower 
proliferation. Therefore, the requirement for cooperating lesions that interfere 
with this block is not surprising. 
1.6.2 TEL-RUNX1 in t(12; 21) 
TEL-RUNX1 is generated by the t(12; 21) chromosomal translocation, which 
occurs in approximately 25% of cases of childhood common B-cell precursor 
acute lymphoblastic leukaemia (Golub et al 1995). In the TEL-RUNX1 fusion 
protein (794 amino acids), the N-terminus of TEL (336 residues) is fused to 
nearly all of the RUNX1 protein, including the Runt domain and the entire C-
terminal portion. TEL (also ETV6) is a member of Ets family of transcription 
factors that have the Ets DNA binding domain at the C-terminus and a protein-
binding helix-loop-helix (HLH) domain at the N-terminus. The Runt domain of 
TEL-RUNX1 can form a heterodimer with CBFβ and specifically bind to target 
sequences but despite having the entire C-terminal region of RUNX1, this fusion 
protein generally represses the reporter activities and antagonises RUNX1-driven 
transactivation (Fears et al 1997; Hiebert et al 1996; Meyers et al 1993). This 
repressor property is attributed to the recruitment of HDACs and N-CoR by the 
TEL moiety and the recruitment of mSin3a by both TEL and RUNX1 (Fenrick et al 
1999; Guidez et al 2000). The RUNX1 moiety is capable of recruiting 
transcriptional coactivators as well as repressors, however the generation of the 
fusion protein seems to increase the overall affinity towards corepressors and 
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subsequent constitutive repressor complex stability (Guidez et al 2000). TEL-
RUNX1 may also suppress not only the normal function of RUNX1 but also TEL 
through HLH-mediated heterodimerisation (Gunji et al 2004). Wild-type TEL 
function is known to be essential for establishing haematopoiesis in the bone 
marrow (Wang et al 1998), therefore its disruption by the chimeric protein may 
also contribute to leukaemogenesis. The role of TEL-RUNX1 in inducing 
leukaemia has been assessed in mice. TEL-RUNX1 expressed under the control of 
immunoglobulin heavy chain enhancer/promoter did not cause leukaemia in 
mice (Andreasson et al 2001). However, retroviral delivery of TEL-RUNX1 into 
bone marrow strongly collaborated with deficiency in p16INK4a as well as p19ARF in 
promoting leukaemogenic transformation (Bernardin et al 2002b). A detailed 
analysis using similar experimental system showed that TEL-RUNX1 inhibits B-cell 
differentiation, leading to an accumulation of early B-cell progenitors and a 
corresponding deficit of mature B-cells (Morrow et al 2004; Tsuzuki et al 2004). 
1.6.3 CBFβ-MYH11 in Inv(16) 
The Inv(16) does not involve the RUNX1 locus directly but instead creates the 
CBFβ-MYH11 (smooth muscle myosin heavy chain) fusion protein that also 
inhibits RUNX1-dependent transactivation (Kanno et al 1998b; Lutterbach et al 
1999). Inv(16) is a common chromosomal inversion event in myelomonocytic 
leukaemias (M4Eo). A model that has been proposed as an explanation of the 
mechanism of repression assumes that CBFβ-MYH11 binds to its RUNX1 α-chain 
partner with increased affinity, and might directly suppress or sequester RUNX1 
in the cytoplasm (Adya et al 1998; Kanno et al 1998b; Lutterbach et al 1999). 
Thus CBFβ-MYH11 would be predicted to interfere with RUNX1 transcriptional 
activity. However, CBFβ-MYH11 cooperated with RUNX1 to repress the p21WAF1 
promoter, suggesting that it is present and functional in the nucleus. A 
repression domain in the MYH11 fragment of fusion was identified and CBFβ-
MYH11 was found to interact with mSin3, but only when RUNX1 was coexpressed, 
indicating that RUNX1 is bridging the interaction between CBFβ-MYH11 and 
mSin3 protein (Lutterbach et al 1999). Furthermore, a strong argument for 
dominant-negative function of CBFβ-MYH11 was obtained from the analysis of 
the phenotype of Inv(16) knock-in mice, which recapitulates RUNX1 and CBFβ 
homozygous knock-out phenotypes (Castilla et al 1996). The development of an 
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Inv(16) animal model in which to test the mechanism of pro-leukaemogenic 
action of CBFβ-MYH11 has been extremely difficult. Previous murine models of 
the Inv(16) have involved the expression of CBFβ-MYH11 coupled with ENU (N-
ethyl N-nitrosourea) mutagenesis, retroviral insertional mutagenesis (Castilla et 
al 1999; Castilla et al 2004), the removal of two tumour suppressors (Yang et al 
2002) or the coexpression of oncogenes (Bernardin et al 2002a; Kogan et al 
1998). However, only the use of chimeric mice carrying a knock in Inv(16) allele 
plus random mutagenesis yielded an AML that mimicked the human disease 
(Castilla et al 1999, Castilla et al 2004). In a recent study it has been reported 
that Inv(16) cooperates with p19ARF haploinsufficiency to induce AML (Moreno-
Miralles et al 2005). 
1.7 Cellular senescence and its impact on aging and 
cancer 
At one time it was believed that cells could proliferate indefinitely and 
that the maintenance of a cell culture was just a question of finding the right 
conditions. This idea was radically changed more than 40 years ago by the 
outstanding work of Hayflick (Hayflick 1965) which demonstrated that for most 
normal cells proliferation has an end, despite optimal culturing conditions. When 
mammalian cells are isolated from tissue and cultured, they undergo a limited 
number of population doublings and then arrest (having reached the ‘Hayflick 
limit’). The process underlying this observation is known as replicative 
senescence. The discovery of senescence led to two important hypotheses that 
were proposed to explain its physiological relevance. The first was related to the 
fact that cancer cells are immortalised and therefore proliferate indefinitely in 
culture. Hence, cellular senescence was suggested to be a tumour suppressive 
mechanism. The second hypothesis originated from the fact that tissue 
regenerative capacity diminishes with age. In this context, cellular senescence 
was proposed to mimic aging at a single cell level (Campisi 2005). Four decades 
of subsequent intensive research have unravelled the primary mechanisms by 
which cellular senescence occurs and have shed light on central aspects of 
organismal aging and cancer (Campisi 2005). Furthermore, it is now evident that 
cellular senescence, like apoptosis, is an important biological stress response 
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programme that can be triggered by various stimuli. Finally, it is clear that there 
are marked differences among species in the propensity of cells to spontaneously 
escape senescence and acquire an immortal replicative lifespan. In this regard 
rodent cells are much more prone to spontaneous immortalization than human 
cells (Itahana et al 2004; Sherr and DePinho 2000). 
 
1.8 The signals initiating cellular senescence 
Senescence-inducing signals can originate from telomeric (intrinsic) or non-
telomeric (extrinsic) sources (Figure 1.7) (Itahana et al 2004). Senescence 
mediated by non-telomeric signals is termed “premature senescence”, 
“accelerated senescence” or “extrinsic senescence”. Another term: stress- or 
aberrant signalling senescence (STASIS) has been suggested to convey the notion 
that cells engage a common senescence-like arrest mechanism in response to 
diverse stimuli (Drayton and Peters 2002). Both telomere-based and non-
telomere-based growth arrest may be due in part to repression of genes required 
for cell cycle progression and upregulation of growth inhibitory genes. The 
existence of non-telomere-induced senescence was anticipated by the behaviour 
of primary murine cells in culture. Normal mouse cells, like normal human cells, 
have a finite replicative potential. However, their replicative lifespan is 
substantially shorter than that of human cells (10-15 population doublings 
compared to 50-70) despite murine fibroblasts having very long telomeres (~60kb 
versus ~12kb) and in some cases expressing telomerase (Itahana et al 2004; Sherr 
and DePinho 2000). Thus, it is unlikely that the replicative senescence of 
primary mouse fibroblasts is due to telomere shortening. It has been proposed 
that the senescence phenomenon in  primary mouse cells is due to a stress 
response to culture conditions (Sherr and DePinho 2000) which can be abrogated 
by decreasing the oxygen concentration used in culturing these cells (Parrinello 
et al 2003). These observations have led to the hypothesis that rodent cells 
repair DNA damage much less efficiently than human cells and are thus much 
more sensitive to a variety of agents or conditions that produce oxidative stress 
(Parinello et al 2003). It is now apparent that a diverse spectrum of stress signals 
can elicit a senescence response. Of most importance are certain types of DNA 
damage, including DNA breaks and oxidative lesions (Chen et al 1995; Robles and 
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Adami 1998). It seems that cells may senesce when the damage is irreparable or 
is likely to impair the DNA repair machinery. Interestingly, many normal cells 
undergo senescence when they overexpress certain oncoproteins. The activated 
components of RAS-RAF-MEK signalling cascade (Lin et al 1998; Serrano et al 
1997; Zhu et al 1998) were the first oncogenic inducers of premature senescence 
to be identified. A common feature of these non-telomeric inducers of cellular 
senescence is their potential to cause or facilitate tumourigenic transformation. 
It is not surprising, then, that overexpression of certain tumour suppressor genes 
also causes normal cells to undergo rapid premature senescence. Tumour 
suppressors that strongly induce this phenotype include p16INK4a cyclin-
dependent kinase inhibitor (CDKI), p21WAF1, p27 (McConnell et al 1998), p14ARF 
(Dimri et al 2000) and PML (Ferbeyre et al 2000). Moreover, cells can senesce in 
response to epigenetic changes to chromatin organisation, for example those 
caused by pharmacological agents or altered expression of proteins that modify 
DNA or histones (i.e. histone deacetylase inhibitors) (Neumeister et al 2002; 
Ogryzko et al 1996). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 Cellular senescence is triggered by wide spectrum of stimuli 
Telomere shortening as well as non-telomeric signals such as DNA damaging 
agents, oncogenic signalling, oxidative stress, overexpression of tumour 
suppressors, cytokines, HDAC and DNMT inhibitors, and undefined stress signals 
(‘culture shock’) induce senescence 
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1.8.1 Telomere attrition 
Telomere shortening is a universal mechanism that limits the proliferative 
potential of normal cells (lacking endogenous telomerase) following extensive 
cell divisions. The role of telomere exhaustion in the suppression of 
tumourigenesis in vivo by initiating cellular senescence has been demonstrated 
recently (Cosme-Blanco et al 2007; Feldser and Greider 2007). It is believed that 
telomere erosion beyond a certain limit triggers a DNA damage response, 
thereby activating a checkpoint, resulting in growth arrest. Recent investigations 
provide some evidence that signals induced by the telomere dysfunction appear 
to be similar to those induced by double strand DNA breaks and that inactivation 
of the checkpoint kinases (CHK) can reinstate S phase progression in senescent 
cells (Gire et al 2004; d'Adda di Fagagna et al 2003). Other studies suggested 
that telomere shortening-induced senescence is a DNA damage response 
mediated by the ATM/ATR-p53-p21 pathway (Herbig et al 2004). Cells that fail to 
senesce and continue to proliferate despite dysfunctional telomeres develop 
chromosomal aberrations, which can result in malignant transformation (Artandi 
and DePinho 2000). 
1.8.2 DNA damage 
If cellular senescence induced by attrition of telomeres is a DNA damage 
response, then the DNA damaging agents should also be able to provoke cellular 
senescence. In fact this seems to be the case since DNA damaging agents that 
influence the integrity of the genome can trigger senescence. The direct DNA 
damaging of DNA caused by sublethal doses of irradiation or by treatment with 
chemotherapeutic drugs (like etoposide or cyclophosphamide) can induce 
senescence. Interestingly, such agents induce senescence in normal cells as well 
as in some tumour cells, both in culture and in vivo (Di Leonardo et al 1994; 
Roninson 2003; Schmitt et al 2002; Shay and Roninson 2004; Te Poele et al 2002; 
Wahl and Carr 2001). Such damage can either cause cell death or reversible cell-
cycle arrest, depending on the type of agent or the dose administered, and the 
type of cell treated (Wahl and Carr 2001). Disruption of DNA repair genes such as 
Brca1, Xrcc4, DNA ligase IV and others in mice induces the premature 
senescence of MEFs cultured from these animals and symptoms of premature 
aging in the mice themselves (Frank et al 2000; Gao et al 2000; Ongusaha et al 
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2003). Many of these senescent phenotypes can be rescued by p53 inactivation 
indicating a pivotal role for p53 in DNA-damage induced senescence (Frank et al 
2000; Gao et al 2000; Ongusaha et al 2003). Moreover, cancer cells that retain 
intact p53 are much more susceptible to senescence in response to 
chemotherapy at least in cell culture and mouse models (Roberson et al 2005; 
Roninson 2003; Schmitt et al 2002; Shay and Roninson 2004; Te Poele et al 
2002). 
1.8.3 Oxidative stress 
Oxidative stress and the accumulation of intracellular reactive oxygen species 
(ROS) play crucial roles in the induction of senescence. Human fibroblasts 
undergo premature senescence when grown in high ambient oxygen conditions, 
but their proliferative lifespan can be substantially extended when cultured in 
low ambient oxygen (2-3%) which more closely resembles physiological oxygen 
levels (Chen et al 1995). The senescence of MEFs has also been linked oxidative 
stress in culture. When these cells are grown in 3% oxygen instead of 20%, 
senescence is greatly delayed or prevented altogether (Parrinello et al 2003). 
Moreover, MEFs that are propagated in 20% oxygen suffer from a high level of 
DNA damage that is much more apparent than in human cells grown in the same 
conditions (Busuttil et al 2003; Parrinello et al 2003). This indicates that human 
cells cope with the oxidative stress much more efficiently than murine cells 
either due to ability to neutralize ROS or to detect and repair DNA lesions. 
Increase of intracellular ROS levels through hydrogen peroxide treatment or 
through the inhibition of ROS scavenging enzymes (e.g. superoxide dismutase 
Sod1) causes premature senescence (Blander et al 2003; Chen et al 1998). 
Internal ROS can not only damage cellular components through the oxidation of 
DNA, proteins and lipids but can also act as second messengers in specific signal 
transduction pathways (Halliwell 2007). There is some evidence that oxidative 
stress-induced senescence, like telomere dysfunction operates through the p53-
p21-Rb axis. This idea is supported by the observation that a reduced ambient 
oxygen level reduces the proportion of pre-senescent p21-expressing cells 
without any effect on p16-expressing cells (Itahana et al 2003). However, other 
studies indicate that oxidative stress can induce p16, possibly through the action 
Kamil K. Wolyniec, 2008   Chapter 1,37  
of p38 MAPK, a member of the stress-activated protein kinase family (Iwasa et al 
2003). 
1.8.4 Oncogene activation 
Proto-oncogenes are genes that have the potential to transform cells when 
mutated or overexpressed usually in cooperation with other accompanying 
mutations. The expression of oncogenes in primary cells triggers defence 
responses that prevent their uncontrolled proliferation. Some oncogenes such as 
c-Myc or adenovirus E1A induce apoptosis whereas others such as activated Ras 
(H-RasV12) trigger a permanent arrest that is reminiscent of replicative 
senescence (de Stanchina et al 1998; Serrano et al 1997; Zindy et al 1998). 
Prototypical Ras-driven senescence has been extensively studied over the last 
decade in various human and mouse cell systems and has been shown to occur in 
epithelial cells of human and mouse origin as well as fibroblasts (Jones et al 
2000; Lin and Lowe 2001; Serrano et al 1997). These studies have yielded a 
wealth of information about the molecular pathways relevant to oncogenesis. 
The tumour suppressor p16INK4a which inactivates D-type cyclins and p19ARF 
(p19ARF(mouse) = p14ARF(human)) which activates p53  together with general cell 
cycle regulators pRb, p107 and p130, play  key roles in Ras-induced senescence 
(Dannenberg et al 2000; Jones et al 2000; Lin et al 1998; Palmero et al 1998; 
Sage et al 2000; Serrano et al 1997). In mouse cells, induction of senescence by 
RAS occurs through the p19ARF-p53 pathway. Targeted mutations that exclusively 
disrupt p16INK4a but not p19ARF have revealed that p16INK4a is a less potent tumour 
suppressor in the mouse and that p16INK4a null MEFs are susceptible to Ras-
induced senescence whereas p19ARF null cells are not (Krimpenfort et al 2001; 
Sharpless et al 2001). In contrast to MEFs, in human fibroblasts p16INK4a seems to 
have a more prominent role than p14ARF. It has been reported that Ras-mediated 
senescence in human diploid fibroblasts occurs independently of p14ARF (Wei et 
al 2001) and human fibroblasts with biallelic mutation in p16INK4a (Leiden cells) 
are resistant to RAS induced senescence (Brookes et al 2002). Other members of 
the RAS signalling pathway (for example, RAF, MEK, MOS and BRAF) as well as 
other oncoproteins such as nuclear protein E2F or tyrosine kinase receptor 
erbB2, were shown to cause premature senescence through engagement of 
Kamil K. Wolyniec, 2008   Chapter 1,38  
various pathways (Bartkova et al 2006; Dimri et al 2000; Lazzerini et al 2005; Lin 
et al 1998; Michaloglou et al 2005; Trost et al 2005; Zhu et al 1998). 
1.8.5 Other inducers of cellular senescence 
There are also other less well understood cellular senescence initiating signals. 
Chemical histone deacetylase inhibition, which involves decondensation of 
chromatin and formation of euchromatin was found to induce senescence in 
primary fibroblasts of murine and human origin (Munro et al 2004; Ogryzko et al 
1996). Interestingly, whereas in human cells the p16INK4a-pRb pathway is critical 
for this response, in murine cells p53 pathway is more important (Munro et al 
2004). Inhibition of DNA methyl transferase (DNMT) with 5-azacytidine also 
results in senescence-like growth arrest (Weller et al 1993). Intriguingly, 
prolonged signalling by the anti-proliferative cytokine, interferon-β can induce 
ROS accumulation, DNA damage response and p53-dependent senescence 
(Moiseeva et al 2006). Likewise, chronic signalling by TGF-β promotes 
senescence in normal and cancer cells (Katakura et al 1999; Vijayachandra et al 
2003; Zhang and Cohen 2004). Finally, a phenomenon known as ‘culture shock’ 
can induce senescence by a p16-dependent but telomere-independent route. 
Human keratinocytes and mammary epithelial cells spontaneously express p16 
and enter premature senescence with long telomeres under standard in vitro 
culture conditions. These effects can be reversed by culturing cells on 
fibroblastic feeder layers suggesting that inadequate growth conditions also 
causes senescence and supporting the notion that senescence is a cellular stress 
response programme (Ramirez et al 2001). 
1.9 Characteristics of senescent cells 
Cellular senescence, originally defined as proliferative arrest that occurs in 
normal cells after a limited number of cell divisions (cell aging, replicative 
senescence), has now become regarded more generally as a biological 
programme of signal transduction leading to terminal, irreversible growth arrest, 
accompanied by a distinct set of alterations in the cellular phenotype (Dimri 
2005). Cells that undergo senescence cannot divide even if stimulated by 
mitogens but they remain metabolically and synthetically active and display 
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dramatic changes in chromatin structure and gene expression. This is 
accompanied by characteristic and easily observed changes in morphology such 
as an enlarged and flattened cell shape with increased granularity and formation 
of intracellular vacuoles (Campisi 2001; Dimri et al 1995). Senescence has been 
most widely studied in fibroblasts in vitro but is also well-defined in 
melanocytes and epithelial cells as well as cancer cells (Jones et al 2000; Lin 
and Lowe 2001; Michaloglou et al 2005, Olsen et al 2002; Serrano et al 1997; 
Shay and Roninson, 2004). Other cell types suggested to undergo senescence 
include haematopoetic and neural progenitors (Geiger and Van Zant 2002; 
Palmer et al 2001). The most widely used marker for senescent cells is 
senescence-associated-β-galactosidase (Dimri et al 1995). The senescent 
phenotype also entails type specific changes. Some senescent cells, for example 
human fibroblasts but not endothelial cells, become resistant to apoptosis 
(Hampel et al 2004). In addition, senescent fibroblasts secrete proteins that can 
influence the tissue microenvironment (Chang et al 2002; Mason et al 2004; 
Shelton et al 1999; Trougakos et al 2006; Zhang et al 2003a) as well as 
inflammatory cytokines such as IL-6 (Kuilman et al 2008). Interestingly, 
paracrine factors produced by senescent cells have major effects on the growth 
and survival of tumour cells (Krtolica et al 2001). Hence, senescence should not 
be viewed as merely the end point in a cell’s life cycle but rather as a 
physiological state determined by the homeostatic programmes of an organism. 
1.9.1 Growth arrest 
Somatic cell cycles consist of alternating DNA synthetic (S) and mitotic (M) 
phases, separated by gap phases (G1 and G2) (Figure 1.8). Senescent cells are 
unable to progress through the cell cycle and usually arrest growth with G1 DNA 
content. Once arrested they cannot be stimulated to resume proliferation by 
physiological mitogens. This is primarily caused by upregulation of cell cycle 
inhibitors and chromatin condensation (Campisi 2005; Narita et al 2003). The 
preferred theories emphasising G1 arrest have been overthrown by several 
reports that have shown that cellular senescence can be also associated with 
G2M arrest. For example, a defect in the stress signalling kinase MKK7 caused 
G2M arrest (Wada et al 2004) and also overexpression of oncogenic RAF results in 
a preferential accumulation in the G2M phase of the cell cycle (Zhu et al 1998). 
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Although earlier studies of H-RASV12 induced senescence have described 
predominant G1 arrest, recent work from our laboratory has revealed a stronger 
block in G2M, and an increased number of cells with a 4N DNA content (Kilbey et 
al 2007). 
 
 
 
 
 
 
 
 
 
Figure 1.8 Schematic diagram of checkpoints in the eukaryotic cell cycle 
The cell cycle consists of alternating S phase (DNA synthesis) and M phase 
(mitosis), separated by two gap phases G1 and G2. Cyclin D-dependent kinases 
(CDKs) accumulate in response to mitogenic signals and initiate the 
phosphorylation of pRb, a process that is completed by cyclin E-cdk2. Once cells 
enter S phase, cyclin E is degraded and cyclin A enters into complexes with 
cdk2. Cyclin B-Cdc2 mediates G2/M transition. INK4 proteins (p16INK4a, 
p15INK4b, p18INK4c, p19INK4d) oppose the activities of the various cyclin D-
dependent kinases, whereas Cip/Kip proteins (p21Cip1, p27Kip1, p57Kip2) 
specifically inhibit cyclin E-cdk2 and cyclin A-cdk2. Gadd45, 14-3-3σ and p21Cip1 
interefere with cyclin B-Cdc2. 
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1.9.2 Altered gene expression 
Cells that undergo senescence show dramatic changes in gene expression 
patterns, especially cell-cycle inhibitors which are activated and cell cycle 
progression genes that are downregulated (Trougakos et al 2006; Zhang et al 
2003a). p16INK4a and p21WAF1, which are governed by two tumour suppressors, p53 
and pRb respectively, are the most common cell cycle inhibitors that are 
expressed in senescent cells (Campisi 2005). P53 and pRb are often dysfunctional 
in cancer (Sherr and McCormick 2002). p21WAF1 is a direct downstream target of 
p53, whereas induction of p16INK4a remains poorly understood, although 
transcription factors of the Jun, Ets and Id families together with polycomb 
group proteins, Bmi, have been implicated in the regulation of INK4a expression, 
thereby governing cellular senescence (Lowe and Sherr 2003; Gil and Peters 
2006). Ultimately, p16INK4a and p21WAF1 maintain pRb in a hypophosphorylated, 
active state (Lowe and Sherr 2003). Repressed genes during senescence include 
replication-dependent histones, c-FOS, cyclin A, cyclin B and PCNA (proliferating 
cell nuclear antigen) (Narita et al 2003; Pang and Chen 1994; Serrano et al 1997; 
Seshadri and Campisi 1990). The repression of some of these genes is believed to 
reflect pRb mediated inactivation of E2F target genes and pRb-dependent 
epigenetic chromatin reorganisation and formation of discrete foci termed 
senescence-associated heterochromatin foci (SAHF) within the nucleus (Narita et 
al 2005). 
1.9.3 Senescence markers 
The extensive study of senescence has yielded several markers that are useful 
for the detection of this phenotype not only in vitro but more importantly in 
vivo. Senescent cells do not replicate their DNA, which can be detected by the 
lack of incorporation of 3H-thymidine or BrdU. Alternatively, immunostaining for 
PCNA or Ki-67 can be performed. SA-β-gal staining serves as a reliable and 
extensively used marker. In addition, components of two main pathways 
involved in senescence: ARF-p53 and p16INK4a-pRb are now used to identify 
senescent cells (Campisi 2005). Recently, the Serrano group has reported new 
markers that could help to describe senescence in vivo e.g. p15INK4b, DCR2 and 
DEC1 (Collado and Serrano 2006). Senescent cells can also be detected by 
cytological markers: formation of SAHF (senescence-associated heterochromatin 
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foci) and senescence associated DNA-damage foci (SDFs) (Bartkova et al 2006; 
DiMicco et al 2006; Mallette et al 2007; Narita et al 2003) 
1.9.3.1 Senescence-associated β-galactosidase 
The most widely used assay for senescence cells is the cytochemical detection of 
β-galactosidase activity at pH 6, termed senescence-associated β-galactosidase 
(SA-β-Gal) (Dimri at al 1995). Most cells express a lysosomal β-Gal that is 
optimally active at about pH 4 and either pre-senescent or senescent cells stain 
equally when assayed at pH 4, but only senescent cells stain for β-Gal activity at 
pH 6. Neither pre-senescent nor senescent cells stain at pH 7.5 which is the 
optimum for bacterial β-Gal enzyme (Dimri at al 1995). β-galactosidase activity 
reflects increased lysosomal biogenesis (Kurz et al 2000). It has been recently 
reported that SA-β–Gal is expressed from GLB1, the gene encoding lysosomal 
beta-D-galactosidase and that downregulation of this gene by RNAi did not 
prevent cellular senescence indicating that SA-β–Gal is not required for cells to 
undergo senescence (Lee et al 2006). There is also evidence for a positive SA-β–
Gal reaction in settings of cellular stress that are unrelated to senescence such 
as serum withdrawal or high confluency in culture dish (Severino et al 2000). 
Although SA-β–Gal is not necessary for senescence it is still a useful and 
extensively used assay for detection of senescent phenotypes. 
1.9.3.2 Senescence-associated heterochromatin foci (SAHF) 
When stained with DAPI (4’-6-Diamidino-2-phenylindole) or PI (propidium iodide) 
normal human cells exhibit a relatively even distribution of DNA across the cell 
nucleus. However most of the senescent cells undergo dramatic chromatin 
condensation which can be visualised by staining with DAPI as bright, punctate 
DNA foci (Narita et al 2003). SAHF are characterised by the presence of certain 
heterochromatin-asscociated histone modifications (for example, 
hypoacetylation of histones or methylation of Lys9 of histone H3 - H3K9Me) and 
bound heterochromatin proteins (e.g. HP1, heterochromatin protein 1) (Narita et 
al 2003) as well as loss of the linker histone H1 and enrichment in histone variant 
macroH2A and HMGA proteins (Funayama et al 2006; Narita et al 2006; Zhang et 
al 2005). The molecular mechanism of SAHF assembly is very complex and still 
largely unexplored but histone chaperones, ASF1a and HIRA together with PML 
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bodies play a critical role in this process (Figure 1.9) (Adams 2007). SAHF are 
believed to reflect p16-pRB mediated silencing of E2F target genes involved in 
cell cycling (Narita et al 2003). In mice, pericentric heterochromatin is much 
more prominent than in human cells and therefore it can be mistaken for SAHF 
(Adams 2007). Whether SAHF always occur in response to various stimuli and 
how exactly they are formed are questions that remain to be answered. It seems 
that not all cells have equal propensity to form SAHF. For instance WI-38 and 
IMR90 lung embryonic fibroblasts and primary melanocytes accumulate 
pronounced SAHF, whereas BJ foreskin fibroblasts form less marked SAHF (Adams 
2007). It is very possible that the nature of pro-senescent stimuli may account 
for the SAHF occurrence, for example, STAT5A does not promote obvious SAHF 
formation (Hemann and Narita 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 A model of SAHF formation in senescent human cells 
The HIRA/ASF1a complex cooperates with p16INK4a/pRB pathway to drive 
chromatin condensation. HP1 and macroH2A are deposited into SAHF. HIRA and 
HP1 transiently localise to PML bodies where are activated through 
phosphorylation (adapted from Adams 2007) 
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1.9.3.3 Senescence-associated DNA-damage foci (SDF) 
As discussed before, telomere uncapping can trigger a DNA damage response 
that results in senescence-like growth arrest (d’Adda di Fagagna et al 2003; 
Herbig et al 2004). In addition γ-irradiation and genotoxic drugs can also drive 
cellular senescence through DNA damage response pathways (Schmitt et al 2002; 
Wahl and Carr 2001). Interestingly, oncogenes such as H-RASV12. MOS, Cdc6 or 
STAT5a induce DNA double strand breaks (DSBs) and a DNA damage response due 
to replication stress that engages activation of ATM/ATR, CHK2 and CHK1 
(Bartkova et al 2006; Di Micco et al 2006; Mallette et al 2007). SDFs can be 
detected in senescent cells from mice and humans and contain proteins that are 
involved in DNA damage such as γ-H2AX, 53BP1, MDC1 and NBS1 (Bartkova et al 
2006; d’Adda di Fagagna et al 2003; DiMicco et al 2006; Herbig et al 2004). 
Importantly, it seems that not all oncogenes effectively induce DNA damage 
(Hemann and Narita 2007) and the role of SDF as a general marker of senescence 
remains to be investigated further. 
1.10 Signalling pathways in cellular senescence 
1.10.1 p53 and pRb, two master regulators of senescence 
Regardless of the senescence initiating signals, tumour suppressor pathways are 
critical for initiation and maintenance of the senescent phenotype in human and 
mouse cells. These pathways are controlled by the tumour suppressor proteins 
p53 and pRB with a wide range of upstream regulators and downstream effectors 
(Figure 1.10). It was in the early 90s when Shay and colleagues identified p53 
and pRB as two principal regulators of senescence (Shay et al 1991) and since 
then the molecular networks regulated by these proteins have become a subject 
of extensive research. Various studies have examined the relative functions of 
p53 and pRB in the initiation of senescence by assessing the outcomes of their 
inactivation. Numerous methods have been used to this end, for example: 
ectopic expression of SV40 large T-antigen and the human papilloma virus E6 and 
E7 oncoproteins (Shay et al 1991), germline homologous recombination in the 
mouse (Dannenberg et al 2000; Sage et al 2000], somatic homologous 
recombinations in human cells (Brown et al 1997) or RNAi knock-down models 
(Wei et al 2003). In mouse embryo fibroblasts, disruption of p53 alone is 
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sufficient to prevent senescence (Dirac and Bernards 2003). Likewise, 
inactivation of pRb gene together with other members of Rb family such as p107 
and p130, but not pRb alone, is sufficient to escape senescence (Dannenberg et 
al 2000; Sage et al 2003). This implies that both p53 and the Rb family are 
required for the induction of senescence. P53 and pRb were also found to be 
necessary for the maintenance of the senescent state because inactivation of 
either of these genes in senescent MEFs was enough for proliferation to resume 
(Dirac and Bernards, 2003; Sage et al 2003). These observations suggested a 
model of linear signalling, whereby a stress signal activates p53 which in turn 
activates pRb. The p21WAF1 protein, an inhibitor of cyclin E/Cdk2 complexes 
which is a direct transcriptional target of p53 was proposed to act as a linking 
chain between these two pathways. However, p21 null MEFs undergo RAS 
induced senescence (Pantoja and Serrano 1999), therefore exactly how the 
signal is transduced remains elusive. Unlike the behaviour of mouse cells, the 
inactivation of both p53 and pRb is essential to prevent the onset of replicative 
senescence in human cells (Smogorzewska and de Lange 2002), whereas 
disruption of only one of these proteins only delays the onset of senescence. This 
indicates that in human cells, p53 and pRb operate in two parallel pathways. A 
degree of complexity arises from other studies where it has been demonstrated 
that inactivation of either p53 or pRb by somatic homologous recombination in 
human lung fibroblasts allows bypass of senescence, suggesting that a linear 
model could be also applicable to human cells in some contexts (Wei et al 2003). 
This idea is supported by the fact that abrogation of p21WAF1 by homologous 
recombination is sufficient to prevent replicative senescence in human 
fibroblasts (Brown et al 1997). 
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Figure 1.10 Control of cellular senescence by p53 and pRB pathway   
Shown here are pathways that are activated by senescence-inducing signals. The 
model assumes linear crosstalk between the p53 pathway (red) and the pRB 
pathway (green). Positive and negative regulators of these two pathways are 
indicated and the effects of their action illustrated by arrows(        - positive 
effect;       - negative effect) 
1.10.1.1 pRb 
It is well established that pRb is constitutively hypophosphorylated (in its active 
state) in senescent cells and there is a growing body of evidence that this is 
achieved at least to some extent by p16INK4a. The p16INK4a, an inhibitor of 
CDK4/CDK6/Cyclin D complex activity, is upregulated during either replicative 
senescence or premature senescence in human fibroblasts (Alcorta et al 1996; 
Serrano et al 1997; Stein et al 1999). Therefore, it has been proposed that 
p16INK4a prevents phosphorylation of pRb resulting in its activation. Consistent 
with this hypothesis, p16INK4a and its upstream regulators such as Bmi-1, CBX7, 
JunB, ID1 and Ets-1 regulate senescence in a pRb-dependent fashion (Gil et al 
2004; Itahana et al 2003; Ohtani et al 2001; Passegue and Wagner 2000). 
Moreover, inactivation of p16INK4a in human cells causes a delay in the onset of 
replicative senescence, quite significantly in some cases (Brookes et al 2004) and 
p16 deficient human fibroblasts are resistant to RAS induced senescence 
(Brookes et al 2002). However, whereas in certain fibroblastic strains such as the 
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frequently used WI-38 strain, p16INK4a is clearly upregulated, in the other strains 
such as BJ fibroblasts, p16INK4a is only minimally expressed (Itahana et al 2003). 
Intriguingly, fibroblasts with low or undetectable p16INK4a levels, in contrast 
those with high p16INK4a expression levels, can be induced to re-enter cell cycle 
by inactivation of p53 (Beausejour et al 2003). Interestingly SAHF which are 
known to be responsible for the irreversibility of senescence are present only in 
human fibroblasts that contain high levels of p16INK4a (Narita et al 2003). In view 
of recent studies, it is plausible that there might be CDK inhibitors other than 
p16INK4a, playing a surrogate role in the regulation of pRb. Using a p16INK4a knock-
down strategy, it was shown that p16INK4a inactivation is not functionally 
equivalent to pRb inactivation (Wei et al 2003). Given that p21WAF1 
overexpression in human fibroblasts results in premature senescence (McConnel 
et al 1998) and its induction can also lead to the inhibition of pRb 
phosphorylation by suppressing CDK2/Cyclin E activity, p16INK4a and p21WAF1 may 
cooperate in maintaining pRb in the active state during cellular senescence. 
1.10.1.2 p53 
p53 is considered to be a guardian of the genome and depending on the severity 
of the damage it can activate genetic programmes that stop cell proliferation 
transiently (G1 and G2 arrest) or permanently (senescence), or eliminate the 
cell (apoptosis). The signals that induce a DNA damage response such as ionizing 
radiation or telomere dysfunction induce senescence primarily via the p53 
pathway. p53 activity, and in some cases protein level, increases when cells 
undergo senescence (Itahana et al 2001). The mechanisms responsible for this 
are incompletely understood, but some molecular details are emerging. One 
cause of p53 activation appears to be an increase in the expression of ARF 
(p14ARF in human; p19ARF in mouse), a tumour suppressor encoded by the 
INK4a-ARF locus. It stimulates p53 activity due to sequestration of HMDM2 (MDM2 
in mice), an E3 ubiquitin ligase that targets p53 for proteosome-mediated 
degradation. Thus, ARF prevents negative-feedback regulation of p53 by MDM2 
(Bringold and Serrano 2000; Gil and Peters 2006). ARF is upregulated in cultured 
senescent murine cells as well as during premature senescence induced by H-
RASV12 and has been reported to be absolutely required for telomeric and non-
telomeric senescence in MEFs (Kamijo et al 1997; Kamijo et al 1999; Sharpless et 
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al 2004). In human cells the role of ARF is more complicated. For example it has 
been proven to be a critical regulator of E2F induced senescence (Dimri et al 
2000; Wei et al 2001) but not H-RASV12 induced senescence in human primary 
fibroblasts (Wei et al 2001). ARF can be transcriptionally activated by DMP1, a 
transcription factor that was found to be essential in RAS-RAF-ARF signalling in 
murine cells (Inoue et al 2000; Sreeramaneni et al 2005). ARF can be also 
negatively regulated by TBX2 and Pokemon that can bind to the ARF promoter 
and repress its transcription (Jacobs et al 2000; Maeda et al 2005). Another 
cause for the increase in p53 activity is reported to be the promyelocytic 
leukaemia (PML) tumour suppressor. PML is upregulated in replicatively 
senescent cells and mediates premature senescence in response to oncogenic H-
RASV12 by interaction with CBP/p300 acetyltransferase and acetylation of p53 
and its stimulation (Ferbeyre et al 2000; Pearson et al 2000). PML was also found 
to bind to MDM2 and sequester it into the nucleolus (Bernardi et al 2004). 
1.10.2 Reactive oxygen species as signal transducer in 
cellular senescence 
The results discussed earlier in this chapter in the section ‘oxidative stress’ 
(1.8.3) suggest that oxygen concentration limits cellular lifespan in vitro by 
induction of cellular senescence. The relationship between intracellular oxidants 
and the senescent programme has been strengthened by the observation that 
treatment with sub-lethal doses of hydrogen peroxide can trigger certain 
primary cells to rapidly enter senescence (Chen and Ames 1994; Chen  et al 
1998; Frippiat et al 2002). Molecular analysis of these hydrogen peroxide treated 
cells revealed a predominant G1 arrest with an increase in p53 protein levels 
and increased p53 activity, accompanied by subsequent upregulation of p21WAF1 
(Chen et al 1998). Interestingly, an increase in the expression of a subset of p38 
MAPK-dependent genes in H202-induced premature senescence was identified 
suggesting a link between reactive oxygen species (ROS) and p38 activation 
(Zdanov et al 2006). A strong argument supporting the role of ROS in mediating 
senescence stems from the fact that overexpression of H-RASV12 induces 
senescence and increases ROS levels (Lee et al 1999). Interestingly, Seladin-1, 
which encodes an oxidoreductase enzyme involved in cholesterol synthesis 
(Waterham et al 2001) and protection of neurons from oxidative stress in 
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Alzheimer’s disease (Greeve et al 2000) has been identified as a crucial mediator 
of H-RASV12 induced senescence and has been linked to RAS-induced reactive 
oxygen species signalling (Wu et al 2004). Moreover, the p53 transcriptional 
target p21WAF1, when ectopically expressed induces the hallmarks of senescence 
with an accompanying rise in intracellular ROS (Macip et al 2002). Treatment 
with antioxidant NAC (N-acetyl cysteine) has been shown to prevent both RAS-
induced senescence and p21-induced senescence (Lee at 1999; Macip et al 
2002). Recently, Takahashi and coworkers have demonstrated that p16INK4a/pRb 
pathway can also induce a rise in intracellular ROS levels through activation of 
PKCδ (Protein Kinase C δ), which, in turn seems to lead to further production of 
ROS by activating NADPH oxidase, thus establishing a self-sustained positive 
feedback loop. In addition, the activation of PKCδ results in dramatic depletion 
of WARTS protein (WTS/large tumour-suppressor 1 mitotic kinase) expression, 
the kinase essential in cytokinesis, and G2M cell cycle arrest which act as a 
second barrier ensuring irreversibility of senescence (Takahashi et al 2006). 
1.10.3 p38 Mitogen-acivated protein kinase represents a 
common senescence pathway 
The p38 kinase belongs to the family of mitogen-activated protein kinases 
(together with extracellular regulated kinase, ERK and c-Jun N-terminal kinase, 
JNK) and is also known as stress-activated protein kinase (SAPK). The 
mammalian genome encodes four isoforms of p38 (α, β, γ, δ). P38 plays a crucial 
role in various processes such as inflammation, cellular responses to micro-
organisms and other environmental stresses (Bulavin and Fornace 2004; Nebreda 
and Porras 2000) and has aslo been also been strongly linked to cellular 
senescence in mouse and human cells. It has emerged as a common signalling 
pathway that is required by various stimuli to cause senescence including 
replicative stress, oncogene overexpression, hydrogen peroxide and culture 
shock (Iwasa et al 2003; Trost et al 2005; Wang et al 2002). The mitogen-
activated protein kinase (MAPK) signalling cascade is the principal Ras-effector 
pathway responsible for premature senescence (Lin et al 1998). Remarkably, this 
is the same pathway whereby Ras induces mitogenesis in immortal cells 
suggesting the existence within the RAS signalling cascade of a signalling branch 
that mediates premature senescence and therefore limits transformation. It has 
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been shown that activation of MEK-ERK pathway by RAS in primary fibroblasts 
leads to activation of p38 MAPK, which in turn induces accumulation of cell cycle 
inhibitors and senescence. RAS-induced p38 activation is achieved by its 
upstream kinases MKK3 and MKK6 (Wang et al 2002). Constitutive activation of 
p38 signalling by overexpression of active mutants of MKK3 or MKK6 results in 
premature senescence. Conversly, suppression of p38 by the inhibitor SB203580 
or by dominant negative mutants of MKK3/MKK6, substantially rescues 
senescence induced by RAS (Wang et al 2002; Iwasa et al 2003). In addition, 
expression of Wip1 (a p38 phosphatase) which inactivates p38, renders primary 
human fibroblasts refractory to RAS induced senescence (Bulavin et al 2002), 
whereas inactivation of Wip1 causes p38 activation and premature senescence in 
MEFs (Bulavin et al 2004). Furthermore, MEFs that are deficient in Gadd45a, a 
DNA damage and stress-induced protein that binds and activates p38, are unable 
to undergo senescence induced by RAS (Bulavin et al 2003). Interestingly, 
expression of RAS oncogene in human osteosarcoma U2OS results in a 
p16INK4a/ARF independent senescence-like growth arrest that can be rescued by 
the inhibition of p38 MAPK (Bihani et al 2004). Another oncogene, erbB2, the 
tyrosine kinase receptor that is frequently overexpressed in breast carcinomas 
and other human cancers induces premature senescence that requires intact p38 
MAPK (Trost et al 2005). These studies strongly implicate p38 MAPK in oncogene-
induced senescence. Currently, it remains largely unknown what are the 
downstream effectors of p38 in the context of senescence. However, the p16INK4a 
and p53 are believed to be two major downstream targets of p38 in RAS induced 
senescence. It has been suggested that p38 activation stabilises p16INK4a and p53 
mRNA by as yet elusive mechanisms (Wang et al 2002). Other studies identified 
PRAK (p38-regulated/activated protein kinase), a downstream regulator of p38 
MAPK to be essential for RAS induced transcriptional activity of p53. PRAK 
directly phosphorylates p53 at Ser37, a residue required for p53 to drive RAS 
induced senescence. In addition to PRAK, p38 directly phosphorylates p53 at 
Ser33 and Ser46 during RAS-induced senescence (Sun et al 2007). It is also not 
very clear what is the mechanism by which MKK3/6-p38 is activated since there 
is a profound delay in the transduction of signal from MEK-ERK to MKK3/6 and 
p38, indicating that it occurs via an indirect and slow route (Wang et al 2002). 
Reactive oxygen species emerged as a potential missing link given that they are 
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induced by RAS and mediate both p38 activation and oncogene-induced 
senescence (Colavitti and Finkel 2005); Iwasa et al 2003; Lee et al 1999). In 
support of this hypothesis, recent studies demonstrated that MINK kinase is 
activated by RAS induced ROS and subsequent activation of p38 by MINK (a 
Ste20/germinal center kinase family MAP kinase kinase kinase)  results in 
premature senescence (Nicke et al 2005). Moreover, p38 itself has also been 
shown to restrict RAS-induced tumourigenesis by acting as a sensor of ROS 
(Dolado et al 2007). 
1.11 Oncogene induced senescence as a cancer fail-safe 
mechanism 
In principle, cellular senescence is thought to be an important, evolutionary 
conserved fail-safe mechanism, a natural barrier that cells must overcome in 
order to become immortal and induce tumourigenesis. Apoptosis has been a well 
established mechanism of tumour suppression for a long time (Brown and Attardi 
2005; Kim et al 2006) but to what extent the observed cellular senescence in 
vitro reflects a relevant anti-cancer mechanism in vivo has been controversial. It 
was important to address this issue especially in view of some studies showing 
that not all primary fibroblasts undergo H-Ras induced senescence. Galloway and 
collegues reported that ectopic expression of Ras in human foreskin fibroblasts 
(HFFs) freshly established from the primary tissue does not result in premature 
senescence but instead causes mild transformation of these cells (Benanti and 
Galloway 2004). Interestingly freshly established HFFs were found to differ from 
routinely used strain of IMR90 fibroblasts in the basal levels of p16 (undetectable 
in HFFs, detectable in IMR90s) and the relative extent of p16 upregulation by H-
Ras. The authors suggested that passaging of cells leads to culture-imposed 
stress causing accumulation of p16 allowing for Ras-induced arrest. Hence HFFs 
used directly after isolation from the tissue had been exposed to considerably 
less environmental stress, did not express any detectable p16 and were resistant 
to senescence. In support of this hypothesis it has been demonstrated that 
extended passaging of HFFs may render them sensitive to H-Ras induced 
senescence. Several recent studies, however, have reported that oncogene-
induced senescence can occur in vivo in human tumours and mouse cancer 
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models, and indeed provides a vital mechanism that constrains neoplastic 
transformation (Figure 1.11). Abnormal activation of oncogenic Ras, BRAF, E2F 
or loss of PTEN tumour suppressor can promote aberrant cell proliferation, which 
eventually provokes activation of a cellular senescence programme in vivo. If 
the programme remains intact, the neoplastic growth may remain benign for 
many years. However, mutations that disrupt p53, p16INK4a or Suv39H1 which are 
sustaining cellular senescence cooperate with tumour progression (Braig et al 
2005; Chen et al 2005; Collado et al 2005; Lazzerini et al 2005; Michaloglou et al 
2005). Probably the most spectacular example of oncogene-induced senescence 
in vivo is the appearance of naevi or moles on human skin, which are benign 
tumours of cutaneous melanocytes containing senescent cells (Michaloglou et al 
2005). In addition several studies have demonstrated that re-expression of 
endogenous p53 rapidly induces senescence and curtails oncogenesis in 
genetically engineered mouse models of sarcoma and hepatocellular carcinoma 
(Ventura et al 2007; Xue et al 2007). Xue and coworkers showed that even brief 
reactivation of p53 in p53-deficient tumours can result in complete tumour 
regression. This response also triggered an innate immune response that was 
associated with tumour clearance (Xue et al 2007). Importantly cellular 
senescence has also been found to be involved in the tumour regression related 
to the inactivation of the c-Myc oncogene in diverse tumour types including 
lymphoma, osteosarcoma, hepatocellular carcinoma (Wu et al 2007). 
 
 
 
 
 
 
 
 
 
 
Figure 1.11 Oncogene induced senescence as an anti-cancer fail-safe 
mechanism 
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Activating mutations of RAS or BRAF or inactivation of PTEN resulting in 
hypermitogenic signalling produce premalignant lesions. Disruption of tumour 
suppressors p53 and p16/pRb allows escape from senescence and progression to 
malignant tumours 
1.12 RUNX genes and senescence 
It has been reported by our laboratory that all three RUNX proteins are capable 
of inducing senescence-like growth arrest in primary MEFs (Kilbey et al 2007; 
Wotton et al 2004). RUNX1 induced senescence in MEFs was found to be p53 
dependent and pro-oncogenic activity of RUNX1 could be revealed in p53 null 
MEFs (Wotton et al 2004). RUNX expressing MEFs were found to undergo 
profound growth arrest without the initial burst of proliferation which 
characterizes oncogenic RAS induced senescence (Kilbey et al 2007, Wotton et al 
2004). However, issues such as whether RUNX1 can also induce senescence in 
primary human fibroblasts or which structural domains of RUNX1 are required for 
the senescence induction have not been previously investigated. Furthermore 
the mechanism by which RUNX1 expressing cells acquire a senescent phenotype 
and the potential of RUNX1 fusion oncoproteins to cause senescence had not 
been addressed at the outset of my studies. 
1.13 Aims of the project 
1. To investigate the mechanism and structural requirements for senescence-like 
growth arrest induced by RUNX1.  
2. To test the effect of ectopic RUNX1 expression in human primary fibroblasts 
as well as characterise a system to study oncogene-induced senescence. 
3. To compare the effects of RUNX1 and its derivatives to RasV12, a prototypic 
inducer of oncogene-induced senescence in human fibroblasts. 
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2 Materials and methods 
2.1 Materials 
2.1.1 Antibodies 
Antibodies were used for Western blotting or immunolocalisation in microscopy. 
The dilution used for each antibody is provided in brackets. 
Active Motif Europe (Belgium) 
Anti-AML1/Runx1 (39000), (1:1000) 
Cell Signalling Technology (New England Biolabs, UK) 
Anti-p38 (9212), (1:1000) 
Anti-phospho-p38 (9211), (1:1000) 
DAKO Ltd, UK 
Polyclonal rabbit Anti-mouse immunoglobulins/HRP, (1:1000) 
Polyclonal swine Anti-rabbit immunoglobulins/HRP, (1:3000) 
Polyclonal rabbit Anti-goat immunoglobulins/HRP, (1:2000) 
Dr. Nancy Speck (Department of Biochemistry, Dartmouth Medical School, 
Hanover, USA) 
Monoclonal supernatant recognising CBFβ (peptide 42-214 amino acids) 
Dr. Scott Hiebert (Vanderbilt Cancer Center, USA) 
Anti-Runx1-ETO polyclonal rabbit antibody that recognising ETO zinc finger motif 
was a kind gift from Dr. Scott Hiebert, (1:500) 
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Dr. Tina Rich (University of Glasgow, UK) 
Anti-PML (N19, Santa Cruz) (1:200) and Alexa Fluor-conjugated secondary 
antibody (Molecular Probes) (1:100) 
Jackson Immuno Reasearch Laboratories, Inc (Stratech Scientific Ltd., UK) 
Fluorescein (FITC)-conjugated Affinity Purified Sheep Anti-Mouse IgG, (1:100) 
Medical and Biological Laboratories Co., Ltd (MBL) (Stratech Scientific Ltd, 
UK) 
Anti-Runx (D207-3), (1:1000) 
NeoMarkers (Lab Vision Products Thermo Fisher Scientific, UK) 
Anti-p14ARF (Ab-2), (1:500) 
Positive control for anti-p14 (MS-850-PCL) 
Oncogene Research Products (Merck, UK) 
Anti-H-ras (Ab-1), (1:200) 
Roche Diagnostics Ltd, UK (In situ Cell Proliferation Kit, FLUOS) 
Monoclonal anti-BrdU conjugated with fluorescein  
Santa Cruz Biotechnology Inc (Insight Biotechnology, UK) 
Anti-p16 (sc-468), (1:1000) 
Anti-p21 (sc-397), (1:250) 
Anti-p53 (sc 126), (1:1000) 
Anti-actin (sc-1616), (1:1000) 
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Upstate Cell Signalling Solutions (Millipore, UK) 
Anti-phospho-Histone-H2A.X (Ser139) (05-636), (1:200) 
2.1.2 Cell culture 
2.1.2.1 Cell lines 
Wild type and p53-/- mouse embryo fibroblasts (MEFs) were prepared from 
E13.5 day embryos of wild-type (C57B16/CBA) and p53 null mice as described 
before (Wotton et al 2004). Briefly, the head and red organs were removed and 
the body minced and treated with 0.5% trypsin for 15 min to disperse the cells. 
The cells were expanded in culture and frozen at passage two in 60% FCS, 10% 
DMSO 
Hs68 strain of human neonatal foreskin fibroblasts (passage 30; ATCC: CRL 
1635). These were rendered sensitive to ecotropic retroviruses by expression of 
murine leukaemia virus receptor have been previously described (Brookes et al 
2004) and kindly provided by Prof. Gordon Peters (CR-UK, London). 
Leiden cells (passage 29). These are a p16INK4a deficient human diploid 
fibroblasts that were originally isolated from a male patient who from the age of 
6 developed multiple prominent naevi which by puberty had become atypical. 
Dermal fibroblasts were isolated from a region of normal epidermis adjacent to 
one of the dysplastic naevi removed when the patient was 24 years of age. 
Leiden cells expressing mouse ecotropic receptor were kindly provided by Prof. 
Gordon Peters (CR-UK, London) (Brookes et al 2002) 
Phoenix ecotropic packaging cell line is a second-generation retrovirus producer 
lines for the generation of helper free ecotropic retroviruses. The line is based 
on the 293T cell line (a human embryonic kidney line transformed with 
adenovirus E1a and carrying a temperature sensitive T antigen co-selected with 
neomycin). The unique feature of this cell line is that it is highly transfectable 
with either calcium phosphate mediated transfection or lipid-based transfection 
protocols. The lines were created by placing into 293T cells constructs capable 
of producing gag-pol, and envelope protein for ecotropic and amphotropic 
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viruses. Phoenix cell line was obtained from G. Nolan, Stanford University, Palto 
Alto, CA, USA. 
2.1.2.2 Media and supplements 
All supplements and media for cell culture were supplied by Invitrogen Life 
Technologies 
Media 
The media was delivered as sterile 1x solution and stored at 4°C. 
Dulbecco’s Minimum Essential Medium (DMEM) with 4500 mg/L glucose, L-
Glutamine and pyruvate. 
Supplements 
Foetal Bovine Serum (FBS), HyClone, Perbio: virus and mycoplasma screened. 
FBS was heat inactivated at 56 °C for 30 minutes by the supplier and routinely 
used at a concentration of 10%. 
L-glutamine: supplied as a 200 mM (100x) stock solution.  This was routinely 
added to culture media prior to use to a final concentration of 2mM. 
Penicillin/streptomycin (P/S): supplied as a 100x stock solution of 10,000 units 
penicillin and 10,000 units streptomycin per millilitre. This was used to 
supplement media to a final concentration of 100 units penicillin/100 units of 
streptomycin. 
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2.1.2.3 Solutions, reagents and antibiotics 
Antibiotics 
Puromycin (Sigma), solid was dissolved in water, aliquotted and stored as 
5mg/ml stock solution in –20 °C 
Transfection Reagent 
Superfect transfection Reagent (Qiagen) stored in –4 °C 
SA-β-galactosidase staining 
25% glutaraldehyde stock solution stored in –4 °C (5% PBS pH 7.2) solution freshly 
prepared prior to use) 
0.12 M stock solution of K3Fe[CN]6 and K4[Fe]CN6 stored in –4 °C 
1M stock solution of MgCl2  stored in –4 °C 
Ultra pureTM X-Gal (Invitrogen) stored as solid in –4 °C 
Fresh SA-β-gal staining solution in PBS (pH 6) prepared immediately prior to use 
consisted of: X-gal (1mg/ml), 0.12 mM  K3Fe[CN]6 and K4[Fe]CN6 and 1mM MgCl2 
Inhibitors 
SB203580, a highly specific p38 kinase inhibitor (Calbiochem) was dissolved in 
DMSO,  aliquoted and stored in –20 °C as 8mM stock solutions  
Other 
Trypsin-EDTA (Invitrogen): supplied as 0.5% 1x liquid, stored at –20 °C 
DCF (2’, 7’-dichlorofluorescein diacetate, Calbiochem), cell-permeable 
fluorogenic probe that is used for the detection of reactive oxygen species was 
stored in –20 °C as a powder and diluted in DMSO prior to use 
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2.1.2.4 Plasticware 
Tissue culture flasks, pipettes (5, 10, and 25 ml), 100 mm cell culture dish, 12 
well plates were supplied by Costar (Corning Incorporated, Netherlands) 
Cryotubes 1.8 ml were supplied by Nunc (DK 400, Roskilde, Denmark) 
Falcon conical centrifuge tubes (15 and 50 ml) were supplied by Becton 
Dickinson Labware Europe 
Syringe filters (0.2 µm and 0.45 µm) were supplied by Sartorius (Hannover, 
Germany); used for sterilising of filtering small volumes of solutions 
Syringes (2, 5, 10, 20, 50) ml were supplied by Becton Dickinson 
Chamber Slide System-2 well glass slide was supplied by Lab-Tek (Nalge Nunc 
International, Rochester, New York). Chamber slides were coated with poly-L-
lysine (13.3 µg/ml) prior to use 
2.1.3 Bacteriology 
2.1.3.1 Bacterial strain 
E. coli One shot ® TOP10: One Shot Chemically Competent E.coli cells (~1 x 109 
colony forming units/µg) (Invitrogen). Genotype: F- mcrA ∆(mrr-hsdRMS-
mcrBC)Φ80 lacZ∆M15 ∆lacX74 deoR recA1 araD139 ∆(ara-leu)7697 galU galK rpsL 
(StrR) endA1 nupG.  
2.1.3.2 Antibiotics 
Ampicillin (Sigma): 100 mg/ml in ddH2O.  Filtered through a 0.22 µm filter, 
aliquotted and stored at –20°C until use 
2.1.3.3 Bacteriological media 
Media were sterilised by autoclaving at 121 °C for 15 minutes, unless otherwise 
stated. 
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LB (Luria Bertani) medium: 1% (w/v) Tryptone, 0.5% (w/v) Yeast extract, 1% 
(w/v) NaCl in dH20.  pH then adjusted to 7.0 with NaOH. 
LB-agar: as for LB medium but also containing 1.5% (w/v) agar. 
SOC medium: 2% Tryptone, 0.5% Yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 10 mM MgSO4, and 20 mM Glucose. (Invitrogen, UK). 
2.1.3.4 LB agar plates supplemented with ampicillin  
Plates were prepared (Sterilin, Staffordshire, UK) with LB agar which was 
supplemented with 100 µg/ml ampicillin. Plates were stored in -4°C for no more 
than two weeks. 
2.1.4 Complete kits 
Big Dye® Terminator Version 1.1 Cycle Sequencing Kit (Applied Biosystems) 
ECLTM Western Blotting Detection Reagents (Amersham Biosciences) 
EndoFree® Plasmid Maxi Kit (Qiagen) 
QIAquick® PCR Purification Kit (Qiagen) 
QIAquick® Gel Extraction Kit (Qiagen) 
Klenow Fill-In Kit (Stratagene) 
Quick LigationTM Kit (New England Biolabs) 
In Situ Cell Proliferation Kit, FLUOS (Roche) 
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2.1.5 DNA 
Plasmid, molecular weight markers and oligonucleotide DNAs were stored at       
–20 °C. 
2.1.5.1 Retroviral vectors 
pBabe puro  
The pBabe puro retroviral vector facilitates the transmission of inserted genes at 
high viral titres and their expression them from the Long Terminal Repeat (LTR) 
of the Moloney murine leukaemia virus (Mo MuLV). This vector includes a 
dominantly acting selectable marker, conferring resistance to puromycin to 
infected mammalian cells during selection with puromycin (Figure 2.1) 
(Morgenstern and Land 1990). pBabe puro also contains an ORI origin of 
replication and the AmpR gene for propagation and antibiotic selection in 
bacteria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Structure of pBabe puro retroviral vector 
LTR-long terminal repeats; MCS-multiple cloning sites; SV40-simian virus 
promoter; Puro-puromycin resistance gene; ORI-origin of replication; ; AmpR-
ampicillin resistance gene 
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pBabe puro plasmids containing human RUNX1 P1, RUNX1-ETO and RUNX1-
ETO∆469 were kindly provided by Dr. Scott Hiebert (USA) (Linggi et al 2002). The 
pBabe puro plasmids containing H-RASV12 was a kind gift from Dr. Scott Lowe 
(USA) and the plasmid encoding p53 was supplied by Prof. Gordon Peters 
(London). The other pBabe puro vectors including AML1a and TEL-RUNX1 or 
RUNX1 mutants: K83N and T161A were constructed as described in Section 
2.2.2.7. All of the constructs were sequenced as described in Section 2.2.3. 
pLXSN 
pLXSN contains elements derived from Moloney murine leukaemia virus 
(MoMuLV) and Moloney murine sarcoma virus (MoMuSV) and is designed for 
retroviral gene delivery and expression. Upon transfection into packaging cell 
line, pLXSN can transiently express or integrate and stably express the gene of 
interest. The 5’ viral LTR in this vector contains promoter/enhancer sequences 
that control expression of the gene in the multiple cloning site. The SV40 early 
promoter (PSV40) controls expression of the neomycin resistance gene which 
allows antibiotic selection in eukaryotic cells. pLXSN also includes the ColE1 
origin of replication and Ampr gene for propagation and antibiotic selection in 
bacteria (Figure 2.2). 
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Figure 2.2 Structure of pLXSN retroviral vector 
LTR-long terminal repeats; MCS-multiple cloning sites; PSV40-simian virus 
promoter; Neo-puromycin resistance gene; ColE1-origin of replication; Amp-
ampicilllin resistance gene 
Empty vector (pLXSN) and vector containing Human papilloma virus 16 E6 
oncoprotein (pLXNS-E6) were kindly provided by Prof. Saveria Campo (University 
of Glasgow) 
2.1.5.2 Molecular size standards 
Molecular size standards used include φX174 RF DNA/HaeIII fragments (size range 
72 bp to 1,353 bp), λ DNA/HindIII fragments (size range 125 bp to 23,130 bp), 
and Low DNA Mass™ Ladder (size range: 100-2000 bp) all supplied by Invitrogen 
Life Technologies. 
2.1.5.3 Oligonucleotide primers 
Oligonucleotides for sequencing were synthesised by MWG Biotech, and 
delivered as high purity salt free lyophilised DNA.  Primers were reconstituted at 
100 pmol/µl in distilled water (dH20) and stored at –20 °C. 
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2.1.6 Enzymes 
All enzymes were stored at –20 °C and were removed from storage immediately 
before use. 
2.1.6.1 Restriction enzymes 
All enzymes and their associated buffers were supplied by Invitrogen Life 
Technologies (UK) except for SnaBI which was supplied by Promega (UK). 
Details of restriction enzymes, their restriction sites and reaction conditions are 
shown in Table 2.1. 
Table 2.1 Restriction enzymes. 
Restriction 
enzyme 
Restriction site Buffer Temperature of 
incubation (°C) 
EcoR I [5´-G↓AATTC-3´] REACT® 3 37 
Sna BI [5´-TAC↓GTA-3´] Buffer B 37 
Not I [5´-GC↓GGCCGC-3´] REACT® 3 37 
Hind III [5'-A^A G C T T-3'] REACT® 3 37 
Sal I [5´-G↓TCGAC-3´] REACT® 10 37 
 
2.1.6.2 Antarctic phosphatase 
Recombinant Antarctic phosphatase (New England Biolabs) supplied with 10x 
buffer 
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2.1.7 Protein SDS-PAGE standards 
Prestained SDS-PAGE (Sodium Dodecyl Sulphate - Polyacrylamide Gel 
Electrophoresis) standard was the Precision Plus ProteinTM Standards, supplied by 
Biorad. This standard contains ten highly purified recombinant proteins ranging 
from 10 kDa to 250 kDa.  The stock was aliquoted and stored at –20 °C.  Each 
aliquot was heated to 95 °C for 3 minutes prior to use to dissolve any 
precipitated solids. 
2.1.8 General chemicals 
Chemicals used were of analytic, ultrapure or molecular grade quality and were 
supplied by Sigma Aldrich, Fisher Scientific UK Limited, Invitrogen Life 
Technologies, unless stated otherwise. 
Acetic acid sodium salt (Sodium acetate) 
Agarose  
Albumin from bovine serum (BSA) 
Butanol 
β-Mercaptoethanol 
Crude ethanol (University of Glasgow Stores) 
Crystal Violet 
Dimethyl sulfoxide (DMSO) 
D-(+)-Glucose 
Ethanol 
Ethidium Bromide 
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Ethylene diamine tetra acetate (EDTA) disodium salt 
Glycerol 
Glycine 
Hi-Di™ Formamide (Applied Biosystems) 
4-(2-Hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES) 
Hydrochloric acid 
Magnesium Chloride  
Methanol 
Nonident P-40 (NP40) 
16% paraformaldehyde (Science Services Ltd) 
Propan-2-ol (Isopropanol) Molecular Biology Grade 
Potassium Chloride 
Potassium hexacyanoferrate(III) (K3Fe[CN] 6) 
Potassium hexacyanoferrate(IV) (K4[Fe]CN6) 
Sodium Acetate 
Sodium Chloride 
Sodium dodecyl sulphate (SDS) 
3′,5′,5′′-Tetrabromophenolsulfophethalein (Bromphenol Blue) 
Tris Base (2-Amino-2-(hydroxymethyl)-1, 3-propanediol) 
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Triton X-100 
Tween 20 (Polyoxethylene sorbitan nonolaurate) 
2.1.9 Equipment 
2.1.9.1 Major Equipment 
Automated Processor: SRX-101A Compact X4 (Xograph Imaging Systems, 
Gloucestershire, UK) 
Automatic Sequencing Apparatus: ABI Prism 3100 Genetic Analyzer (Applied 
Biosystems, Foster City, USA) 
Benchtop centrifuge:  LegendTM Sorvall (Kendro Laboratory Products, Germany), 
Avanti® J-E Centrifuge (Beckman Coulter, USA), Centrifuge 5810, 5810R 
(Eppendorf, Cambridge, UK), EBA-12R (Hettich Zentrifugen, Tuttlingen, 
Germany), Biofuge 13 (Heraeus, Germany) 
Bench-top microprocessor pH meter: pH 213 Microprocessor pH Meter (Hanna 
Instruments, Sarmeola di Rubano, Italy) 
Biological safety cabinet: Fume Cupboard (Premier Laboratory Systems, 
Scotland), and TriMAT2, Class II Microbiological Safety Cabinet (Medical Air 
Technology Ltd, Oldham, UK) 
Flow cytometer: Coulter Epics XL MCL (Beckman Coulter Company, Florida, USA) 
Gel cast: AE-6210 Slab Gel Cast (Atto Incorporation, Japan); casting stand and 
casting frames from Mini-Protean 3 Cell and Systems, and gel caster from Sub-
Cell Systems (Bio-Rad Hertfordshire, UK) 
Gel electrophoresis systems: Biomax QS710 Horizontal Unit (Scientific Imaging 
Systems – Eastman Kodak Company, New York, USA); Sub-Cell GT Submerged 
Horizontal Agarose Gel Electrophoresis System, and MiniProteanIITM (Bio-Rad, 
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Hertfordshire, UK); AE-6200 Slab EP Chamber, and AE-6220 Slab EP Chamber, for 
two gels (Atto Incorporation, Japan) 
Hemocytometer (Bright Line Sigma), cell counting chamber 
Horizontal orbital shaker: Orbital Incubator (Gallenkamp, Leicester, UK) 
Incubator: MIR-262 (Sanyo Electric Biomedical Co. Ltd., Japan) 
Incubators for tissue culture: Hera cell 150 (Heraeus, Surrey, UK) 
Microcentrifuges: Minispin (Eppendorf, Cambridge UK), Mikroliter (Hettich 
Zentrifugen, Tuttlingen, Germany) 
Microscopes: Laser Confocal Scanning Microscope (Leica DM IRE2), Inverted 
Microscope (Leica DM IL) 
Microwave Micro chef St44 (Proline, UK) 
Oven Maxi 14 (Hybaid Limited, Middlesex, UK) 
PCR Machine: PTC-220 DNA Engine Dyad® Cycler (MJ Research Incorporated, 
Massachusetts, USA) 
PCR workstation: PCR 6 Vertical Laminar Airflow Cabinet with UV Sterilisation 
(Labcaire Systems Ltd, North Somerset, UK) 
Pipettes: Pipetman (P10, P20, P200, and P1000) supplied by Gilson Medical 
Electronics (Villiers-le-Bel, France) 
Power packs: Electrophoresis Power Supply EPS 500/400 (Pharmacia Fine 
Chemicals, Uppsala, Sweden), and Power PAC 300 (Bio-Rad, Hertfordshire, UK)  
Rotator: Spiramix 5 (Denley Instruments Ltd, England) 
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Semi-dry electrophoretic transfer: Trans-blot® SD Semi-Dry Transfer Cell (Bio-
Rad Hertfordshire, UK) 
Shaker: Model R100 Rotatest Shaker (Luckham, England), Stuart SSL1 Orbital 
Shaker (Bibby Sterilin Ltd, Staffordshire, UK), and Orbital Shaker (Bellco 
Biotechnology, New Jersey, USA) 
Spectrophotometer: DU® 640 Spectrophotometer (Beckman, California, USA), 
Agilent 2100 Bioanalyzer (Agilent Technologies, Germany) 
Stirrer: Magnetic Stirrer Hotplate B212 (J. Bibby Science Products Limited, 
Staffordshire, England), and Stir SB161 (Stuart Scientific Laboratory, Surrey, UK) 
Thermo Block: Dri-block® DB-2A (Techne, Cambridge, UK) 
Ultraviolet trans-illuminator: High Performance Ultraviolet Transluminator (UVP-
Ultra Violet Products, San Gabriel, CA), and Geneflash Syngene Bio Imaging 
(Fisher Scientific- Synoptics Ltd, UK) 
Vortex: WhirliMixerTM (Fisons Scientific Equipment, Leicestershire, UK) 
Water baths: Grant, SBB6, and Y14 (Grant Instruments Ltd, Cambridge, England)  
2.1.9.2 Consumables 
Caterers foil (Morrisons, Anniesland, Glasgow) 
Eppendorf tubes: Flip-top 0.5 ml and 1.5 ml, and screw-top 1.5 ml (Elbkay 
Laboratory Products, Hampshire, UK), and Rnase-free Microfuge Tubes (Ambion, 
Cambridgeshire, UK) 
Filter paper: Qualitative Circles 185 mm Ø (Whatman®, Kent, England) 
Filter tip pipette tips: A range of capacities (10, 20, 200, 1000) µl supplied by 
Rainin Instrument Co (Woburn, MA); for use in setting up PCR reactions 
Fine Tip Pastette Sterile were supplied by Alpha Laboratories (Hampshire, UK) 
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HybondTM-ECL nitrocellulose membrane (Amersham Biosciences, 
Buckingshamshire, UK) 
Hyperfilm ECL (Amersham Biosciences, Buckingshamshire, UK) 
Marvel Dried Skimmed Milk (Premier Beverages, Stafford, UK) 
Parafilm was supplied by Pechiney Plastic Packaging (Menasha WI) 
Petri dishes were supplied by Sterilin (Staffordshire, UK) 
Pipette tips were supplied by Sarstedt (Nümbrecht, Germany) 
Pipette tips RNAse free: 1000 µl and 200 µl supplied by Starlab (Ahrensburg, 
Germany), and 1 µl to 20 µl supplied by Elkay Laboratory Products Ltd 
(Hampshire, England) 
Saran barrier food wrap (Morrisons, Anniesland, Glasgow) 
Scalpel blades: Sterile disposable scalpels (Schwann-Morton , Sheffield, UK) 
Spreaders, L shaped were supplied by VWR International (Lutterworth, UK) 
Sterile plastic containers: Bijoux and Universals (Greiner Bio-One, 
Gloucestershire, UK) 
Syringes (2, 5, 10, 20, 50) ml were supplied by Becton Dickinson 
Syringe filters (0.2 µm and 0.45 µm) were supplied by Sartorius (Hannover, 
Germany); used for sterilising of filtering small volumes of solutions 
Vectashield Mounting Medium with DAPI (Vector Laboratories, Ltd) 
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2.1.10 Buffers and solutions  
Water 
Diethylpyrocarbonate (DEPC) treated RNAse free water was supplied by Ambion, 
Cambridgeshire, UK. Tissue culture grade distilled water was supplied by 
Invitrogen Life Technologies. Ultrapure water (for procedures involving 
recombinant DNA, PCR etc.) was provided by a Milli Q® ultrapure water 
purification system (Millipore Ltd., Watford, UK). An Elix® purification system 
(Millipore Ltd., Watford, UK) was used to supply water for preparation of general 
solutions and media. 
Buffers and solutions 
10x Dry Blot Buffer: 0.5 M Tris base, 0.4 M Glycine, 12.8 mM Sodium Dodecyl 
Sulfate (SDS). Working stock was prepared prior to use at a 1:10 dilution with 
20% (v/v) Methanol. 
10x SDS-PAGE Running Buffer: 0.25 M Tris base, 1.92 M Glycine, 34.7 mM SDS 
10x TBE (Tris-borate-EDTA) Buffer Solution: 0.9 M Tris base, 0.9 M Boric acid,   
23 mM Na2EDTA.  pH 8.2/8.3.  Stored at room temperature. 
10x TBST (Tris-buffered-saline-tween) Buffer Solution: 0.1 M Tris base, 1.5 M 
NaCl, 0.5% Tween-20, adjusted to pH 8.0. 
10x Tris-glycine buffer for electrotransfer of proteins onto membranes (transfer 
buffer): 0.25 M Tris base, 1.92 M Glycine.  Working stock was prepared prior to 
use at a 1:10 dilution with 15% (v/v) Methanol. 
1M Tris HCl: 121 g Tris base, 800 ml dH2O.  Adjusted to desired pH with 
concentrated HCl and made up to 1 L. 
1x Phosphate buffered saline (PBS): 140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 
1.8 mM KH2PO4 (pH 7.3)  
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20x Propidium iodide (PI) stock solution:  made to a working solution of 1 mg/ml 
with ddH2O in a fume cupboard.  This was filtered through a 0.22 µm syringe 
filter, and stored at 4 °C in the dark. 
50x TAE (Tris-acetate-EDTA) Buffer Solution: 2 M Tris base, 50 mM Na2EDTA,    1 
M glacial acetic acid. 
Ammonium persulphate: 10% (w/v) stock solution in ddH2O, freshly made. 
Ethidium bromide: made to a working solution of 3 mg/ml with ddH2O in a fume 
cupboard.  Stored at room temperature in the dark. 
Gel loading buffers: 
1. DNA- 30% Glycerol, 0.25% (w/v) Bromophenol blue, 0.25% (w/v) Xylene 
cyanol, in ddH2O.  Stored at room temperature and used at a 1:5 dilution. 
2. Protein- SDS-PAGE Protein 2x Sample Loading Buffer: 120 mM Tris-HCl, pH 6.8, 
20% (v/v) Glycerol, 5% SDS, 7.4% β-mercaptoethanol, 0.5% (w/v) Bromophenol 
blue in ddH2O. Stored in aliquots at –20 °C. Sample diluted at least 1:2 with 
buffer and heated at 100 °C for 5 minutes prior to loading gel. 
PI Staining solution: 50 µg/ml 20x PI stock solution, 100 U/ml Rnase A in sample 
buffer (1 g/l Glucose in PBS.  This was filtered through a 0.22 µm syringe filter, 
and stored at 4 °C) 
TE Buffer: 10 mM Tris-HCl, 1 mM Na2EDTA adjusted to pH 8.0.  Autoclaved and 
stored at room temperature. 
Whole Cell Lysis Buffer (Marais et al  1993): 20 mM Hepes pH 7.0, 5 mM EDTA, 
10 mM EGTA, 5 mM NaF, 1 mM DTT, 0.4 M KCl, 0.4% (v/v) Triton X-100, 10% (v/v) 
Glycerol.  Stored in aliquots at –20 °C.  Working Whole Cell Extract buffer was 
prepared prior to use by addition of 0.1 µg/ml Okadaic acid, and protease 
inhibitors as follows: 5 µg/ml Aprotinin, 5 µg/ml Leupeptin, 5 µg/ml Pepstatin A, 
1 mM Benzamidine, 50 µg/ml PMSF. 
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Mild stripping solution: prepared fresh by adding 20 ml 2M glycine pH 2.5, 20 ml 
10% SDS to 160 ml dH20  
Sringent sripping solution: 100mM 2-Mercaptoethanol, 2% SDS, and 62.5mM Tris-
HCl pH 6.7 
3.7% paraformaldehyde in PBS: prepared fresh from 16% solution obtained from 
Science Services Ltd) 
0.1 % Triton X-100 in PBS 
10% FBS (Fetal Bovine Serum), 0.5% BSA(Bovine Serum Albumin/) in PBS 
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2.2 Methods 
Many of the methods described here are based on standard protocols, which are 
found in several laboratory manuals (Sambrook et al 1989). 
2.2.1 Growth, manipulation of mammalian cells and cell assays 
All procedures involving mammalian cells were carried out in a laminar flow 
hood using standard aseptic procedures. 
2.2.1.1 Cryopreservation of cells 
Stocks of cells for long-term storage were preserved over liquid nitrogen. Cells 
to be frozen were grown to confluence and removed into a sterile 50 ml 
centrifuge tube (using 1x trypsin-EDTA solution).  Cells were centrifuged at 1000 
rpm for 5 minutes and the supernatant discarded.  The cells were then re-
suspended in freezing medium at a concentration of 2-4 x 106 cells/ml. Freezing 
medium consisted of the DMEM culture medium supplemented with FBS to 50% 
for MEFs, 20% for Hs68 cells and Leiden cells and 10% dimethylsulphoxide (DMSO, 
Sigma Aldrich) as a cryoprotectant. Phoenix cell were frozen down as advised in 
90% FBS and 10% DMSO. The cell suspension was transferred in one millilitre 
aliquots, to labelled cryovials (Nunc cryotubes) and brought to –70 °C at a 
controlled rate of –1 °C per minute using a NALGENE™ Cryo 1 °C Freezing 
container (NALGENE, USA).  The vials were transferred to a liquid nitrogen 
freezer for long-term storage after 24hs. Cell stocks were revived by rapid 
thawing in a 37 °C water bath and maintained following standard techniques 
(described below). 
2.2.1.2 Cell counting 
Cells were counted in a haemocytometer (Bright-Line Hemacytometer, Sigma) as 
follows. Cell pellets were suspended in an appropriate volume of media to allow 
ease of counting in the haemocytometer chamber. A 10 µl volume of the cell 
suspension was then diluted 1:1 in trypan blue stain 0.4% (Invitrogen Life 
Technologies) and incubated at room temperature for 1 minute. The suspension 
was then introduced to the haemocytometer chamber and cell counts made 
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using an inverted microscope with a 4x or 10x objective. Cells lying on the top 
and right hand perimeter of each large square (1 mm) were included; those on 
the bottom or left hand perimeters were excluded. Cell concentrations 
(cells/ml) were calculated by multiplying the mean numbers of cells per large 
marked square by 2 x 104 to account for the volume of the haemocytometer 
chamber and to correct for the dilution factor. Dead cells were differentiated by 
uptake of the trypan blue stain. 
2.2.1.3 Maintenance of mammalian adherent cell lines 
All cell lines (MEF, Hs68, Leiden, Phoenix) form adherent monolayers in culture, 
and were cultured in 75 cm2, 162 cm2 tissue culture flasks or 100mm cell culture 
dishes kept at 37 °C in a humidified incubator containing 5% (v/v) CO2.  Cells 
were cultured in 20 ml, 50 ml or 10 ml DMEM (Section 2.1.2.2) supplemented 
with 10% FBS, 100 international units (IU)/ml penicillin, 100 µg/ml streptomycin, 
and 2 mM glutamine. Cultures were passaged, every 3-4 days, when they have 
reached approximately 80% of confluence. To split cultures the medium was 
decanted from the cell monolayer and cells washed with 10 ml of warm PBS.  
Then, 3 ml to 5 ml of 1x trypsin-EDTA solution was added, cells were incubated 
at  37 °C for 5 to 15 minutes and observed by microscopy to ensure cell layer 
dispersal. The detached cells were then washed in fresh medium, pelleted by 
centrifugation at 1000 rpm for 5 minutes, prior to resuspending in fresh medium 
and seeding new tissue culture flasks. 
2.2.1.4 Retroviral transduction 
Phoenix cells were plated at 5 x 106 in 10 cm dishes and incubated overnight at 
37°C. Transfections of Phoenix cells with relevant retroviral plasmids were 
performed using Superfect Transfection Reagent (Qiagen) according to the 
manufacturer's protocol for transient transfection of adherent cells. Viral 
supernatants were harvested after 48 h incubation at 37°C and filtered through 
0.45 µm filters (Sartorius). The media was replaced and the cells incubated for a 
further 24 h before retrieval of a second viral supernatant. Each 10 ml of 
supernatant was supplemented with 4µg/ml polybrene and split between two 10 
mm plates of target cells plated at 8 x 105 per dish 24 h earlier. Cells were 
incubated with the appropriate first harvested supernatant overnight and with 
Kamil K. Wolyniec, 2008   Chapter 2,77  
the second harvested supernatant during the day for 8 h. Infected cells were 
then incubated overnight in normal growth medium after which selection was 
applied using puromycin (Sigma) at 2ug/ml for 4 days. The efficacy of the 
selection protocol was confirmed using untransduced cells which all died under 
these selection conditions. Following selection (designated day 0), transduced 
cells were replated for experimental purposes. Puromycin selection was 
maintained throughout. 
2.2.1.5 Growth curves 
MEFs were plated at day 0 (day following 4 days of puromycin selection) at 2.5 x 
104/well in 12 well plates in selection DMEM medium containing 2µg/ml 
puromycin (2ml/well). Live cell counts were carried out in triplicate using a 
haemocytometer and trypan blue exclusion to assess viability. Media changes 
were carried out every 3-4 days. Graphs were plotted using Sigma plot and 
significance values determined by Student’s t-test. Error bars relate to standard 
deviations. 
2.2.1.6 Senescence-Associated-β-galactosidase 
SA-β-gal activity was detected as previously described (Serrano et al., 1997). 
Cells were washed once with PBS (pH 7.2), fixed with 0.5% glutaraldehyde (PBS 
pH 7.2) and washed in PBS (pH 7.2) supplemented with 1mM MgCl2. Cells were 
stained in X-Gal solution (1mg/ml [Invitrogen], 0.12 mM  K3Fe[CN]6 and K4[Fe]CN6 
and 1mM MgCl2 in PBS at ph 6.0) overnight at 37°C. 
2.2.1.7 Cell cycle analysis 
Hs68s plated at 1 x 106 cells/10cm dish were sampled for flow cytometry on day 
7 post-selection. The protocol for cell cycle analysis has been described 
previously (Blyth et al 2006). For simultaneous labelling with bromodeoxyuridine 
(BrdUrd), cells were incubated at 37oC for 3-hours with 10µM BrdUrd (Sigma) 
then rinsed three times in warmed PBS. After harvesting, cells (106 ) were 
washed in 2ml cold PBS, resuspended in 0.2ml cold PBS and fixed for at least 30 
minutes in 2mls 70% ethanol at 4oC.  BrdUrd incorporation was identified using 
FITC-conjugated anti-BrdUrd antibody (In situ Cell Proliferation Kit, Roche) 
according to manufacturers’ instructions. Samples were resuspended in PBS 
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containing 10µg/ml PI and analysed on a Beckman Coulter Epics XL.  The analysis 
was performed using EXPO32 software 
2.2.1.8 Analysis of intracellular ROS 
To assess the generation of intracellular ROS levels at day 7 of cell culture 
period, cells were incubated for 20 min in the dark at 37oC with 15µm DCF-DA 
(Calbiochem). Then cells were washed in PBS, trypsinised and DCF fluorescence 
was measured using a flow cytometer (Beckman Coulter Epics XL) with excitation 
at 488 nm and emission at 530 nm 
2.2.1.9 Visulisation of ROS by confocal laser microscopy 
Cell were grown on plated on poly-L-lysine-coated glass chamber slides (Section 
2.1.2.4) and at day 7 of cell culture period were incubated for 20 min in the 
dark at 37oC with 15µm DCF-DA (Calbiochem). Then cell were washed in PBS and 
fixed with freshly prepared 4% paraformaldehyde (in PBS) for 10 minutes and 
subsequently coverslips were mounted in glycerol mixed with water (1:1). DCF 
fluorescence was detected using a FITC filter and fluorescent images were 
captured using a confocal microscope (Leica DM IRE2) (Section 2.1.9.1) 
2.2.2 Recombinant DNA techniques 
2.2.2.1 Storage and growth of bacteria 
Plasmid DNA was maintained and stored in the E.coli strain One Shot Chemically 
Competent cells®. Glycerol stocks were prepared from transformed bacteria and 
their long-term storage as outlined below. 
The desired bacterial culture was streaked onto a LB agar plate (Section 2.1.3.4) 
as the plasmid conferred ampicillin resistance the medium was supplemented 
with 100 µg/ml ampicillin. The plate was then incubated overnight at 37 °C and 
the following day single colonies were picked using a sterile pipette tip into a 
sterile universal containing 5 ml LB medium supplemented with 100 µg/ml 
ampicillin. Cultures were incubated at 37 °C overnight in a horizontal orbital 
incubator at 220 rpm. Confirmation that overnight cultures were derived from 
bacteria containing the correct plasmid was achieved by DNA isolation and 
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restriction digestion.  Glycerol stocks were prepared by addition of 150 µl of 
glycerol to 850 µl of culture broth to produce a 15% glycerol mixture. Glycerol 
stocks were then stored at –70 °C.  Bacterial stocks were revived for subsequent 
work by using a sterile platinum loop dipped into the glycerol stock and streaked 
onto an agar plate as outlined above. 
2.2.2.2 Extraction and purification of plasmid DNA 
Small scale plasmid preparation 
Plasmid DNA was isolated using a modification of the alkaline lysis technique 
described by Birnboim and Doly (Birnboim and Doly 1979). 
Large-scale plasmid preparation 
Large quantities of highly pure, endotoxin free plasmid were prepared using the 
EndoFree® Plasmid Maxi Kit (Qiagen,UK). 50 µl of glycerol stock from the desired 
transformant was used to seed an overnight multiplier culture in 100 ml of LB 
medium incubated at 37°C with shaking at 220 rpm. These exponentially growing 
bacteria were harvested by centrifugation of the culture in 50 ml sterile 
centrifuge tubes at 4000 g for 20 minutes at 4°C. The remainder of the protocol 
was performed according to the manufacturers instructions. DNA was stored at –
20°C. 
2.2.2.3 Determination of nucleic acid concentration and 
quality 
Determination by spectrophotometry 
Nucleic acid samples were diluted either at 1:20 by addition of 25 µl of 
resuspended nucleic acid in 475 µl of dH2O, or 1:100 by addition of 5 µl of the 
resuspended nucleic acid in 495 µl of dH2O. Optical density readings were taken 
at 260 nm and 280 nm, using dH2O as a blank. An optical density reading of 1.0 
at 260 nm corresponds to an approximate nucleic acid concentration of 50 µg/ml 
for double stranded (ds) DNA and 40 µg/ml for single stranded (ss) RNA. The 
ratio of the readings taken at 260 nm and 280 nm (OD260/OD280) was used to give 
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an estimate of the purity of the nucleic acid. Pure preparations of DNA and RNA 
have an OD260/OD280 of 1.8 and 2.0 respectively; a lower value suggests 
contamination, typically with protein or phenol. 
Estimation of double stranded DNA concentration and quality by agarose gel 
electrophoresis. 
This method was used when there were insufficient amounts of dsDNA for 
spectrophotometry, or when purity of a particular DNA fragment needed to be 
investigated. The concentration of dsDNA was determined by running the sample 
on an agarose gel electrophoresis (Section 2.2.3.5), and the intensity of the 
fluorescence of the unknown DNA was compared to that of a known quantity of 
the appropriate size marker (φX174 RF DNA/HaeIII fragments or Low DNA Mass™ 
Ladder) following staining with ethidium bromide and visualisation by UV 
transillumination. Smearing of a DNA band indicated degradation of the sample 
and resulted in exclusion of that DNA from further analysis. 
2.2.2.4 Restriction endonuclease digestion 
Typically, 1 µg of DNA was digested in a 20 µl reaction mix containing the 
appropriate buffer for the restriction endonuclease(s) and 10 units of the desired 
restriction enzyme. The reactions were incubated at 37 °C for a minimum of 1 
hour. Where the isolation of restriction fragments was required, larger 
quantities of DNA, generally 10 µg, were digested with 50 units of enzyme, and 
the reaction volume and others components increased proportionally. In this 
case, reactions were incubated at 37 °C overnight. 
2.2.2.5 Electrophoresis of DNA 
Agarose gel electrophoresis 
DNA fragments of 1.0 kb to 10 kb were separated by agarose gel electrophoresis 
using a Biomax QS710 Horizontal Unit (Scientific Imaging Systems – Eastman 
Kodak Company, New York, USA) or Sub-Cell GT Submerged Horizontal Agarose 
Gel Electrophoresis Systems (Bio-Rad, Hertfordshire, UK).  Typically, 0.6 g to 0.9 
g or 2 g to 3 g agarose was added to 60ml or 200ml 1x TAE buffer, respectively; 
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melted in a microwave for 1 minute to 2 minutes and mixed to produce a 1% to 
1.5% gel (w/v).  Once the gel mix had cooled to 55 °C, the gel was poured into a 
100 mm x 65 mm or 150 mm x 200 mm gel support in its casting tray and an 
appropriate gel comb (eight, twelve or twenty well) inserted. The gel was 
allowed to solidify before transferring to an electrophoresis tank; the gel was 
immersed in 1x TBE or 1x TAE buffer and the comb carefully removed. Gel 
loading buffer (Section 2.1.1) was added to DNA samples and samples loaded 
into the wells using a micropipette. Known concentrations of DNA size markers 
were prepared similarly and run alongside the samples in order to gauge both 
product size and yield.  Gels were run at 100 volts for 60 to 120 minutes, then 
removed from the gel apparatus and stained in buffer solution containing 0.5 
µg/ml ethidium bromide for 20 minutes. Following destaining for 20 minutes in 
dH2O, gels were visualised on a medium wave UV transilluminator (UVP Inc. and 
Geneflash Syngene Bio Imaging) and photographed using black and white Video 
Graphic Printer Sony UP-895MD (Fisher Scientific- Synoptics Ltd, UK). 
2.2.2.6 Purification of restriction enzyme fragments 
Purification of the DNA fragments required for construction of recombinant 
plasmids was purified from agarose gels using the QIAquick® Gel Extraction Kit 
(Qiagen). The DNA fragments of interest were cut from an agarose gel using a 
clean scalpel blade and extracted according to the manufacturers instructions. 
2.2.2.7 Subcloning the cDNAs of RUNX1 mutants (K83N, 
T161A), TEL-RUNX1 and AML1a 
Preperation of relevant inserts 
Inserts containing cDNAs of RUNX1 mutants (K83N and T161A) were excised from 
the pGFP retroviral vectors (kind gift from Dr. Carol Stocking, Hamburg) by 
digestion with NotI. After fragment separation and purification by 
electrophoresis on 1% Agarose TBE gel, the NotI restriction fragments were 
extracted using the QIAquick Gel Extraction Kit (Qiagen) (Section 1.2.2.6) and 
suspended in 30µl of TE buffer. The overhanging 5’ ends (NotI) of the obtained 
fragments were blunt ended using a Klenow Fill-in Kit (Klenow) according to 
manufacturers protocol.  
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The cDNA insert of TEL-RUNX1 was excised from pcDNA3 vector (kindly provided 
by Dr. Olivier Bernard, Paris), by digestion with EcoRI. After fragment separation 
and purification by electrophoresis on 1% Agarose TBE gel, the EcoRI restriction 
fragments were extracted using the QIAquick Gel Extraction Kit (Qiagen) 
(Section 1.2.2.6) and suspended in 30µl of TE buffer 
The cDNA insert of AML1a was excised from pCR®II-TOPO® by digestion with 
EcoRI (The AML1a DNA had been previously PCR amplified from thymus and 
cloned into EcoRI site using Invitrogen TOPO TA Cloning® kit by Dr. Monica 
Stewart from this laboratory). After fragment separation and purification by 
electrophoresis on 1% Agarose TBE gel, the EcoRI restriction fragments were 
extracted using the QIAquick Gel Extraction Kit (Qiagen) (2.1.4) and suspended 
in 30µl of TE buffer 
Ligation of vector and insert DNA 
The quantity of vector and insert DNA used in ligations was calculated to 
produce a molar ratio between 1:3 using the equation: 
X ng of vector x Y kb of insert x insert : vector ratio = ng of insert required Z kb 
of vector 
Vector DNA (pBabe puro) was linearised using appropriate restriction enzyme(s). 
For the blunt-end cloning of K83N and T161A RUNX1 mutants pBabe puro was cut 
with SnaBI whereas for cloning of AML1a and TEL-RUNX1 pBabe puro was cut 
with EcoRI. To prevent re-circularisation of the vector DNA following digestion 
with a single enzyme, both 5’-phosphate groups were dephosporylated with  5 
units of antarctic phosphatase according to the manufacturer protocol (New 
England Biolabs) at 37 °C for 15 minutes. Generally, 50 ng of vector DNA and a 
three fold molar excess of insert DNA were ligated, using Quick LigationTM Kit 
(New England Biolabs) according to manufacturer protocol. A control ligation, 
omitting insert DNA was set up in parallel to the above, in order to check for 
‘background’ when performing subsequent bacterial transformations. 
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Transformation of bacteria with plasmid DNA 
All transformations included a positive control using supercoiled plasmid DNA (eg 
pUC19 10 pg/ml) to monitor the efficiency of the transforming bacteria and a 
ligation control (vector DNA, no insert) to monitor the background rate of 
transformation due to recircularisation of vector DNA. 
2 µl of a 1:5 dilution of ligation mix, 2 µl of neat ligation mix or 2 µl of TA 
ligation mix were added to 50 µl of One ShotTOP10 Chemically Competent E. 
coli cells (Invitrogen). Cells and DNA were mixed by gentle tapping to avoid 
damage to the bacterial cells. In all cases the reactions were then incubated on 
ice for 30 minutes. Cells transformed with ligation mix were subsequently heat 
shocked at 42 °C for exactly 40 seconds and 30 seconds respectively, and then 
returned to ice. 250 µl of SOC medium (Invitrogen) was then added and 
incubated at 37 °C for 1 hour with shaking at 220 rpm. Cells (50 µl and 200 µl) 
were plated onto LB plates containing 100 µg/ml ampicillin. Plates were 
incubated overnight at 37 °C. 
Screening for transformants with the right orientation of insert 
All plasmid strains used in this project conferred ampicillin resistance, allowing 
selection and maintenance of transformed bacteria with ampicillin 
supplemented media. 
The DNA from 10-20 clones was prepared and used for restriction fragment 
length polymorphism analysis to find clones with the appropriate orientation of 
insert. SalI restriction analysis were performed for K83N and T161A mutants of 
RUNX1 and HindIII restriction analysis for TEL-RUNX1 and AML1a.  
2.2.3 DNA sequence analysis (automated sequencing) 
2.2.3.1 Sample preparation 
DNA sequencing was carried out using the Big Dye® Terminator Version 1.1 Cycle 
Sequencing Kit (Applied Biosystems). Generally, 200 ng to 500 ng of highly 
purified DNA template was added into the cycle sequencing reaction containing 
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3.2 pmol of sequencing primers (Table 2), 0.5x sequencing buffer (80 mM Tris-
HCl, 2 mM MgCl2) and 4 µl of cycle sequencing mix (Big Dye
® Terminator Version 
1.1 Cycle Sequencing Kit, Applied Biosystems). Samples were prepared in the 
PTC-220 DNA Engine Dyad® Cycler (MJ Research Incorporated) employing 25 
cycles of amplification, each cycle consisting of a denaturing step at 96 °C for 30 
seconds followed by an annealing step at 50 °C for 15 seconds, and an 
elongation phase at 60 °C for 4 minutes. Sequencing products were purified by 
precipitation using ethanol (80%) at room temperature for 15 minutes. Pelleted 
DNA (14000 rpm for 20 minutes) was washed in ethanol (70%) and repelleted 
(14000 rpm for 10 minutes). After all the ethanol was removed, the pellet was 
dried at 90 °C for 1 minute, and was subsequently resuspended in 25 µl of Hi-Di 
Formamide (Applied Biosystems). 
2.2.3.2 Sample sequencing and evaluation 
Samples were loaded into 96 well plates and run on the ABI PRISM® 3100 Genetic 
Analyzer (PE Applied Biosystems, UK) under standard sequencing conditions for 
generation of automated sequence data. Electrophoresis on the ABI PRISM® 3100 
Genetic Analyzer was performed using 36 cm and 80 cm capillaries which read 
up to 500 nucleotides and 950 nucleotides respectively, with a 98.5% base calling 
accuracy and less than 2% ambiguity. A computational software ClustalW was 
used for sequence alignments (http://www.ncbi.nlm.nih.gov/) 
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Table 2. Sequencing primers. 
Primer 
name 
Primer sequence Description 
pBabe 5’ 5’d[CTTTATCCAGCCCTCAC]3’ Forward sequencing 
primer from pBabe 
puro vector 
pBabe 3’ 5’d[ACCCTAACTGACACACATTCC]3’ Reverse sequencing 
primer from pBabe 
puro vector 
Runx1 xd5 5’d[GCAGAAACTAGATGATCAGACC]3’ Forward sequencing 
primer from exon 5 
of Runx1 
Runx1 xd3 5’d[CCTCAAAGTCAGATGCAG]3’ Reverse sequencing 
primer from exon 5 
of Runx1 
2.2.4 Protein analysis 
2.2.4.1 Protein extraction 
Whole cell extracts, from cells grown in tissue culture were prepared for 
western blot analysis according to the method of Marais et al (Marais et al 1993).  
All procedures were performed at 4 °C. Typically, cells were washed twice with 
ice-cold PBS, drained thoroughly, lysed in 100 µl working whole cell lysis buffer 
(Section 2.1.10) per 106 cells or 60 mm dish and rotated for 10 minutes.  The 
crude extract was cleared in a bench top centrifuge at 14000 rpm for 30 minutes 
and the supernatant transferred to a fresh pre-cooled eppendorf.  Extracts were 
quantitated as described below, and stored at –70 °C. 
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2.2.4.2 Estimation of protein concentration 
In order to estimate protein yields, a Bio-Rad Protein Assay (Bio-Rad), based on 
the method of Bradford was used, in which a differential colour change of a dye 
occurs in response to various concentrations of protein (Bradford 1976). 
A protein standard (bovine serum albumin, BSA) was diluted with dH2O to 
concentrations ranging from 0.025 to 0.8 mg/ml to allow the production of a 
standard curve each time the assay was performed.  Aliquots of protein for 
quantification were diluted in order to give a concentration in the above range.  
The dye reagent was prepared by addition of 4 volumes of ddH2O to 1 volume of 
Dye Reagent Concentrate (Bio-Rad) and filtration through a Whatman #1 to 
remove particulates. Samples were diluted 1/500 in diluted dye reagent, and 
incubated in sterile polystyrene cuvettes at room temperature for 5 minutes to 1 
hour. OD595 was determined against the reagent blank. The absorbance of the 
protein standards was used to construct a standard curve from which an 
approximate concentration of the unknown samples could be read. 
2.2.4.3 SDS - PAGE of proteins 
The separation and analysis of proteins was facilitated by one dimensional 
denaturing discontinuous gel electrophoresis, as originally described by Laemmli 
(Laemmli, 1970). 
Standard SDS-PAGE gels (13.8 cm x 13 cm) were formed and run using the AE-
6200 Slab EP Chamber, and AE-6220 Slab EP Chamber, for two gels (Atto 
Incorporation). The separating gel was poured to a depth of approximately 10 
cm; consisting of 16.7 ml 30%: 0.8% w/v acrylamide/bisacrylamide (giving a 10% 
gel), 13.4 ml dH2O, 18.75 ml 1 M Tris-HCl (pH 8.8), 500 µl 10% SDS, 375 µl 10% 
APS and 20 µl TEMED. This was overlain with ddH2O-saturated butanol and 
allowed to polymerise.  The butanol was then poured off and the surface of the 
separating gel rinsed with ddH2O. Excess water was removed with a sheet of 
3mm Whatman filter paper, and the stacking gel poured; consisting of 3.4 ml 
30%: 0.8% w/v acrylamide/bisacrylamide, 13.6 ml dH2O, 2.5 ml 1 M Tris-HCl (pH 
6.8), 200 µl 10% SDS, 200 µl 10% APS and 20 µl TEMED. A 14 well comb was 
inserted and the gel allowed polymerising. Gels were run in 1x running buffer, 
Kamil K. Wolyniec, 2008   Chapter 2,87  
and samples were treated as for mini SDS-PAGE gels (see above). Moreover, 14 µl 
of a protein molecular weight standard (Precision Plus ProteinTM Standards, Bio-
Rad) was loaded in one or both outer wells to allow estimation of the size of 
sample proteins. 
Standard SDS-PAGE gels were electrophoresed 230 volts to 250 volts for 2-3 hours 
until the bromophenol blue dye reached the bottom of the separating gel. The 
gel was then removed from the glass plates, the stacking gel discarded, and the 
protein bands detected by immunodetection (Section 2.2.4.5). 
2.2.4.4 Electroblotting 
After polyacrylamide resolving gel electrophoresis proteins were transferred to a 
nitrocellulose membrane by electroblotting: 
Standard SDS-PAGE gels were removed from the glass plates, and the resolving 
gel equilibrated in 1x dry blot buffer with 20% methanol (Section 2.1.10) for 15 
minutes at room temperature.  The gel was covered in pre-wetted nitrocellulose 
membrane (1x dry blot buffer) and sandwiched between 12 pieces of Whatman 
3MM rinsed in 1x dry blot buffer.  The sandwich was turned over and placed on 
the semi dry blotter (Trans-blot® SD Semi-Dry Transfer Cell, Bio-Rad). Air 
bubbles were removed and transfer effected at 20 volts for 2 hours.  Molecular 
weight marker positions were highlighted and the membrane stored at 4 °C. 
2.2.4.5 ECL detection 
The detection of proteins by immunoblotting (Western Blotting) is a rapid and 
sensitive technique that exploits the inherent specificity of antigen recognition 
by antibodies (Towbin et al 1979):  
Hybond-ECL nitrocellulose membrane (Amersham Biosciences) was immersed in 
1x TBST buffer (Section 2.1.10) containing 5% low fat dried milk (Marvel - 
Premier Beverages, Stafford, UK) and left overnight at 4 °C, to block non-
specific binding sites. The membrane was rinsed briefly with 1x TBST buffer, 
washed once for 15 minutes, and then twice for 10 minutes, with shaking at 
room temperature in 1x TBST buffer. It was then incubated with the primary 
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antibody, at a pre-determined dilution in blocking buffer (either 5% low fat dried 
milk TBST or, 5%BSA TBST), with shaking. This was followed by washing three 
times in 1x TBST buffer for 10 minutes, with shaking at room temperature, prior 
to incubating with secondary antibody (HRP labelled), appropriately diluted in 
5% low fat dried milk TBST, for 1 hour, at room temperature, with shaking. The 
membrane was washed as above before detection using the ECLTM Western 
Blotting Detection Reagents (Amersham Biosciences). The Enhanced 
Chemiluminescence system (ECL) is a light-emitting-non-radioactive method for 
detecting immobilized specific primary antibodies using secondary antibodies 
conjugated with horseradish peroxidase (HPR-linked secondary antibodies). Light 
emission is generated by the HPR/hydrogen peroxide catalysis of luminal to an 
excited oxidated state, and it is dramatically enhanced in the ECL system by 
chemical enhancers such as phenol (Durrant et al 1990). Briefly, an equal volume 
of detection reagent A was mixed with reagent B (typically 4 ml each). Excess 
buffer was drained from the membrane and the detection solution was pipetted 
onto the surface of the membrane to which the protein are bound. After 2-5 
minutes incubation at room temperature, excess reagent was drained from the 
membrane, which was then wrapped in plastic film. The membrane was exposed 
to blue-light sensitive autoradiography film (Hyperfilm ECL, Amersham 
Biosciences) for seconds or minutes, before developing the film in an automated 
processor (SRX-101A Compact X4, Xograph Imaging Systems). 
2.2.4.6 Stripping membranes 
Antibodies and substrate complexes could be removed from the membranes 
allowing for reprobing of the same blot with different antibodies. The 
membranes were stripped by submerging in either mild stripping buffer or 
stringent stripping buffer (Section 2.1.10), and incubating at room temperature 
for 1h or at 50˚C for 30 minutes with agitation. Following this incubation the 
membranes were washed three times for 10 minutes with PBS at room 
temperature, and blocked overnight in 5% milk TBST, before adding the desired 
antibody 
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2.2.5 Confocal laser scanning microscopy 
Cells were plated on poly-L-lysine-coated glass chamber slides (Section 2.1.2.4) 
and fixed for 15 min with freshly prepared 4% paraformaldehyde (in PBS). After 
washing with PBS, cells were permeabilized for 15 min with PBST (PBS with 0.1% 
Triton X-100). The specimens were blocked with 10% FCS, 0.5% BSA in PBS for 30 
min and incubated overnight in 4°C with a relevant primary antibody diluted in 
blocking buffer. After washing x3 in 10% FCS, 0.5% BSA in PBS, cells were stained 
with FITC-conjugated secondary antibody (1:100, Jackson Immuno Research 
Laboratories) (Section 2.1.1) for 45 min at room temperature. Finally, cells were 
washed 3x in PBS and coverslips were mounted in VectaShield containing DAPI 
(4’, 6’-diamidino-2-phenylindole) (Vector Laboratories) (Section 2.1.9.2). 
Fluorescent images were captured using a confocal microscope (Leica DM IRE2) 
(Section 2.1.9.1) 
2.2.6 Statistical significance  
Statistical significance for the data presented in this thesis was typically 
calculated using a Students-T-test to give a significance value (p). This was 
carried out using Sigma Plot Software (T-test function). The cut off for all 
experiments was taken as 0.05, therefore if two sets of data return a p value of 
<0.05 there is a less than 5% chance that the result observed is due to chance, 
and the two groups are therefore statistically significantly different 
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3 Structural requirements for RUNX1 induced 
senescence 
3.1 Introduction 
Previous work in this laboratory established that RUNX1 induces senescence in 
primary murine embryonic fibroblasts (MEFs) (Wotton et al 2004), but the 
structural components of RUNX1 necessary to effect this cellular response have 
not been examined. To investigate this question various mutated or deleted 
forms of RUNX1 were used to dissect out which functional domains were 
required for the induction of premature senescence by RUNX1. It was also 
important to investigate whether RUNX1 retains potential to induce premature 
senescence in human primary fibroblasts and hence if it can be regarded as a 
universal phenomenon caused by ectopic expression of RUNX1. 
3.2 RUNX1 requires DNA binding and CBFβ interaction to 
induce senescence in murine embryonic fibroblasts 
To test whether RUNX1 binding to DNA and heterodimerisation with CBFβ are 
required for the induction of premature senescence, two mutated forms of 
RUNX1 were used in the MEF system. The DNA-binding mutant of RUNX1 (K83N), 
which was identified in a retrospective genetic study of patients with 
myeloblastic leukaemias (Matheny et al 2007; Osato et al 1999) and another 
point mutant, T161A, which was reported to be defective in  heterodimerization 
with CBFβ (Matheny et al 2007; Zhang et al 2003b), MEFs were transduced with 
these mutants of RUNX1 (K83N and T161A), wild type RUNX1 or the empty vector 
(here also referred to as pBabe) via retroviral mediated gene transfer. Following 
infection, cells were kept under puromycin selection for 4 days from which point 
(day 0) monitoring of their proliferative properties using viable cell counts was 
started. All the proteins were expressed at similar levels as determined by 
Western blot (Figure 3.1a). As previously reported MEFs expressing RUNX1 
displayed obvious growth suppression immediately after selection (pBabe vs 
RUNX1 day 10 p≤0.00005) (Figure 3.1b). RUNX1 mediated growth arrest was 
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accompanied by morphological alterations indicative of cellular senescence 
whereby most cells carrying RUNX1 became flat and enlarged between day 2 and 
4 of the culture period. Senescence associated-β-galactosidase (SA-β-Gal) was 
detected at day 7 in virtually every cell (Figure 3.1c). By contrast, cells 
expressing the mutants of RUNX1 continued to proliferate although not as 
rapidly as empty vector control cells (K83N vs RUNX1 day 10 p≤0.00005; T161A vs 
RUNX1 day 10 p≤0.005) (Figure 3.1b). Furthermore, they displayed no 
morphological changes and expressed no SA-β-Gal (Figure 3.1c). The puro-
controls and cultures expressing the mutants of RUNX1 reached high cell 
densities and showed some background SA-β-Gal staining but this was not 
associated with single cells and was not as intense as the specific intracellular 
staining seen in large, flattened senescent cells. Indeed it has been previously 
reported that cellular stress, unrelated to senescence such as high levels of 
confluency in culture can cause positive SA-β-Gal reaction (Severino et al 2000). 
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Figure 3.1 DNA (K83N) and CBFβ (T161A) binding mutants of RUNX1 fail to 
induce senescence-like growth arrest in murine embryonic fibroblasts 
Cells were transduced with retroviral vectors expressing RUNX1, K83N, T161A or 
control vector (pBabe) and selected for 4 days in puromycin. (a) The expression 
of RUNX1 was measured by immunoblotting lysates from MEFs containing an 
empty vector (pB), RUNX1 (RX) or RUNX1 mutants (K83N and T161A) on day 7 
post-selection using anti-AML1/Runx1 (3900, Active Motif) (b) Representative 
growth curves showing viable cell numbers corresponding to cell populations 
containing control vector (pBabe), RUNX1, K83N or T161A. Each experiment was 
performed three times and each time point was determined in triplicate 
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Figure 3.1 continued 
(c) SA-β-Gal staining of cells containing control vector (pBabe), RUNX1, K83N or 
T161A (day 7 post-selection) 
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3.3 RUNX1 requires DNA binding and CBFβ interaction to 
induce senescence in human primary fibroblasts 
Fundamental differences in the requirements for the senescence phenotype in 
mouse and human cells have been reported (Itahana et al 2004; Campisi, 2005), 
therefore it was important to address the question of whether the ability of 
RUNX1 to induce premature senescence could be recapitulated in human cells, 
indicating a general feature of RUNX1 overexpression. To address this issue, 
Hs68 human neonatal foreskin fibroblasts expressing the ecotropic murine 
leukaemia virus receptor were employed (Brookes et al 2002). This enabled the 
same retroviral system as for murine cells to be used. Hs68 cells were infected 
with retroviruses containing RUNX1, the mutants (K83N and T161A) or control 
vector (pBabe) and selected with puromycin. Western blotting confirmed that all 
the introduced constructs were expressed at similar levels (Figure 3.2a). 
Interestingly, it also revealed that the endogenous RUNX1 levels in these cells 
were quite high and could be readily detected in control vector expressing cells 
(Figure 3.2a). Ectopic expression of RUNX1 in human neonatal foreskin 
fibroblasts resulted in a growth arrest as determined by analysis of growth curve 
data (pBabe vs RUNX1 day 9 p≤0.0001) (Figure 3.2b) and SA-β-Gal staining was 
detected by day 7 (Figure 3.2c). These cells were enlarged and flattened, 
although not to the same extent as was observed in murine cells. The two 
mutants of RUNX1 failed to cause a proliferative arrest (K83N vs RUNX1 day 9 
p≤0.0005; T161A vs RUNX1 day 9 p≤ 0.005) (Figure 2b) and did not induce SA-β-
Gal activity nor any change to the enlarged and flattened cellular morphology 
characteristic of senescence (Figure 3.2c). These results indicate that high 
affinity binding to DNA is absolutely critical for RUNX1 to elicit the senescence 
response in human cells. However unlike in the primary mouse cells, Hs68 
expressing T161A mutant did not proliferate as well as K83N mutant (K83N vs 
T161A day 9 p≤0.005) (Figure 3.2b) despite similar levels of expression (Figure 
3.2a) 
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Figure 3.2 The ability of RUNX1 to induce senescence-like growth arrest in 
human neonatal foreskin fibroblasts is impaired in K83N and T161A mutants 
Cells were transduced with retroviral vectors expressing RUNX1, K83N, T161A or 
control vector (pBabe) and selected for 4 days in puromycin. (a) The expression 
of RUNX1 was measured by immunoblotting lysates from Hs68 cells containing 
empty vector (pB), RUNX1 (RX) or RUNX1 mutants (K83N and T161A) on day 7 
post-selection using anti-AML1/Runx1 (3900, Active Motif) (b) Representative 
growth curves showing viable cell numbers corresponding to cell populations 
containing control vector (pBabe), RUNX1, K83N or T161A. Each experiment was 
performed three times and each time point was determined in triplicate 
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Figure 3.2 continued 
 (c) SA-β-Gal staining of cells containing control vector (pBabe), RUNX1, K83N or 
T161A (day 7 post-selection) 
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3.4 The C-terminal transcriptional activation/repression 
domain of RUNX1 is essential for induction of 
senescence in human primary fibroblasts 
AML1a is a short isoform of RUNX1 (250 amino acids), with a large deletion that 
includes the C-terminal transactivation domain (Miyoshi et al 1991, Miyoshi et al 
1995). It has been shown to antagonise wt RUNX1 in vitro and may be important 
for leukaemogenesis and/or myeloid cell differentiation (Tanaka et al 1995). 
AML1a has no transactivational function by itself, but inhibits the transcriptional 
activity of wt RUNX1 by competing for the DNA sequence of target genes with a 
higher affinity (Tanaka et al 1995). Overexpression of AML1a inhibits the myeloid 
terminal differentiation of the myeloid precursor lineage 32Dcl3 induced by 
granulocyte-colony stimulating factor (G-CSF) and importantly levels of AML1a 
are commonly elevated in AML patients (Tanaka et al 1995).  
The RUNX1 protein has a number of transcriptional activation and repression 
domains in the C-terminal region (Aronson et al 1997; Kanno et al1998a). The 
effect of overexpressing the C-terminal truncation isoform, AML1a, in human 
fibroblasts was examined. Retroviral mediated gene transfer was employed to 
introduce control vector (pBabe) or AML1a into Hs68 cells. The AML1a expressing 
cells proliferated almost as well as control cells (pBabe vs AML1a day 6 p≥0.05) 
and displayed no features of senescence as determined by lack of staining for 
SA-β-Gal and lack of characteristic alterations to the cellular morphology (Figure 
3.3). These data demonstrate the requirement for C-terminal transactivation 
and/ or repressor domains in senescence induction by RUNX1 in Hs68 cells.  
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Figure 3.3 C-terminal transactivation/repression domain of RUNX1 is 
required to induce senescence in Hs68 cells 
Cells were transduced with retroviral vectors expressing AML1a or control vector 
(pBabe) and selected for 4 days in puromycin. (a) Representative growth curves 
showing viable cell numbers corresponding to cell populations containing control 
vector (pBabe) or AML1a. Each experiment was performed three times and each 
time point was determined in triplicate. (b) The expression of AML1a was 
measured by immunoblotting lysates from Hs68 cells containing empty vector (pB) 
or AML1a on day 7 post-selection using anti-Runx (D207-3, MBL) (c) Lack of SA-
β-Gal staining of cells containing control vector (pBabe), or AML1a (day 7 post-
selection) 
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3.5 Discussion 
In this study RUNX1 was clearly demonstrated to require both intact DNA binding 
activity and CBFβ interaction, allowing high affinity binding to the target DNA 
sequences to drive premature senescence. Moreover the ability of RUNX1 to 
induce senescence seems to be a general feature as it is observed in both human 
primary fibroblasts and murine primary fibroblasts. Furthermore, neither the 
K83N DNA binding mutant nor the T161A CBFβ interaction mutant was able to 
induce senescence in Hs68 cells or MEFs, although in the higher proliferating 
human cells, the T161A CBFβ mutant produced more dramatic reduction in the 
rate of proliferation than in the MEFs. Could this represent a difference between 
the human and mouse system? Does this demonstrate a greater dependence on 
CBFβ heterodimerisation to drive senescence by RUNX1 in the murine cells? 
Perhaps this observation reflects higher affinity of CBFβ for binding to RUNX1 in 
MEFs compared to Hs68 fibroblasts or relative abundance of CBFβ in murine cells  
compared to human cells. This could be addressed by performing electrophoretic 
mobility shift assays and examining endogenous levels of CBFβ in murine and 
human fibroblasts. Importantly, the AML1a isoform of RUNX1 has been found to 
fail to induce senescence in Hs68 cells indicating that the C-terminal 
transactivation/repression portion of RUNX1 is critical in this response. These 
results are consistent with the well established role of AML1a as an antagonist of 
wild type RUNX1 in the context of myeloid and erythroid cell culture models of 
differentiation (Tanaka et al 1995; Nitsu et al 1997) and with the report that 
overexpression of RUNX1 but not AML1a can transform NIH3T3 cells (Kurokawa et 
al 1996) suggesting that AML1a does not act as an oncogene per se. Given that 
senescence is recognised as an anti-cancer barrier in primary cells it is perhaps 
not surprising that AML1a did not trigger senescence in Hs68 cells. Taken 
together, these data confirm that RUNX1 transcriptional regulatory activity is 
required to drive premature senescence in primary fibroblasts of murine and 
human origin.  
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4 Induction of premature cellular senescence by 
RUNX1 fusion oncoproteins  
4.1 Introduction 
The existence of naturally occurring RUNX1 fusion oncoproteins associated with 
various leukaemias not only makes the investigation into RUNX1 function 
clinically relevant but provides useful tools to carry out that investigation. The 
accepted hypothesis has been that these oncoproteins interfere with RUNX1 
function by acting in a dominant negative fashion or acting as a constitutive 
repressors of RUNX1 target genes. Hence it was of considerable interest to 
address the question as to whether leukaemia-related fusion oncoproteins would 
antagonise senescence induction. 
4.2 RUNX1-ETO is a potent inducer of senescence in 
murine embryonic fibroblasts 
The RUNX1-ETO fusion oncoprotein arises as a consequence of the t(8;21) 
chromosomal translocation and is a frequent feature of acute myeloid leukaemia 
(AML). RUNX1-ETO is a chimeric protein that lacks the transactivation domain of 
RUNX1 but is fused to a putative transcriptional repressor, ETO, and likewise 
AML1a has been shown to have dominant negative activity with respect to wild 
type RUNX1. RUNX1-ETO blocks transactivation of the GM-CSF promoter and the 
T cell receptor beta enhancer by RUNX1 (Frank et al 1995; Meyers et al 1995). 
Consistent with a negative effect on RUNX1 function, RUNX1-ETO has been 
shown to inhibit differentiation of myeloid progenitor cells (Kitabayashi et al 
1998; Westendorf at al 1998). RUNX1-ETO was found to repress p19ARF, the 
upstream effector of p53 which is required for RUNX1 induced senescence in 
murine embryonic fibroblasts (Linggi et al 2002) and was also reported to 
transform NIH3T3 cells (Frank et al 1999).  
It was therefore of particular interest to test the effects of ectopically 
expressing RUNX1-ETO in primary murine embryonic fibroblasts. To this end 
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RUNX1-ETO and RUNX1 were overexpressed in MEFs (Figure 4.1a) and cell growth 
assayed and SA-β-Gal staining carried out to test for senescence, as described in 
Chapter 2 and 3. Again, RUNX1 proved to be an inducer of senescence as these 
cells ceased proliferation (pBabe vs RUNX1 day 9 p≤0.005) (Figure 4.1b) and 
approximately 70% of total cell population were stained for SA-β-Gal (Figure 
4.1c). A more unexpected finding was that the fusion derivative seemed to be at 
least as potent inducer of senescence as RUNX1 itself. The population of RUNX1-
ETO expressing cells underwent a profound proliferative block (pBabe vs RUNX1-
ETO day 9 p≤0.005) (Figure 4.1b)  and approximately 80% of the total cell 
population displayed more intense staining for SA-β-Gal activity compared to 
RUNX1 expressing cells (Figure 4.1c,d). 
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Figure 4.1 RUNX1-ETO induces senescence-like growth arrest in MEFs 
Cells were transduced with retroviral vectors expressing RUNX1, RUNX1-ETO or 
control vector (pBabe) and selected for 4 days in puromycin. (a) Western Blot 
analysis of RUNX1 (using anti-AML1/Runx1, 3900, Active Motif) and RUNX1-ETO 
(using anti-RUNX1-ETO from Dr. Scott Hiebert) expression in cells containing 
empty vector (pB), RUNX1 (RX) or RUNX1-ETO (RX-E) on day 7 post-selection;   
* indicates non-specific bands (b) Representative growth curves of cells containing 
control vector (pBabe), RUNX1 or RUNX1-ETO. Each experiment was performed 
three times and each time point was determined in triplicate 
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Figure 4.1 continued 
(c) SA-β-Gal staining of cells containing control vector (pBabe), RUNX1 or 
RUNX1-ETO (day 7 post-selection) (d) Quantitation of data in (c), showing the 
percentage of SA-β-Gal positive cells. The data represent the mean of three 
independent counts of 200 cells (error bars relate to standard deviation) 
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4.3 RUNX1-ETO induces profound premature 
senescence-like growth arrest in human primary 
fibroblasts 
Again the question arose as to whether RUNX1-ETO retains the capacity to 
induce senescence in human cells and if so whether the phenomenon is as potent 
as in murine cells. Human neonatal foreskin fibroblasts were transduced with 
retroviral constructs encoding RUNX1-ETO, RUNX1, H-RASV12 or control vector 
(pBabe) and following puromycin selection were analysed as previously described 
for proliferative properties and SA-β-Gal activity. In this experiment the 
prototypic inducer of premature senescence, oncogenic H-RASV12 (Lin and Lowe, 
2001; Serrano et al 1997), was also expressed to compare the senescent 
phenotypes of RUNX1, H-RASV12 and potentially RUNX1-ETO. All the introduced 
constructs were expressed at readily detectable levels (Figure 4.2a). 
Interestingly, it was noticeable that H-RASV12 clearly downregulated endogenous 
RUNX1 (Figure 4.2a). Ectopic expression of both RUNX1 and RUNX1-ETO resulted 
in a growth arrest that was more pronounced than that of the H-RASV12 
expressing cells (RUNX1 vs H-RASV12 day 9 p≤0.05; RUNX1-ETO vs H-RASV12 day 9 
p≤0.005) (Figure 4.2a) with RUNX1-ETO expressing cells showing an even more 
profound proliferative arrest than RUNX1 (RUNX1-ETO vs RUNX1 day 9 p≤0.05). In 
addition, in contrast to H-RASV12, which initially stimulated growth as previously 
reported by others (Kilbey et al 2007; Lin et al 1998), RUNX1 and especially 
RUNX1-ETO were potent growth suppressors immediately after puromycin 
selection. This was reflected in the growth rates over first 3 days during which 
period H-RASV12 was not significantly different from the puro control (day 3 
p≥0.1) (Figure 4.2b). Interestingly, RUNX1-ETO expressing cells displayed more 
profound morphological changes (very flat and enlarged) than RUNX1 expressing 
cells and stained more intensly for SA-β-Gal (Figure 4.2c). This more pronounced 
senescent phenotype of RUNX1-ETO expressing cells was also reflected by 
significant quantitative changes in SA-β-Gal staining where as many as 80% of 
RUNX1-ETO cells were positively stained compared to 40% of the RUNX1 
expressing cells (RUNX1-ETO vs RUNX1 p=0.01) (Figure 4.2d). Therefore it 
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appears that RUNX1-ETO can induce an even stronger senescence response than 
RUNX1 or even H-RASV12 in human cells. 
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Figure 4.2 RUNX1-ETO induces more profound senescence than RUNX1 in 
human neonatal foreskin fibroblasts 
Cells were transduced with retroviral vectors expressing  RUNX1-ETO, RUNX1, 
H-RASV12 or control vector (pBabe) and selected for 4 days in puromycin. (a) 
Western Blot analysis of RUNX1-ETO (anti-RUNX1-ETO from Dr. Scott.Hiebert), 
RUNX1 (anti-AML1/Runx1, 3900, Active Motif) and H-RASV12 (Anti-H-ras, Ab-1, 
Oncogene Research) expression in cells containing empty vector (pB), RUNX1 
(RX), RUNX1-ETO (RX-E) or H-RASV12 (R) on day 7 post-selection (b) 
Representative growth curves of cells containing control vector (pBabe), RUNX1-
ETO, RUNX1 or H-RASV12. Each experiment was performed three times and each 
time point was determined in triplicate 
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Figure 4.2 continued 
(c) SA-β-Gal staining of cells containing control vector (pBabe), RUNX1 or 
RUNX1-ETO (day 7 post-selection) (d) Quantitation of data in (c) showing the 
percentage of SA-β-Gal positive cells. The data represent the mean of three 
independent counts of 200 cells (error bars relate to standard deviation) 
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4.4 RUNX1-ETO requires transcriptional repressor 
activity to drive senescence in human primary 
fibroblasts 
To gain more insight into the premature senescence triggered by RUNX1-ETO the 
ability to induce senescence by RUNX1-ETO mutant (RUNX1-ETO∆469) was 
examined. In contrast to RUNX1-ETO this mutant lacks corepressor binding sites 
and fails to repress transactivation of RUNX1 target genes (Lenny et al 1995). In 
addition RUNX1-ETO∆469, as opposed to full length RUNX1-ETO, was reported to 
be unable to transform NIH3T3 (Frank et al 1999). Retroviral mediated gene 
transfer was employed to overexpress mutant RUNX1-ETO∆469 and RUNX1-ETO 
in human neonatal foreskin fibroblasts. In contrast to RUNX1-ETO cells, RUNX1-
ETO∆469 expressing cells continued to proliferate after puromycin selection 
(RUNX1-ETO∆469 vs RUNX1-ETO day 10, p≤0.05), although growth rates were 
reduced compared to empty vector control cells (Figure 4.3a). The RUNX1-
ETO∆469 protein was expressed at an equivalent level to that of RUNX1-ETO 
(Figure 4.3b). Furthermore, RUNX1-ETO∆469 expressing cells did not stain with 
SA-β-Gal, nor did they display the characteristic senescence-associated 
morphology (Figure 4.3c) indicating that RUNX1-ETO∆469 does not induce 
premature senescence in Hs68 cells. These data identify the importance of 
repressor domains of ETO fusion partner in RUNX1-ETO induced senescence in 
Hs68 cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kamil K. Wolyniec, 2008   Chapter 4,111  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 RUNX1-ETO requires ETO transcriptional repressor domains to 
induce senescence in human neonatal foreskin fibroblasts 
Cells were transduced with retroviral vectors expressing RUNX1-ETO∆469, 
RUNX1-ETO or control vector (pBabe) and selected for 4 days in puromycin. (a) 
Representative growth curves showing viable cell numbers corresponding to cell 
populations containing control vector (pBabe), RUNX1-ETO∆469 or RUNX1-ETO. 
Each experiment was performed three times and each time point was determined 
in triplicate. (b) Western Blot analysis of RUNX1-ETO∆469 and RUNX1-ETO 
expression in cells containing empty vector (pB), RUNX1-ETO∆469 (RX1-E∆469) 
or RUNX1-ETO (RX-E) on day 7 post-selection using Anti-Runx (D207-3, MBL) 
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Figure 4.3 continued 
(c) SA-β-Gal staining of cells containing control vector (pBabe), RUNX1-ETO∆469 
or RUNX1-ETO (day 7 post-selection) 
pBabe 
RUNX1-ETO∆469 
RUNX1-ETO 
c) 
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4.5 CBFβ-MYH11 oncoprotein but not TEL-RUNX1 
induces a moderate senescence-like growth arrest in 
human primary fibroblasts 
Since RUNX1-ETO proved to be a very potent inducer of premature senescence it 
was tempting to speculate that other fusion oncoproteins e.g. TEL-RUNX1 or 
CBFβ-MYH11 which target RUNX1 and CBFβ, respectively, and would share the 
same property of being able to execute a senescence programme in human 
primary fibroblasts. TEL-RUNX1 is generated through the t(12;21) chromosomal 
translocation, which occurs in approximately 25% cases of B-cell origin pediatric 
acute lymphoblastic leukaemias. CBFβ-MYH11, is a consequence of a common 
chromosomal inversion event (INV16) which occurs in myelomonocytic 
leukaemias and results in fusion of the CBFβ gene with a smooth-muscle myosin-
heavy-chain gene (MYH11). Both are thought to act as dominant negative 
regulators of RUNX1 function (Speck and Gilliland 2002). To investigate the 
effects of TEL-RUNX1 and CBFβ-MYH11 overexpression, Hs68 cells were 
transduced with either construct and monitored for their growth characteristics, 
morphological changes and SA-β-Gal staining. Interestingly, western blot analysis 
of expression of transgenes revealed that whereas CBFβ-MYH11 seemed to be 
stably expressed over the course of time, TEL-RUNX1 protein levels gradually 
declined over the same period (Figure 4.4a). Intriguingly, overexpression of 
CBFβ-MYH11 fusion protein but not TEL-RUNX1 partially repressed cell growth 
(Figure 4.4b). The proportion of CBFβ-MYH11 expressing cells which acquired flat 
and enlarged morphology and displayed positive staining for SA-β-Gal (Figure 
4.4b) was significantly higher than TEL-RUNX1 or vector control cells and 
accounted for approximately 25% of the total cell population (CBFβ-MYH11 vs 
pBabe, p≤0.05; CBFβ-MYH11 vs TEL-RUNX1, p≤0.05) (Figure 4.4c) indicating that 
CBFβ-MYH11 unlike TEL-RUNX1 can induce senescence-like growth arrest. 
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Figure 4.4 CBFβ-MYH11 but not TEL-RUNX1 induces a moderate 
senescence-like growth arrest in human neonatal foreskin fibroblasts 
Cells were transduced with retroviral vectors expressing TEL-RUNX1, CBFβ-
MYH11 or control vector (pBabe) and selected for 4 days in puromycin. (a) 
Western Blot analysis of TEL-RUNX1 (Anti-Runx, D207-3, MBL) and CBFβ-MYH11 
(anti-CBFβ from Dr. Nancy Speck) expression in cells containing empty vector 
(pB), TEL-RUNX1 (T-R), CBFβ-MYH11 (C-M) on day 0 and day 7 post-selection 
(b) Representative growth curves showing viable cell numbers corresponding to 
cell populations containing control vector (pBabe), TEL-RUNX1 or CBFβ-MYH11. 
Each experiment was performed three times and each time point was determined 
in triplicate 
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Figure 4.4 continued 
(c) SA-β-Gal staining of cells containing control vector (pBabe), TEL-RUNX1 or 
CBFβ-MYH11 (day 7 post-selection) (d) Quantitation of data in (c) showing the 
percentage of SA-β-Gal positive cells. The data represent the mean of three 
independent counts of 200 cells (error bars relate to standard deviation) 
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4.6 Discussion 
The discovery that the RUNX1-ETO oncoprotein is capable of inducing profound 
senescence-like growth arrest both in MEFs and Hs68 cells more dramatically 
than the archetypal RAS inuced senescence was both novel and surprising. Its 
established role as a dominant negative inhibitor of RUNX1 would lead to the 
prediction that, contrary to the senescence phenotype resulting from RUNX1 
expression, RUNX1-ETO would fail to induce senescence, although this assumes 
that RUNX1 induces senescence via its gene activation potential. However, 
unlike AML1a which also lacks the C-terminal domain of wild type RUNX1, 
RUNX1-ETO proved to drive premature senescence, that was even more 
pronounced that of RUNX1 itself. This suggests that it has unique features 
independent of RUNX1 function that are likely to be conferred by its fusion 
partner protein, ETO. Indeed, ETO itself is known to be a strong transcriptional 
repressor (Lutterbach et al 1998; Wang et al 1998) and and the results reported 
here show that the mutant of RUNX1-ETO containing the deletion of corepressor 
binding sites of ETO (RUNX1-ETO∆469) is unable to promote senescence. 
Therefore it is likely that RUNX1-ETO mediated senescence engages a repression 
of important target genes whereas it is not clear from the data presented here 
whether RUNX1 induced senescence relies on transcriptional activation and/or 
repression, although previous work in our laboratory showed a requirement for 
p53 while Linggi et al reported that p19ARF was required and induced by RUNX1 
but repressed by RUNX1-ETO (Linggi et al 2002). This may imply that RUNX1-ETO 
induced senescence occurs independently of p19ARF in MEFs and it is possible that 
RUNX1 and RUNX1-ETO employ distinct signalling pathways for the induction of 
premature senescence or that both can induce a senescence response based on 
gene repression. Given that RUNX1-ETO has oncogenic properties, the 
senescence response may act as an initial barrier that restricts a full blown 
transformation by RUNX1-ETO. 
Interestingly, overexpression of two other leukaemia related oncoproteins TEL-
AML and CBFβ-MYH11 that target RUNX1 or CBFβ, respectively, revealed that 
only the latter displayed a limited activity to induce premature senescence in 
Hs68 human fibroblasts. Only 25% CBFβ-MYH11 expressing cells displayed 
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hallmarks of senescence (compare with approximately 40% for RUNX1, 80% for 
RUNX1-ETO or 75% for RAS as shown in Figure 2d of this chapter). It could be 
possible that CBFB-MYH11 requires more time for manisfestation of the complete 
senescent phenotype and therefore by day 7, when the analysis was performed, 
only 25% of cells displayed SA-β-gal activity. The other explanation could be that 
CBFB-MYH11 requires endogenous RUNX, which would be rate limiting, for 
induction of senescence. TEL-RUNX1 failed to induce senescence at all but 
western blot analysis revealed that whereas CBFβ-MYH11 was stably expressed 
over the course of time, TEL-RUNX1 protein levels rapidly declined making 
interpretation of this result difficult. It is possible that TEL-RUNX1 fails to induce 
senescence due to relatively low levels of expression and that a threshold of 
signal potency may be required to elicit a senescence response that could not be 
achieved by TEL-RUNX1. It is also possible that cells with low expression may 
have a selective advantage in the population if the cells were unable to tolerate 
high levels of TEL-RUNX1 expression. Alternatively since some level of TEL-
RUNX1 did remain throughout the time course the result may be a true 
reflection of TEL-RUNX1 expression conferring a specific advantage to this 
oncoprotein in its target cell and may suggest that TEL-RUNX1 exerts its effect 
by a different mechanism to the other fusion oncoproteins used. 
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5 Characterisation of RUNX1 and RUNX1-ETO 
induced senescence in human primary 
fibroblasts 
5.1 Introduction 
The exciting finding that RUNX1-ETO induces a more profound senescent 
phenotype than H-RASV12 in human fibroblasts clearly warranted further 
investigation. The pathways underlying H-RASV12 induced senescence have been 
largely elucidated, hence I decided to examine RUNX1-ETO and RUNX1 induced 
senescent phenotypes by comparing and contrasting them with H-RASV12. Human 
primary fibroblasts overexpressing H-RASV12 are predominantly arrested in G1 
phase of the cell cycle (Serrano et al 1997). This senescence-like growth arrest 
induced by H-RASV12 is associated with accumulation of growth inhibitors such as 
p21WAF1, p53 and p16INK4a (Serrano et al 1997). Oncogenic RAS induced 
senescence is also characterised by accumulation of PML nuclear bodies 
(Ferbeyre et al., 2000), high levels of reactive oxygen species (ROS) (Lee at al  
1999) and activation of p38 MAPK (Wang et al 2002). Furthermore, formation of 
specific chromatin condensations described as senescence-associated 
heterochromatin foci (SAHF) has been linked recently to H-RASV12 induced 
senescence (Narita et al 2003). Ras also triggers the accumulation of DNA double 
strand breaks (DSBs) following a pre-eliminary burst of proliferation (DiMicco et 
al 2006). 
5.2 RUNX1 and RUNX1-ETO cell cycle arrest 
Since both RUNX1 and RUNX1-ETO have been found to cause growth arrest in 
human neonatal foreskin fibroblasts it was important to define where in the cell 
cycle RUNX1 and RUNX1-ETO expressing cells are arrested. The cell cycle profile 
of RUNX1 and RUNX1-ETO expressing Hs68 cells was analysed at day 7 of growth 
curve, by employing bromodeoxyuridine (BrdU) incorporation combined with 
propidium iodide staining (PI) followed by flow cytometry analysis. H-RASV12 
expressing cells were used as a positive control. In accord with previously 
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published data (Serrano et al 1997, Ferbeyre et al 2000), oncogenic RAS 
expressing cells were arrested in G1 and G2M with a preference to accumulate in 
G1. RUNX1 and RUNX1-ETO expressing cells had slightly different cell-cycle 
profiles to that of H-RASV12 with a prominent G1/G2M arrest and loss of S phase 
DNA content, an effect that was more pronounced in RUNX1-ETO cells (Figure 
5.1 and Table 5.1). RUNX1-ETO containing cells in particular displayed a skew 
towards the G2M phase of the cell cycle (Table 5.1) (pBabe vs RUNX1-ETO, 
p=0.01). In this respect it was interesting to note that this finding corresponded 
to a relatively high proportion of binucleate and multinucleate RUNX1-ETO 
expressing cells observed under the light microscope (Figure 5.2) suggesting a 
defect in cytokinesis. It may also be the case that the arrested cells are G1 
tetraploid binucleates and further analysis of cell cycle arrest will be useful. 
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Figure 5.1 RUNX1 and RUNX1-ETO causes G1/G2M arrest in Hs68 cells 
Representative cell cycle profiles of cells transduced with retroviral vectors 
expressing  RUNX1-ETO, RUNX1, H-RASV12 or control vector (pBabe). The cells at 
day 7 post-selection were pulsed with BrdU for 3 hours and analyzed for BrdU 
uptake and DNA content by two-colour flow cytometry using a FITC-conjugated 
anti-BrdU antibody and propidium iodide. The experiment was performed twice 
and yielded similar results 
 
 
 
 
 
 
 
 
Table 5.1 RUNX1-ETO growth arrested Hs68 cells display a greater tendency 
to accumulate in the G2/M phase of the cell cycle 
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Figure 5.2 Phase-contrast photomicrograph illustrating binucleate (right 
upper corner) and multinucleate (left bottom corner) RUNX1-ETO expressing 
Hs68 cells (day 8 post-selection) 
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5.3 RUNX1-ETO and RUNX1 induced senescence display 
distinct pattern of induction of p16INK4a, p21WAF1 and 
p53 
P16INK4a, p14ARF, p21WAF1 and p53 are well established negative growth regulators 
that are upregulated in senescent cells (Collado and Serrano 2006). P16INK4a and 
p21WAF1 act as inhibitors of cyclin-dependent kinases (CDK) and interfere with G1 
to S progression during the cell cycle. P21WAF1 is induced by p53 and inhibits 
CDK2/Cyclin E activity whereas p16INK4a inhibits CDK4 and CDK6 activity (Sherr 
2000). This in turn results in hypophosphorylation of pRb and cell cycle arrest 
during senescence. P14ARF has been shown to neutralise the ability of Mdm2 to 
promote p53 degradation leading to the stabilisation and accumulation of p53 
(Weber et al 1999; Zhang et al 1998). Overexpression of p16INK4a, p14ARF and 
p21WAF1 in human primary fibroblasts induces the hallmarks of premature 
senescence (Dimri et al 2000; McConnell et al 1998; Wei et al 2001).  
To further explore the nature of the senescence programmes elicited by RUNX1 
and RUNX1-ETO in human primary fibroblasts the levels of expression of p16INK4a, 
p14ARF, p21WAF1 and p53 were analysed in Hs68 cells. The H-RASV12 oncogene has 
been reported to upregulate all of these effectors except for p14ARF (Serrano et 
al 1997; Wei at al 2001]. In the work reported here a similar pattern of 
regulation was seen in human neonatal foreskin fibroblasts expressing H-RASV12 
(Figure 5.3a). It was of particular interest to determine whether p14ARF status is 
affected either by RUNX1 or RUNX1-ETO expression in Hs68 cells since RUNX1 
and RUNX1-ETO have been reported to have opposing effects on this gene locus 
(Linggi et al 2002). Analysis of d7 post selection Hs68 fibroblasts gave contrasting 
results with levels of p14ARF appearing refractory to RUNX1 or RUNX1-ETO status 
(Figure 5.3b). Further western blot analysis revealed interesting differences in 
p16INK4a, p21WAF1 and p53 expression between RUNX1 and RUNX1-ETO expressing 
cells suggestive of distinct senescence execution pathways. Notably RUNX1-ETO 
and RUNX1 induced p53, with RUNX1-ETO the more potent agonist (Figure 5.3a). 
Intriguingly, the levels of p53 did not correlate with the potency of induction of 
p21WAF1, the downstream target of p53 (Figure 5.3b). In this respect p21WAF1 
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expression levels were dramatically induced by RUNX1 but not by RUNX1-ETO 
suggesting possible opposing transcriptional effects on the p21WAF1 promoter. 
Even more surprisingly, especially in comparison to H-RASV12, RUNX1 but not 
RUNX1-ETO upregulated p16INK4a (Figure 5.3a). 
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Figure 5.3 RUNX1-ETO and RUNX1 induced senescence display distinct 
patterns of induction of p16INK4a, p21WAF1 and p53 in Hs68 cells 
(a) Western blot analysis of expression of p16INK4a (anti-p16, sc-468, Santa Cruz) 
p21WAF1 (anti-p21, sc-397, Santa Cruz) and p53 (anti-p53, sc-126, Santa Cruz) in 
cells containing control vector (pB), RUNX1 (RX), RUNX1-ETO (RX-E) and or H-
RasV12 (R) (day 7 post-selection) (b) Western blot analysis of expression of 
p14ARF (anti-p14ARF, Ab-2, Neomarkers) in Hs68 cells containing control vector 
(pB), RUNX1 (RX), RUNX1-ETO (RX1-E) or H-RasV12 (R) (day 7 post-selection). 
Human cells-13 lysate (MS-850-PCL, neomarkers) was used as a positive control 
(+) 
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5.4 Activation of p38 MAPK in RUNX1 and RUNX1-ETO 
induced senescence 
The p38 MAPK pathway mediates responses to environmental stresses, including 
DNA-damaging agents such as UV and γ-irradiation [Bulavin and Fornance, 2004]. 
Interestingly, the mitogen-activated protein kinase p38 plays a pivotal role in 
mediating cellular senescence caused by a broad spectrum of stimuli, including 
oxidative stress, dysfunctional telomeres, culture shock and the proto-oncogene 
erbB2 (Iwasa et al 2003, Trost et al 2005]. Therefore it has been suggested that 
p38 kinase links pro-oncogenic signals to tumour suppressors. P38 MAPK has been 
also implicated in H-RASV12 induced senescence where p38 is phosphorylated by 
two upstream kinases, MKK3 and MKK6 (Wang et al 2002) and was shown to be 
responsible for H-RASV12 induced transcriptional activity of p53 (Sun et al 2007) 
and to contribute to the upregulation of p16INK4a and p53 (Wang et al 2002).  
Therefore, I considered that the p38 MAPK pathway may also mediate RUNX1 
and RUNX1-ETO induced senescence. To investigate this hypothesis, the abilities 
of RUNX1 and RUNX1-ETO to activate p38 MAPK were examined using a specific 
antibody that recognises two phosphorylation sites responsible for p38 MAPK 
activation (Thr180 and Tyr182) (Wang et al 2002). Indeed, western blot analysis 
on day 7 of culture period revealed that both RUNX1 and RUNX1-ETO elevated 
levels of phospho-p38 while RUNX1-ETO was more potent agonist and induced 
phospho-p38 to a similar degree as H-RASV12 (Figure 5.4). Notably, the levels of 
total p38 MAPK remained unaffected (Figure 5.4). These results suggest that the 
p38 MAPK is involved in RUNX1 and RUNX1-ETO induced senescence. 
Furthermore, the upregulation of phospho-p38 by RUNX1 and RUNX1-ETO 
reflected the p53 levels (Section 5.3, Chapter 5) suggestive of a common 
signalling pathway. 
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Figure 5.4 RUNX1-ETO and RUNX1 induce phospho-p38 with differing 
potencies in Hs68 cells 
Western blot analysis of phospho-p38 (anti-phospho-p38, 9211, Cell signalling) 
and p38 (anti-p38, 9212, Cell signalling) expression in cells containing control 
vector (pB), RUNX1 (RX), RUNX1-ETO (RX-E) or H-RasV12 (R) (day 8 post-
selection). 
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5.5 Activation of p38 MAPK correlates with induction of 
intracellular reactive oxygen species 
There is a significant body of experimental evidence supporting the idea that a 
rise in intracellular reactive oxygen species (ROS) contributes to cellular 
senescence (Colavitti and Finkel, 2005; Passos and Zglinicki, 2006). Various 
extrinsic or intrinsic manipulations changing the intracellular antioxidant status, 
raising the ambient oxygen concentration, direct exposure of cells to hydrogen 
peroxide or the expression of certain oncogenes like H-RASV12, all appear to 
produce a rise in intracellular ROS levels (Lee et al 1999; Chen et al 1998; 
Frippiat et al 2000). This rise in ROS within cells accompanies and potentially 
triggers senescence entry (Passos and Zglinicki, 2006). It has been reported that 
ROS induction leads to activation of p38 kinase (Iwasa et al 2003; Guyton et al 
1996) and upregulation of a subset of p38 target genes (Zdanov et al 2006) in 
cells treated with hydrogen peroxide. It was also demonstrated that MINK kinase 
is activated by RAS induced ROS and subsequent activation of p38 by MINK 
results in premature senescence (Nicke et al 2005).  
To investigate whether ROS levels are altered in prematurely senescent cells 
expressing RUNX1 and RUNX1-ETO and could therefore cause the activation of 
p38 MAPK in these cells, the levels of ROS in human neonatal foreskin fibroblasts 
were examined at day 7 post-selection by using FACS based detection of 
fluorescence emitted by the peroxide-sensitive fluorophore DCF. As expected H-
RASV12 cells displayed high levels of intracellular ROS consistent with published 
data (H-RASV12 vs pBabe, p≤0.005) (Figure 5.5a, b) (Lee et al 1999). 
Interestingly, both RUNX1 and RUNX1-ETO expressing cells were found to have 
elevated intracellular ROS levels compared to empty vector control cells  
(RUNX1 vs pBabe, p≤0.05; RUNX1-ETO vs pBabe, p≤0.0001) (Figure 5.5a, b) but 
only RUNX1-ETO expressing cells showed as profound or even greater induction 
than H-RASV12 expressing cells (Figure 5.5a, b). Furthermore, the intracellular 
ROS levels appeared to correlate well with the degree of phospho-p38 activation 
by RUNX1 and RUNX1-ETO as found in previous experiments. The DCF 
fluorescence was also imaged with a laser scanning confocal microscope visually 
confirming the quantitative analysis of ROS levels (Figure 5.5c) 
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Figure 5.5 Activation of p38 MAPK correlates with induction of intracellular 
ROS in Hs68 cells 
Cells were infected with retrovirus encoding RUNX1, RUNX1-ETO, H-RASV12 or 
control retrovirus (pBabe) and analysed with DCF for intracellular ROS levels 7 
days after puromycin selection (a) Intracellular ROS was monitored by FACS 
analysis of DCF fluorescence (b) Quantitation of DCF fluorescence 
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Figure 5.5 continued 
 
(c) Visualisation of DCF fluorescence by confocal laser scanning microscopy (day 
7 post-selection) 
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5.6 DNA damage and senescence associated 
heterochromatin foci in RUNX1 and RUNX1-ETO 
induced senescence 
Severe DNA damage, especially damage that involves DNA double-strand breaks, 
(DSBs) causes many cell types to undergo senescence (DiLeonardo et al 1994). 
Critically short, dysfunctional telomeres can also trigger a classical DNA damage 
response (DDR) (Herbig et al., 2004). Moreover, oncogenic RAS induced 
senescence has been linked to the accumulation of DNA damage. It has been 
suggested that DNA damage is caused by oncogene-driven increases in cellular 
levels of reactive oxygen species which can result in DNA single and double-
strand breaks (Lee et al 1999). Other possible mechanisms have been proposed 
whereby oncogenes such as H-RASV12 induce a robust DDR owing to prematurely 
terminated DNA replication forks and DSBs that are caused by DNA hyper-
replication stress (DiMicco et al 2006; Bartkova et al 2006).  
To determine whether DNA damage signalling is associated with RUNX1 and 
RUNX1-ETO induced senescence in Hs68 cells, confocal laser scanning 
immunofluorescence microscopy was performed on Hs68 fibroblasts on day 7 
post selection following retroviral transduction with RUNX1, RUNX1-ETO and H-
RASV12. The cells were fixed and dual labelled with a monoclonal antibody that 
recognises phosphorylated histone H2AX (γ-H2AX), a marker of DNA double-
strand breaks and DAPI to visualise nuclear DNA. As shown in Figure 5.6, 
overexpression of H-RASV12 resulted in accumulation of multiple γ-H2AX positive 
nuclear foci on day 7 of culture. These correspond to DSBs and have previously 
been reported in H-RASV12 induced senescence. In contrast, RUNX1 and RUNX1-
ETO expressing populations of cells exhibited only one or two fluorescent dots 
and more closely resembled vector control cells than H-RASV12 expressing ones 
(Figure 5.6) DAPI staining of the nuclear content revealed that RUNX1 and 
RUNX1-ETO, in contrast to oncogenic RAS, did not cause specific chromatin 
condensations or senescence associated heterochromatin foci (SAHF) that have 
previously been observed during cellular senescence (Figure 5.6). 
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Figure 5.6 Ras but not RUNX1 or RUNX1-ETO induces DNA damage foci and 
SAHF in Hs68 human fibroblasts 
Indirect immunofluorescence for γH2AX foci (using anti-H2AX, 05-636, Upstate) 
in Hs68 cells expressing control vector (pBabe), RUNX1, RUNX1-ETO or H-RASV12 
(day 7 post-selection). DAPI was used to stain the nuclear DNA 
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5.7 Accumulation of PML nuclear bodies in RUNX1 and 
RUNX1-ETO induced senescence 
PML has recently been described as a senescence regulatory protein. PML is 
upregulated during cellular senescence, and induces premature senescence in 
response to oncogenic H-RAS (Ferbeyre et al 2000). Interestingly, PML has been 
shown to regulate the p53 response to oncogenic signals by binding MDM2 and 
sequestering it into the nucleus, thus protecting p53 from proteosome-mediated 
degradation (Bernardi et al 2004), as well as specifically acetylating p53 
(Pearson et al 2000). Both of these processes stabilize the p53 protein. 
Interestingly PML is also a direct p53 target that modulates p53 functions 
indicating the existence of a regulatory feedback loop between these tumour 
suppressors (de Stanchina et al 2004). 
As shown in section 5.3 of this chapter, RUNX1 and RUNX1-ETO expressing cells 
displayed substantial differences in the levels of expression of p53 protein with 
only RUNX1-ETO inducing p53 as profoundly as H-RASV12. It was therefore 
interesting to establish the status of PML in RUNX1-ETO or RUNX1 senescent cells 
and to determine whether PML could play a role in the differential upregulation 
of p53 in these cells. Hs68 cells were transduced with retroviral vectors 
expressing RUNX1, RUNX1-ETO and H-RASV12, and double stained using a specific 
antibody recognising PML with DAPI as a nuclear DNA marker at day 7 post-
selection. Visualisation of PML nuclear bodies by laser scanning confocal 
microscopy revealed increased PML bodies in H-RASV12 expressing cells, and 
RUNX1-ETO cells but not in RUNX1 cells (Figure 5.7). Again, unlike H-RASV12, 
RUNX1 and RUNX1-ETO expressing cells did not exhibit SAHF. This result suggests 
that PML may be involved in the stabilisation and increased p53 expression in 
RUNX1-ETO expressing cells. 
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Figure 5.7 PML accumulation is induced by RUNX1-ETO but not RUNX1 in 
human fibroblasts Hs68 
Indirect immunofluorescence for PML (anti-PML, N19, Santa Cruz) in Hs68 cells 
expressing control vector (pBabe), RUNX1, RUNX1-ETO or H-RASV12 (day 7 post-
selection). DAPI was used to stain the nuclear DNA 
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5.8 Partial recapitulation of RUNX1-ETO induced 
senescence by ectopic expression of p53 
RUNX1-ETO profoundly elevates levels of p53 expression but importantly while 
RUNX1-ETO induces p53 it simultaneously attenuates downstream upregulation 
of p21WAF1 expression in Hs68 cells. It was therefore particularly interesting to 
address the question of whether the ectopic expression of p53 alone drives 
premature senescence in Hs68 fibroblasts and if so, how does the phenotype of 
p53 expressing cells compares to that of RUNX1-ETO.  
Hs68 cells were infected with retroviruses containing p53 and RUNX1-ETO or  
control vector. Ectopic expression of RUNX1-ETO resulted in a substantial growth 
arrest (RUNX1-ETO vs pBabe, day 8 p=0.01) (Figure 5.8a) and characteristic 
senescence-related alterations to cellular morphology and positive staining of 
RUNX1-ETO expressing cells for SA-β-Gal activity (Figure 5.8b). Overexpression 
of p53 also caused significant growth arrest (p53 vs pBabe, day 8 p≤0.01) (Figure 
5.8a), however p53 expressing cells were not as flat and enlarged as RUNX1-ETO 
expressing cells and the intensity of SA-β-Gal staining was not as pronounced 
(Figure 5.8b). As before (Section 5.3, Chapter 5), RUNX1-ETO expressing Hs68 
fibroblasts, in contrast to p53 expressing cells, were found to be refractory to 
the induction of p21WAF1 despite the upregulation of p53 (Figure 5.8c). 
Interestingly, overexpression of p53 did not cause the accumulation of γ-H2AX 
DNA damage foci or senescence associated heterochromatin foci in Hs68 cells as 
visualised by laser scanning confocal microscopy using anti-γ-H2AX and DAPI 
staining (Figure 5.8d). These data show that ectopic expression of p53 in Hs68 
cells induces senescence-like growth arrest that partially recapitulates that of 
RUNX1-ETO expressing cells clearly indicating that RUNX1-ETO induces 
senescence via p53 yet apparently modulates its signalling pathway. 
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Figure 5.8 Ectopic expression of p53 partially recapitulates RUNX1-ETO 
induced senescence in Hs68 cells 
(a) Representative growth curves of Hs68 cells transduced with control vector 
(pBabe), RUNX1-ETO or p53 (c) SA-β-Gal staining of cells expressing p53 or 
RUNX1-ETO (day 7 post-selection) 
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Figure 5.8 continued 
(c) Indirect immunofluorescence for γ-H2AX foci in cells expressing p53 and 
visualisation of SAHF by staining with DAPI (day 7 post-selection) (d) Western 
blot analysis of p53 (anti-p53, sc-126, Santa Cruz) and p21WAF1 (anti-p21, sc-397, 
Santa Cruz) in lysates from cells containing empty vector (pB), p53 (p53) or 
RUNX1-ETO (RX-E) (day 7 post-selection) 
 
 
DAPI γ-H2AX 
overlay 
c) 
d) 
pB p53 RX-E 
p53 
p21WAF1 
actin 
Kamil K. Wolyniec, 2008   Chapter 5,138  
5.9 Discussion 
Further characterisation of RUNX1 and RUNX1-ETO induced senescence revealed 
interesting differences and common features in their respective phenotypes and 
also highlighted some similarities and differences to H-RASV12 induced 
senescence. Analysis of the cell cycle showed that whereas H-RASV12 or RUNX1 
expressing cells arrest in G1 phase, the RUNX1-ETO cell cycle arrest was skewed 
towards G2M phase and these cells showed an increase in the proportion of bi- 
and multi-nucleate cells suggesting some defects in cytokinesis. The expression 
levels of well established biomarkers of senescence involved in the execution of 
growth arrest were then examined, clearly identifying substantial differences 
between RUNX1, RUNX1-ETO and H-RASV12 induced senescent phenotypes in Hs68 
cells. In contrast to previous reports where RUNX1 has been reported to 
stimulate p19ARF while RUNX1-ETO to have the opposite effect (Linggi et al 
2002), p14ARF status in Hs68 human fibroblasts was unaffected by either RUNX1 
or RUNX1-ETO, consistent with the notion that the ARF locus is not a major 
regulator of cellular senescence in human cells (Wei et al 2001, Brookes at al 
2002). Interestingly, expression levels of the downstream target of p14ARF, p53, 
were profoundly upregulated by RUNX1-ETO and to a much lesser extent by 
RUNX1. Because PML has been shown to be involved in the regulation of p53 in 
senescence (Ferbeyre et al 2000; Langley et al 2002; Pearson et al 2000), 
theoretically it could be responsible for these differences. Indeed, fluorescent 
confocal scanning microscopy revealed increased PML nuclear bodies in RUNX1-
ETO and H-RASV12 expressing cells but not in RUNX1 expressing cells suggesting a 
direct link between PML and p53 status in these cells. Furthermore, although 
p53 was highly elevated by RUNX1-ETO, the expression levels of the downstream 
effector of p53, p21WAF1, were dramatically induced by RUNX1 but not by RUNX1-
ETO. Given that the p21WAF1 promoter contains RUNX1 DNA-binding sites it is 
conceivable that RUNX1 and RUNX1-ETO exert direct and opposing 
transcriptional effects on p21WAF1 promoter in Hs68 human fibroblasts. The 
antagonistic activities of RUNX1 and RUNX1-ETO were also apparent with regard 
to the p16INK4a locus where only RUNX1 induced p16INK4a expression to a 
substantial level although not as strongly as H-RASV12. p38 MAPK has been 
recently identified as a major regulator of cellular senescence caused by a 
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diverse spectrum of signals (Iwasa et al., 2003) and it has been proposed to be 
involved in the downstream activation of negative regulators of the cell cycle 
such as p16INK4A and p53 during H-RASV12 induced senescence (Iwasa et al 2003; 
Wang et al 2002; Sun et al 2007). Western blot analysis revealed profound 
induction of the activated form of p38 MAPK, phospho-p38, in RUNX1-ETO 
expressing cells and a much weaker induction in RUNX1 expressing cells. 
Notably, the degree of activation of p38 in these cells appeared to correlate 
with the potency of p53 upregulation suggesting the existence of a common 
regulatory signalling pathway whereby p38 may regulate p53 expression and vice 
versa. Interestingly, increased p38 activation in RUNX1-ETO expressing cells did 
not have an effect on p16INK4a, in contrast to H-RASV12, where p38 MAPK has been 
demonstrated to stabilise p16INK4a mRNA levels (Wang et al 2002). The next 
question that arose was related to the upstream signals activating p38. In H-
RASV12 induced senescence increased ROS levels have been linked to the 
activation of p38 MAPK (Nicke et al 2002; Sun et al 2007). Both RUNX1 and 
RUNX1-ETO expressing cells were found to have elevated levels of ROS which 
paralleled the induction of p38 phosphorylation suggesting that ROS may play a 
role in the activation of p38 in RUNX1 and RUNX1-ETO expressing Hs68 human 
fibroblasts. The generation of high ROS levels has been postulated to be one of 
the potential causes of DNA double strand break accumulation and DNA damage 
responses in senescent cells (Lee et al 1999). Interestingly, despite increases in 
ROS levels induced by RUNX1 and RUNX1-ETO, convincing DSBs as visualised by γ–
H2AX foci were not observed. It is possible that the activity of ROS could be 
modulated by RUNX1 and RUNX1-ETO due to their action as second messengers 
in signal transduction pathways. The accumulation of γ–H2AX foci associated 
with oncogene-induced senescence has also been associated with ‘replicative 
stress’ occurring due to a strong proliferative burst preceding growth arrest 
(DiMicco et al 2006). Neither RUNX1 nor RUNX1-ETO showed any hyper-
proliferation but instead displayed strong growth suppression immediately after 
viral transductions which may partially explain lack of γ–H2AX foci in these cells. 
Another interesting finding was that both RUNX1 and RUNX1-ETO induced 
senescent cells, in contrast to H-RASV12 expressing cells, exhibited lack of SAHF. 
The p16INK4a/pRb pathway has been shown to be involved in SAHF formation 
(Narita et al 2003), therefore it is possible that RUNX1-ETO expressing cells did 
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not show SAHF because p16INK4a was not upregulated in these cells. In support of 
this, STAT5a induced senescence in human primary fibroblasts also does not 
involve induction of p16INK4a or SAHF formation (Hemann and Narita, 2008), but 
unusually despite p16INK4a upregulation in RUNX1 induced senescent cells, SAHF 
are not present. Since the induction of p16INK4a by RUNX1 was not as potent as 
that of H-RASV12 it is plausible that a certain threshold level of p16INK4a 
expression needs to be achieved in order to initiate the process of SAHF 
formation. Also the mechanism of SAHF formation relies not only p16/pRb but 
also on many other components such as HIRA/ASF1a and PML that are required 
to interact in a specific spatio-temporal manner (Adams 2007). RUNX1 may 
interfere with these processes especially since it fails to induce PML bodies. 
These results identify RUNX1, RUNX1-ETO and H-RASV12 induced senescence as 
distinct programmes engaging diverse signalling pathways, however the 
biological relevance of these findings remains to be investigated further. 
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6 Dissecting functional requirements of the host 
cell for RUNX1 and RUNX1-ETO induced 
senescence 
6.1 Introduction 
Characterisation of RUNX1 and RUNX1-ETO induced senescence has revealed a 
number of interesting differences from the pathways previously reported to 
execute this cellular programme. Of particular importance was the finding that 
overexpression of RUNX1 or RUNX1-ETO led to differing levels of p16INK4a, p53 
and p38 MAPK induction. Hence it was important to examine the functional 
requirements for these mediators in RUNX1 and RUNX1-ETO induced senescence 
in primary fibroblasts. In human cells, as opposed to murine cells, Ras has been 
reported to drive premature senescence by a p53 independent mechanism 
despite strong induction of p53 (Wei et al 2001; Bischof et al 2005). It relies, 
however, on intact p16INK4a and p38 MAPK for senescence induction (Wang et al 
2002; Brookes et al 2002). 
6.2 The requirement for p38 MAPK in RUNX1 and 
RUNX1-ETO induced senescence in Hs68 cells 
Inactivation of p38 MAPK by the inhibitor SB203580 or dominant-negative 
mutants of MKK3 and MKK6 at least partially rescues senescence induced by H-
RASV12 or replicative and oxidative stress-induced senescence (Wang et al 2002, 
Iwasa et al 2003). RUNX1-ETO and to a lesser extent RUNX1 activates p38 
(Section 5.4, Chapter 5). Requirement for p38 in RUNX1 and RUNX1-ETO induced 
senescence was investigated using the p38 inhibitor (SB203580) to 
pharmacologically abrogate p38 function. If p38 activation is an important 
mediator of RUNX1 and or RUNX1-ETO induced senescence, its inhibition should 
prevent or delay onset of the phenotype. 
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RUNX1, RUNX1-ETO and H-RASV12 were introduced to human neonatal foreskin 
fibroblasts via retroviral gene transfer and after puromycin selection cells were 
cultured in the presence or absence of 8µM SB203580. Cells containing the 
empty vector grew well in both the presence and absence of SB203580. By day 7 
there was a substantial fraction of cells positive for SA-β-Gal in the RUNX1, 
RUNX1-ETO and H-RASV12 expressing cells (Figure 6.1a). However, in the 
presence of the p38 MAPK inhibitor there was a significant increase in the 
growth rate of RUNX1-ETO expressing cells (RUNX1-ETO(SB) vs RUNX1-
ETO(DMSO), day12 p≤0.005) (Figure 6.1a), and fewer cells had a flattened 
morphology or SA-β-Gal activity (Figure 1b). A similar effect was observed for H-
RASV12 expressing cells (RAS(SB) vs RAS(DMSO), day12 p=0.01) (Figure 6.1a) 
consistent with previous reports (Wang et al., 2002). Treatment of RUNX1 
expressing cells with SB203580 also resulted in a partial rescue of the growth 
arrest (Figure 6.1a) (RUNX1(SB) vs RUNX1(DMSO), day 12 p≤0.05) and reduced 
senescence associated characteristics (flat, enlarged cells with SA-β-Gal activity) 
(Figure 6.1b), however the effect was clearly less pronounced relative to RUNX1-
ETO expressing cells. These results indicate that RUNX1-ETO and RUNX1 are 
dependent at least to some extent on p38 MAPK to induce senescence in Hs68 
fibroblasts. However, the growth rates of RUNX1-ETO, RUNX1 or H-RASV12 in the 
presence of inhibitor were still lower than that of the control cells (Figure 6.1a). 
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Figure 6.1 Inhibition of p38MAPK rescues RUNX1-ETO and RUNX1 induced 
senescence in Hs68 cells 
Cells were transduced with retroviral vectors expressing RUNX1, RUNX1-ETO, H-
RasV12 or control vector (pBabe), selected in puromycin and then fed daily with 
fresh medium containing 8µM SB203580 (SB) or vehicle alone (DMSO) (a) 
Representative growth curves illustrating the effects of p38MAPK inhibitor 
(SB203580) on proliferation of RUNX1-ETO, RUNX1 or H-RasV12 cells 
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Figure 6.1 continued 
(b) SA-β-Gal staining of SB203580-treated (SB) cells and mock-treated Hs68 cells 
(DMSO) containing control vector (pBabe), RUNX1, RUNX1-ETO or H-RASV12 (H-
RASV12) on day 9 post-selection 
b) 
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6.3 RUNX1 and RUNX1-ETO differ in their requirement 
for p16INK4a to induce senescence 
Elevated p16INK4a levels are usually seen in human cells that have undergone 
either replicative senescence or H-RASV12 induced senescence (Brookes et al 
2004; Serrano et al 1997). While increased p16INK4a was found in cells transduced 
with RUNX1, no such effect was found in RUNX1-ETO induced senescence in Hs68 
cells suggesting that a different mechanism may be involved. Therefore it was 
important to determine whether p16INK4a was required for RUNX1-ETO induced 
senescence. Leiden human diploid fibroblasts were originally isolated from a 
rare individual homozygous for an intragenic 19bp deletion in the second exon of 
CDKN2A, and therefore lacking functional p16INK4a but retaining p14ARF activity. It 
has been reported previously that Leiden cells are resistant to H-RASV12 
mediated senescence-like growth arrest (Brookes at al 2002) indicating that 
p16INK4a is absolutely required by oncogenic RAS. 
To this end Leiden cells previously engineered to express an ecotropic virus 
receptor were transduced either with control vector (pBabe), RUNX1, RUNX1-
ETO or H-RASV12. Interestingly, these p16-deficient cells underwent profound 
premature senescence when RUNX1-ETO was overexpressed. The senescent 
phenotype was confirmed by a cessation of proliferation (RUNX1 vs pBabe, day8, 
p≤0.001) (Figure 6.2a) morphologic alterations (increased cell volume, gross 
flattening) and SA-β-Gal staining (Figure 6.2b, c). Initially, RUNX1 and H-RASV12 
caused a moderate growth suppression but despite this, these cells continued to 
increase their numbers exponentially from day 6 onwards (RUNX1 vs RUNX1-ETO, 
day 9, p=0.01; H-RASV12 vs RUNX1-ETO, day 9, p≤0.005) (Figure 6.2a) and 
displayed no SA-β-Gal activity at day 8 (Figure 6.2b). All the ectopic proteins 
were readily expressed as determined by western blot analysis (Figure 6.2c). It 
seems that RUNX1 and H-RASV12 induced senescence share a requirement for 
p16INK4a but RUNX1-ETO can induce senescence even in the absence of p16INK4a. 
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Figure 6.2 RUNX1-ETO does not require p16 to induce senescence in 
contrast with RUNX1 
Leiden cells were transduced with retroviral vectors expressing RUNX1, RUNX1-
ETO, H-RasV12 or control vector (pBabe) and selected for 4 days in puromycin (a) 
Representative growth curves of cells containing control vector (pBabe), RUNX1, 
RUNX1-ETO or H-RasV12. Similar results were observed in three independent 
experiments and each time point was determined in triplicate 
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Figure 6.2 continued 
(b) SA-β-Gal staining of Leiden cells containing control vector (pBabe), RUNX1, 
RUNX1-ETO or H-RasV12 (day 8 post-selection) 
(c) Western blot analysis of RUNX1 (anti-AML1/Runx1, 3900, Active Motif), 
RUNX1-ETO (anti-RUNX1-ETO from Dr. Scott Hiebert) or H-RasV12 (anti-H-ras, Ab-
1, Oncogene Research) expression in Leiden cells containing control vector (pB), 
RUNX1 (RX), RUNX1-ETO (RX-E) or H-RasV12 (R) (day 7 post-selection) 
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6.4 The requirement for p53 in RUNX1 and RUNX1-ETO 
induced senescence in human primary fibroblasts 
Given that p16INK4a was not required to mediate senescence-like growth arrest in 
response to RUNX1-ETO but p53 expression was profoundly upregulated under 
the same conditions it was of interest to determine the functional role of p53 
during RUNX1-ETO induced senescence in human fibroblasts. To this end Hs68 
cell were transduced with HPV16 E6 oncoprotein (E6), which acts to 
downregulate p53, or empty vector (LXSN). It was not possible to select these 
cells on the basis of neomycin resistance as this was already a property 
conferred on the cells through neomycin selection for the ecotropic virus 
receptor. However, cultures transduced with HPV16 E6 showed an obvious 
growth advantage over cultures transduced with the empty vector (E6 vs LXSN, 
day 7, p≤0.05) (Figure 6.3a). After 4 days neomycin pseudo-selection, these cells 
were subsequently infected with retroviruses encoding RUNX1, RUNX1-ETO, H-
RASV12 or control vector (pBabe) and selected with puromycin. The capability of 
HPV16 E6 to downregulate p53 was confirmed by western blot analysis (Figure 
6.3b). Consistent with previous reports [Wei et al., 2001; Bischof et al., 2005], 
H-RASV12 did not require p53 to induce senescence in human primary fibroblasts 
as shown by growth curves (H-RASV12 (E6) vs H-RASV12 (LXSN), day 7, p=0.5) 
(Figure 6.3a) and SA-β-Gal staining (Figure 6.3b). RUNX1 induced a growth arrest 
that was partially rescued by E6 but only at day 10 was this statistically 
significant (RUNX1(E6) vs RUNX1(LXSN), day 10, p=0.05) (Figure 6.3a) and some 
flat and enlarged cells remained that exhibited the SA-β-Gal marker (Figure 
6.3c). In contrast, proliferation of RUNX1-ETO expressing cells was substantially 
rescued by E6 (RUNX1-ETO(E6) vs RUNX1-ETO(LXSN), day 7, p≤0.01) (Figure 6.3a) 
and SA-β-Gal staining as well as the characteristic flattened cell morphology 
were dramatically reduced (Figure 6.3c). These data suggest that RUNX1-ETO 
induced senescence has a greater dependence on p53 than RUNX1. 
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Figure 6.3 HPV16 E6 abrogates RUNX1-ETO induced senescence but only 
partially abrogates RUNX1 senescence in Hs68 cells 
Hs68 cells containing HPV16 E6 (E6) or control vector (LXSN) were cotransduced 
with retroviral vectors expressing RUNX1, RUNX1-ETO, H-RasV12 or control 
vector (pBabe). (a) Representative growth curves of cells containing HPV16 E6 
(E6) or control vector (LXSN) cotransduced with RUNX1, RUNX1-ETO or H-RASV12. 
Similar results were observed in three independent experiments and each time 
point was determined in triplicate. (b) Western Blot analysis of p53 expression 
(anti-p53, sc-126, Santa Cruz) in the indicated populations of cells containing 
control vector (pB), RUNX1 (RX), RUNX1-ETO (RX-E) or H-RASV12 (R) on day 7 
post-selection 
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Figure 6.3 continued 
(c) SA-β-Gal staining of cells containing HPV16 E6 (E6) or control vector (LXSN) 
cotransduced with RUNX1, RUNX1-ETO, H-RASV12 or control vector (pBabe) (day 8 
post-selection) 
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6.5 RUNX1-ETO fails to induce senescence in p53 
deficient murine embryonic fibroblasts 
It has been shown in this laboratory previously that p53 is a critical regulator of 
RUNX1 induced senescence in MEFs since RUNX1 pro-oncogenic potential can be 
revealed on p53 null genetic background (Wotton et al 2004). Unlike RUNX1, 
RUNX1-ETO displayed obvious p53 dependence in human fibroblasts Hs68, hence 
it was interesting to see if the p53 pathway is also relevant in murine cell.  
To determine whether p53 is required for RUNX1-ETO induced senescence in 
murine primary cells, p53-/- MEFs were infected with retroviruses containing 
RUNX1-ETO, RUNX1 or empty vector (pBabe). RUNX1 and RUNX1-ETO transduced 
cells expressed detectable levels of transgene (Figure 6.4a), accumulated 
exponentially and had comparable growth rates, although RUNX1 expressing cells 
grew slightly better (RUNX1 vs RUNX1-ETO, day 9, p≤0.05) (Figure 6.4b). The 
populations of RUNX1-ETO and RUNX1 cells were quite heterogeneous but no 
flattened and enlarged cells indicative of senescence were observed. As 
reported previously (Wotton et al 2004), RUNX1 expressing p53 null MEFs can 
show two distinct morphological phenomena i) a shift to an epithelial-like 
morphology (Figure 6.4c)  and ii) the sporadic appearance of transformation foci 
(Figure 6.4d). Similar changes were not observed in RUNX1-ETO expressing or 
empty vector control cells (Figure 6.4c, d). Interestingly, p53 null primary MEFs 
expressing RUNX1-ETO morphologically resembled immortalised 3T3 cells and 
were quite distinct from either RUNX1 expressing or control cell populations 
(Figure 6.4c, d). These results show that RUNX1-ETO requires p53 in MEFs and 
highlights the importance of p53 in RUNX1-ETO induced senescence. 
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Figure 6.4 p53null MEFs are resistant to RUNX1-ETO induced senescence 
p53-/- MEFs were transduced with retroviral vectors expressing RUNX1, RUNX1-
ETO, H-RasV12 or control vector (pBabe) and selected for 4 days in puromycin (a) 
Western blot analysis of RUNX1 (anti-AML1/Runx1, 3900, Active Motif), RUNX1-
ETO (anti-RUNX1-ETO from Dr. Scott Hiebert) expression in p53-/- MEFs 
containing control vector (pB), RUNX1 (RX) or RUNX1-ETO (RX-E) (day 7 post-
selection); * - non-specific bands (b) Representative growth curves of cells 
containing control vector (pBabe), RUNX1, RUNX1-ETO or H-RasV12. Similar 
results were observed in three independent experiments and each time point 
was determined in triplicate  
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Figure 6.4 continued 
(c) Phase-contrast photomicrographs of p53-/- MEFs containing empty vector 
(pBabe), RUNX1 or RUNX1-ETO taken on day 7 post-selection (d) Microscopic 
photographs of p53-/- MEFs containing empty vector (pBabe), RUNX1 or RUNX1-
ETO taken on day 20 post-selection 
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6.6 Discussion 
These investigations into the requirement for p16INK4a, p53 and p38 kinase in 
RUNX1 and RUNX1-ETO induced senescence have revealed significant differences 
in the pathways executing these cellular programmes in primary fibroblasts. The 
exciting finding was that RUNX1-ETO, in contrast to RUNX1 and H-RASV12 could 
drive premature senescence in the absence of p16INK4a. Very few oncogenes 
bypass p16INK4a signalling in primary human cells to provoke a senescence 
response. One example is RAF in human mammary epithelial cells (Olsen et al 
2002). Further analysis identified p53 and p38 MAPK as important signal 
transducers in RUNX1-ETO induced senescence since their inactivation either by 
HPV16 E6 (p53) or the selective inhibitor of p38 MAPK SB203580, substantially 
rescued the senescent phenotype. In both cases, however, it was not a complete 
effect and rescued RUNX1-ETO expressing cells did not proliferate as well as 
control cells. Given that HPV16 E6 profoundly downregulated p53 as determined 
by western blot it seems unlikely that it was due to incomplete p53 ablation and 
it is possible that there are other cooperating factors that regulate growth arrest 
during RUNX1-ETO induced senescence. The evidence supporting an important 
role for p53 in RUNX1-ETO induced senescence was provided by the lack of 
premature senescence in p53 null primary MEFs. In this system, RUNX1-ETO 
expressing cells proliferated slower than control cells and in contrast to RUNX1 
expressing cells displayed no signs of foci formation, indicating that RUNX1-ETO 
requires additional events to become oncogenic. Notably, while substantial 
proportion of RUNX1 expressing p53 null MEFs aquired epitheloid morphology, 
RUNX1-ETO cells remained fibroblastic. As far as p38 MAPK is concerned it should 
be stressed that the inhibitor used in this study inhibits only the α and β isoforms 
of p38, therefore the two other isoforms γ and δ may account for the partial 
complementary effect. Also, because the inhibitor was added to cultures 4 days 
after the actual viral transduction, irreversible changes refractory to the effects 
of the inhibitor might have occurred by this time. In contrast to RUNX1-ETO, 
RUNX1 was found to require p16INK4a since it failed to drive premature 
senescence in p16 deficient Leiden human fibroblasts and showed a lesser 
response to p53 inactivation in Hs68 fibroblasts. Interestingly, RUNX1 induced 
senescence also relies on p38 MAPK since its inhibition with SB203580 partially 
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rescues senescence-like growth arrest. Taken together these data identify p38 
MAPK as a common signalling pathway in RUNX1 and RUNX1-ETO induced 
senescence in human fibroblasts consistent with its universal role in various 
types of senescence. On the other hand differential requirements for p16INK4a 
and p53 by RUNX and RUNX1-ETO have been identified. Unlike RUNX1-ETO 
induced senescence which is p53 dependent, RUNX1 induced senescence 
predominantly requires p16INK4a. 
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7 General discussion and future directions 
Currently cellular senescence is regarded as an important anti-cancer 
mechanism that restricts uncontrolled proliferation of cells and prevents 
neoplastic transformation in vitro and in vivo and is recognised as a tumour 
suppressor mechanism that is equally important as apoptosis and governed by 
the p53 and pRb pathways. While its importance is beyond doubt, there are 
many key questions yet to be answered: 
• Why certain oncogenes induce senescence while others induce apoptosis, 
is this due to the strength and/or duration of a signal or perhaps to the 
cell type and specificity of oncogenic signal or both? 
• How homogeneous is this response in different cellular contexts?  
• Which features of senescent phenotype are of fundamental importance? 
•  How universal is DNA damage signalling or chromatin remodelling in the 
context of senescence and do they represent cause or effect?  
• What are the fundamental mechanisms leading to senescence and why do 
they appear to differ in mouse and human cells? 
In this study I have demonstrated for the first time that RUNX1 induces 
senescence in human primary fibroblasts and that RUNX1/CBFβ derived 
oncogenic fusion proteins associated with human leukaemias such as: RUNX1-
ETO and CBFβ -MYH11 also retain the potential to drive premature senescence. 
Further characterisation of RUNX1 and RUNX1-ETO induced senescence has not 
only revealed interesting similarities and differences with regard to the 
signalling pathways underlying these senescence programmes, but also provided 
evidence that these senescent phenotypes are distinct from classical oncogene 
induced senescence as exemplified by RAS. This study has shed new light on 
central aspects of cellular senescence and demonstrates how complex and 
heterogeneous this important biological programme can be. 
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Previous studies in this laboratory showed that inducible RUNX1-ER (RUNX1 fused 
to oestrogen receptor) is a potent inducer of premature senescence in MEFs 
(Wotton et al 2004). The disruption of p53 allowed bypass of senescence and 
promoted increased survival and partial transformation (Wotton et al 2004). 
Interestingly, the promotion of senescence by RUNX1 was seen in the presence 
and absence of inducer (tamoxifen) and some RUNX1-ER protein was present in 
the nucleus even without treatment with tamoxifen suggesting that the 
senescence response was either mediated by protein-protein interactions or that 
there was a leakiness in the system sufficient to induce the phenotype (Wotton 
et al 2004). Therefore it was important to dissect RUNX1 functional 
requirements for induction of premature senescence. I addressed this issue by 
testing the ability of DNA and CBFβ binding mutants of RUNX1 to induce 
senescence. Unlike RUNX1, ectopic expression of these constructs failed to 
trigger a senescence response, providing evidence that RUNX1 absolutely 
requires both intact DNA and CBFβ binding activity and indicating that high 
affinity binding to the target DNA sequences in the nucleus is probably critical. 
Importantly, I have found that the ability of RUNX1 to induce senescence seems 
to be a universal feature of RUNX1 overexpression since RUNX1 also induces 
senescence in human primary fibroblasts Hs68. As found in MEFs, neither the 
DNA binding mutant nor the CBFβ interaction mutant was able to induce 
senescence in human cells. Further investigations into functional domains of 
RUNX1, revealed that RUNX1 relies on its C-terminal domain to induce 
senescence in Hs68 fibroblasts as shown by comparison with AML1a, a truncated 
isoform of RUNX1. Given that the C-terminal portion of RUNX1 contains both a 
transactivation domain and a repression domain it remains unclear which mode 
of action is more important once RUNX1 has bound to the DNA target sequences. 
This could be examined by testing the ability of RUNX1 fused to constitutive 
transactivation domain such as VP16 to induce senescence in primary cells (Cao 
et al 1998). Conversely, it was also of particular interest to examine effects of 
RUNX1-ETO overexpression since RUNX1-ETO, like AML1a, not only lacks the 
RUNX1 C-terminal domain but is also thought to act as a constitutive repressor of 
wild type RUNX1. 
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The finding that RUNX1-ETO induced senescence in murine and human primary 
fibroblasts more potently than RUNX1 itself was exciting and surprising since it is 
reported to repress the ARF promoter (Linggi et al 2002). This not only suggests 
that, in contrast to RUNX1, ARF is dispensable for RUNX1-ETO induced 
senescence in MEFs, but also indicated that RUNX1-ETO oncoprotein may have 
additional functions independent of RUNX1 that may be attributed to its fusion 
partner protein, ETO. Indeed, overexpression of the mutant of RUNX1-ETO 
containing the deletion of ETO corepressor binding sites (RUNX1-ETO∆469) failed 
to induce senescence, suggesting that RUNX1-ETO mediated senescence results 
from repression of important target genes whereas it is not clear whether RUNX1 
induced senescence relies on transcriptional activation and/or repression. One 
explanation may be that RUNX1 functions as a repressor whereas RUNX1-ETO 
acts as a super-repressor and therefore induces a more profound senescent 
phenotype. If this was true the signalling pathways underlying RUNX1 and 
RUNX1-ETO induced senescence would be commonly engaged.  
 
The discovery that the RUNX1-ETO oncoprotein drives premature senescence in 
murine and human fibroblasts may have more general clinical implications. The 
relevance of senescence in haematopoietic tissues and cancer is an area of 
growing interest (Braig et al 2005; Wu et al 2007). Given that the RUNX1-ETO 
fusion protein, a product of t(8;21) translocation in AML, is not sufficient to 
cause leukaemia alone in various experimental models (Yuan et al 2001; Higuchi 
et al., 2002, Peterson et al., 2007), one possibility is that it initially triggers 
cellular senescence, a cancer fail-safe mechanism which needs to be overcome 
to induce full blown malignancy. Interestingly, a truncated form of RUNX1-ETO 
(552 amino acids) with a deleted C-terminal NcoR/SMRT-interacting region [Yan 
et al 2004] as well as an alternatively spliced AML-ETO9a isoform (572 amino 
acids) that has been recently identified in AML patients (Yan et al 2006) both 
strongly induce leukaemogenesis in mice. These two leukaemogenic forms of 
RUNX1-ETO show remarkable similarity to RUNX1-ETO∆469 which, in contrast to 
RUNX1-ETO, failed to induce senescence in Hs68 cells. Hence, it is tempting to 
speculate that these two RUNX1-ETO isoforms are highly leukaemogenic because 
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they are intrinsically capable of overcoming senescence. In view of these 
observations, it was interesting to discover that another leukaemia-related 
fusion oncoprotein CBFβ-MYH11 also induced senescence in human primary cells, 
although less potently than RUNX1-ETO. Importantly, recent studies show 
collaboration between RUNX1-ETO and CBFβ-MYH11 oncoproteins and genetic 
inactivation of senescence mediators such as p19ARF, p16INK4a and p21WAF1 in 
murine in vivo models of leukaemogenesis (Peterson et al 2007; Moreno-Miralles 
et al 2005; Yang et al 2002). However, the TEL-RUNX1 oncoprotein which is 
associated with B-ALL, did not induce senescence in Hs68 cells suggesting that 
TEL-RUNX1 functions differently from RUNX1-ETO and CBFβ-MYH1 and/or it 
requires higher levels of expression to trigger cellular senescence in this system. 
This may also suggest an important loss-of-function event of TEL-RUNX1, 
intracellular misdirection or steric hindrance at crucial target gene promoters. It 
will be important to explore these hypotheses by analysis of deletion mutants of 
TEL-RUNX1 lacking domains of TEL to look for rescue of the ability to induce 
senescence. 
 
The comparative characterisation of RUNX1, RUNX1-ETO and H-RASV12 induced 
senescence in human primary fibroblasts revealed interesting differences and 
similarities in the phenotypes and pathways regulating these cellular 
programmes (Table 7.1). From the analysis of the expression of growth inhibitory 
proteins it became apparent that RUNX1 but not RUNX1-ETO expressing cells had 
elevated levels of p16INK4a (Chapter 5, Section 5.3). The requirement for p16INK4a 
was confirmed by the lack of senescence induction by RUNX1 in p16null Leiden 
human fibroblasts.  
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  pBABE RUNX1 RUNX1-ETO RAS 
P16 - ++ + +++ 
P53 +/- + +++ +++ 
P21 +/- ++ + +++ 
P14 - - - - 
Phospho-p38 - + +++ +++ 
Cell cycle 
arrest 
- G1>G2M G1<G2/M G1≥G2M 
ROS - + +++ +++ 
Hyper-
proliferation 
- - - + 
γ-H2AX foci - - - + 
SAHF - - - + 
PML bodies 
accumulation 
- - + + 
Senescence –
asscociated 
β-gal 
- + + + 
 
Table 7.1 Comparison of known hallmarks of senescence 
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However, RUNX1-ETO, unlike RUNX1 or H-RASV12, was able to drive profound 
premature senescence even in the absence of p16INK4a indicating that different 
pathways are required by RUNX1 and RUNX1-ETO (Chapter 6, Section 6.3). 
Interestingly, it has been recently reported that p16INK4a deficiency does not 
promote RUNX1-ETO associated leukaemia in mice (Ko et al 2008). In contrast to 
RUNX1, RUNX1-ETO strongly upregulated p53 and inactivation of p53 by HPV16 
E6 substantially supressed RUNX1-ETO but not the RUNX1 senescent phenotype, 
re-emphasising the fact that RUNX1 and RUNX1-ETO operate via distinct routes 
(Chapter 5, Section 5.3 and Chapter 6, section 6.4). RUNX1-ETO also induces a 
p53-dependent senescence in primary MEFs (Chapter 6, Section 6.5). This 
suggests that p53 may play an important role in RUNX1-ETO driven 
tumourigenesis. While p53 is central to the process in vitro, the mechanism by 
which senescence pathways are overcome in leukaemias is as yet unknown. The 
mutations of tumour suppressor genes are common events in human 
haematological malignancies. Mutations of p53 have been found in 
haematological malignant diseases, but the frequency of theses alterations is 
much lower than in solid tumours (14% vs >50%) (Krug et al 2002). The p53  gene 
is not commonly mutated in primary t(8;21) AML (Imamura et al 1994; Krug et al 
2002) but is frequently lost, mutated or modulated in t(8;21) cell lines such as 
Kasumi-1 and SKNO (Banker et al 1998a; Banker et al 1998b) and mutations of 
p53 are commonly associated with therapy related AML/MDS (Christiansen et al 
2001; Fenaux et al 1992; Horiike et al 1999; Jonveaux et al 1991; Lai et al 1995). 
Loss of p53 function has been also linked to drug resistance and correlates with 
poor prognosis in AML patients (Melo et al 2002; Nakano et al 2000). 
Paradoxically, the expression of p21WAF1, the downstream effector of p53 was 
dramatically increased in RUNX1 but not RUNX1-ETO expressing Hs68 fibroblasts 
(Chapter 5, Section 5.3). Given that p21WAF is a well known direct target of 
RUNX1 (Lutterbach et al 2000) it is possible that RUNX1 and RUNX1-ETO exert 
opposing direct effects on the p21WAF1 promoter in this cell system and it will be 
important to investigate the requirement for p21WAF1 further. Given that p21WAF1 
was not completely downregulated in RUNX1-ETO expressing cells and that the 
p21WAF1 pathway has been demonstrated to be involved in blocking 
leukaemogenesis induced by RUNX1-ETO in mice (Paterson et al 2007) it would 
be interesting to evaluate the role of p21WAF1 in senescence either by knocking-
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down its expression by shRNA or employing p21-/-    MEFs (Pantoja et al 1999) or 
p21-/- human fibroblasts (Wei et al 2001). Consistent with a dominant role of p53 
in RUNX1-ETO induced senescence, the ectopic expression of p53 alone partially 
recapitulates the senescent phenotype in Hs68 cells, causing a profound growth 
arrest, although with less pronounced alterations to cellular morphology and 
weaker SA-β-Gal staining compared to RUNX1-ETO (Chapter 5, Section 5.8), 
indicating that RUNX1-ETO induces senescence via p53 yet apparently modulates 
its signalling pathway. Therefore, it was important to find out how p53 is 
upregulated. ARF-MDM2-p53 is a well established regulatory pathway whereby 
ARF is thought to antagonise MDM2-mediated ubiquitination of p53 through 
translocation of MDM2 to the nucleolus, thereby stabilising p53 (Lowe and Sherr, 
2003). It was of particular interest to determine whether p14ARF is affected 
either by RUNX1 or RUNX1-ETO expression in Hs68 cells since RUNX1 and RUNX1-
ETO have been reported to have opposing effects on this gene locus in primary 
MEFs (Linggi et al 2002). Intriguingly p14ARF was not upregulated neither by 
RUNX1-ETO nor RUNX1 (Chapter 5, Section 5.3). This observation supports the 
notion that p14ARF is not strongly implicated in cellular senescence in human 
cells, except for its crucial role in E2F induced senescence (Dimri et al 2000). 
Another molecule that could potentially stabilise p53 is PML. PML is an important 
component of senescence pathways and has been demonstrated to regulate p53 
via several post-translational modifications (Bischof et al 2002; Ferbeyre et al 
2000, Pearson et al 2000). It has been also reported to stabilize p53 by 
sequestering MDM2 to the nucleolus (Bernardi et al 2004). Fluorescence 
microscopy has revealed increased size of PML bodies (also known as PODs for 
PML oncogenic domains) in RUNX1-ETO but not RUNX1 expressing cells suggesting 
that PML may indeed be at least partially responsible for increased p53 
expression and vice versa consistent with the notion that PML is a downstream 
target of p53 (DeStanchina et al 2004) (Chapter 5, Section 5.6). It will be 
important to validate this finding by overexpressing RUNX1-ETO in human diploid 
fibroblasts containing shRNA for PML. Another growing body of evidence suggests 
that p38 MAPK can contribute to p53 regulation (Bulavin et al., 1999; (Huang et 
al 1999); Wang et al 2002, Sun et al 2007). Indeed, levels of the activated form 
of p38, phospho-p38, were significantly elevated in RUNX1-ETO or H-RASV12 
expressing cells (Chapter 5, Section 5.4) as previously reported (Wang et al 
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2002) and correlated well with the induction of p53. Furthermore, 
pharmacological inhibition of the p38 MAPK pathway rescued the senescent 
phenotype induced by RUNX1-ETO and therefore implicated p38 as a critical 
mediator of RUNX1-ETO induced senescence in Hs68 cells (Chapter 6, Section 
6.3). It will be important to see whether inhibition of p38 MAPK itself would 
prevent p53 accumulation, confirming the sequential mode of action. The 
involvement of p38 MAPK in t(8;21) associated AML has not been investigated but 
it seems possible that the disruption of p38 could explain the lack of p53 
mutations in primary t(8;21) AML, assuming that the p38-p53 activating pathway 
is operative in myeloid cells. A weak upregulation of p38 kinase has also been 
identified in RUNX1 expressing cells and its inhibition partially rescued the 
senescence-like growth arrest suggesting that p38 MAPK is commonly engaged by 
RUNX1 and RUNX1-ETO consistent with its established role in various types of 
senescence (Ischikawa et al 2003; Wang et al 2002). Given that p38 has been 
also reported to regulate expression of p16INK4a during senescence through 
stabilisation of its mRNA (Wang et al 2002) it is possible that it may contribute to 
the increase in p16INK4a in RUNX1 induced senescent cells. However, other not 
necessarily mutually exclusive mechanisms may be responsible for p16INK4a 
upregulation by RUNX1. It will be interesting to see if regulators of p16INK4a such 
as ETS, ID (Itahana et al 2001) or polycomb INK4a repressors e.g. BMI1 or CBX7 
(Alani et al 2001; Bracken et al 2007; Gil et al 2003; Ohtani et al 2001) are 
affected in RUNX1 induced senescence.  Importantly inactivation of p16 and p15 
is common in human leukaemias. P15 and p16 loci are frequently found to be 
deleted in acute lymphoblastic leukaemia (>30%), whereas hypermethylation of 
the promoter region of p16 and p15 is particularly prevalent in acute myeloid 
leukaemia (40-80%) (Drexler 1998) 
 
A further consideration given the involvement of p38 MAPK is the question of 
how RUNX1 and in particular RUNX1-ETO achieve the activation of p38 MAPK? 
Gadd45α which contains bona fide RUNX DNA binding sites adjacent to p53 sites 
in intron 3 is a potential link as it has been demonstrated to be required for p38 
activation in the presence of H-RASV12 (Bulavin et al 2003). It is possible that 
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RUNX1-ETO which has been previously reported to activate some genes such as 
bcl-2 (Klampfer et al 1996) may stimulate the expression of Gadd45α more 
effectively than RUNX1 which would result in profound p38 activation. While the 
role of Gadd45α  remains to be investigated, increased ROS levels were found in 
RUNX1 and RUNX1-ETO expressing cells (Chapter 5, section 5.5) which could also 
be responsible for p38 activation.  
 
Reactive oxygen species have not only been shown to be critical mediators of H-
RASV12 induced senescence (Lee et al 1999) but have also been tightly linked to 
the activation of p38 MAPK (Dolado et al 2007; Iwasa et al 2003; Nicke et al 
2005; Zdanov et al 2006). The induction of ROS by RUNX1 was much weaker 
compared to RUNX1-ETO and, importantly, ROS levels seem to parallel the levels 
of phospho-p38 in the senescent human fibroblasts Hs68 (Chapter 5, Section 5.4 
and 5.5). Therefore, one can speculate that ROS may play an important role 
especially in RUNX1-ETO induced senescence where the levels of ROS were even 
higher than these observed in H-RASV12 expressing cells. This, however, would 
need to be tested directly either by culturing cells in low oxygen tension or in 
the presence of antioxidant such as NAC (N-acetyl cystein). Recently, it has been 
shown that increased levels of ROS are associated with the formation of the 
activated, catalytic fragment PKCδ (protein kinase C δ), which, in turn, seems to 
lead to further production of ROS and irreversible senescence (Takahashi et al 
2006). Activation of PKCδ causes profound reduction of WARTS (WTS/large 
tumour-suppressor 1 mitotic kinase) kinase which is required for cytokinesis and 
subsequent G2M arrest (Takahashi et al 2006). The role of PKCδ and WARTS in 
RUNX1-ETO induced senescence is of particular interest given that 
overexpression of RUNX1-ETO causes cell cycle arrest with a strong G2M 
component and is associated with high ROS levels. Reactive oxygen species have 
been also demonstrated to oxidise and inactivate Cdc25 phosphatases and 
therefore may control the cell cycle directly (Nilsson and Hoffmann 2000). Cdc25 
phosphatases are responsible for dephosphorylation of pThr14 and pTyr15 and 
thereby trigger the activation of the Cdk/cyclin complexes which are required 
for the progression of cell cycle, however high ROS levels interfere with the 
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function of Cdc25 phosphatases and may cause growth arrest (Nilsson and 
Hoffmann 2000). Cdc25A controls G1/S transition by its activity on the 
Cdk2/cyclin E and Cdk2/cyclin A complexes, whereas Cdc25B and Cdc25C are 
primarly required for entry into mitosis (Boutros et al 2007). Interestingly, a 
contrasting result with respect to ROS has been recently reported, where 
overexpression of RUNX1-ETO in CD34+ umbilical blood early progenitor cells did 
not cause the accumulation of ROS (Krejci et al 2008). This may, of course, 
reflect cell-type specific differences, however there was a major difference in 
that the ROS levels in senescent fibroblasts were measured on day 11 after 
transduction (Chapter 5, Section 5.5) whereas Krejci at al measured ROS five 
weeks after transduction. Thus it is conceivable that ROS induction by RUNX1-
ETO is an early event. If ROS is demonstrated to be an absolute requirement for 
RUNX1-ETO or RUNX1 induced senescence the question arises as to how ROS are 
generated. Notably, none of the studies published so far has clearly defined the 
origin of ROS generation in senescence or why it is generated in the first place. 
It is still not known if this response is a mitochondrial specific ROS production or 
whether ROS are generated by, for instance, NADPH oxidase. It is clear that ROS 
generation is intimately associated with the senescent phenotype, however the 
details of this association still need to be unravelled. Due to its unspecific 
nature it is unlikely that ROS could have evolved as a specific signalling pathway 
in senescence. In RAS induced senescence, one potential candidate responsible 
for high ROS levels is 5-lipoxygenase (5LO). This enzyme generates ROS in the 
process of its enzymatic conversion of arachidonic acid to leukotrienes. In 
primary cells overexpressing RAS, 5LO activity increases (Catalano et al 2005) 
and ectopic expression of 5LO promotes senescence in a redox dependent, 
p53/p21 mediated fashion (Catalano et al 2005). The involvement of this enzyme 
in other routes to senescence seems worthy of further investigation. 
 
DNA damage signalling has been recently proposed to be an important 
mechanism by which senescence occurs. Oncogenes such as H-RASV12 have been 
shown to trigger a classical DNA damage response mediated by the ATM/ATR and 
Chk1/Chk2 proteins which cause the post-translational stabilisation of p53 
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through phosphorylation (DiMicco et al 2006; Barkova et al 2006). RUNX1-ETO 
was found to induce p53-dependent senescence (Chapter 6, Section 5.4 and 5.5), 
accompanied by high ROS accumulation (Chapter 5, Section 5.5) therefore it 
seemed possible that DNA damage signalling may also underlie RUNX1-ETO 
induced senescence. However, fluorescent confocal microscopy revealed no 
convincing γ-H2AX foci, a marker of DSB, in either RUNX1-ETO or RUNX1 
expressing human fibroblasts (Chapter 5, Section 5.6), although they were  
readily detected in H-RASV12 expressing cells as previously reported (DiMicco et 
al 2006). This result was not surprising for RUNX1, given that it primarly involves 
p16INK4a and does not generate large amounts of ROS. However, the result was 
unexpected in the case of RUNX1-ETO induced senescence. Nevertheless, there 
are some possible explanations. Firstly, ROS could be modulated by an as yet 
unknown mechanism such that it mainly acts as a signalling molecule more than 
as DNA damaging agent. Secondly, neither RUNX1 nor RUNX1-ETO induced 
senescence involves a preliminary hyper-proliferative burst (Chapter 4, Section 
4.3) which has been linked to DNA damage signalling caused by H-RASV12 due to 
‘replicative stress’-related DSB formation (DiMicco et al 2006; Bartkova et al 
2006). Thirdly, lack of γ-H2AX foci may not necessarily mean that DNA damage 
response is not involved in senescence as it has been demonstrated recently that 
activation of ATR by TopBP1 induces premature senescence in the absence of 
DNA double strand breaks (Toledo et al 2008). Further investigations are 
required to see if ATM/ATR and/or Chk1/Chk2 are affected by RUNX1 and 
RUNX1-ETO. Finally, RUNX1 and RUNX1-ETO could exert their effects 
downstream of DNA damage signalling pathways. Interestingly, it has been 
reported recently that overexpression of RUNX1-ETO in human CD34+ cells drives 
DNA damage and p53 dependent apoptosis (Krejci et al 2008). There is however, 
one caveat in this study, which is that γ-H2AX foci were detected five weeks 
after transduction. It is quite likely that by this time the secondary changes may 
occur, including accumulation of DNA damage. It was also reported that DNA 
repair enzymes were downregulated in these CD34+ cells which may suggest that 
these cell were actually survivors that escape apoptosis or growth arrest.  It is 
also important to remember that this observation may also reflect intrinsic cell 
type differences in the propensity to accumulate DSBs (fibroblasts vs 
haematopoetic progenitors).  
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Another interesting finding that distinguishes RUNX1 and RUNX1-ETO from H-
RASV12 induced senescence is the lack of chromatin condensation. Senescence-
associated heterochromatin foci (SAHF) were not observed in either RUNX1 or 
RUNX1-ETO expressing cells as visualised by staining with DAPI (Chapter 5, 
Section 5.6). SAHF formation is a multi-step process involving cooperation 
between p16-pRb and HIRA/ASF1 pathways. PML bodies play an important role in 
this process as they serve as a molecular integrating platform for assembly and 
modification of HIRA-containing complexes, prior to export of these complexes 
to sites of nascent SAHF. Also it has been suggested that senescent cells may 
maintain their irreversible growth arrested state, at least in part, by stably 
forming heterochromatin and epigenetically silencing proliferation-promoting 
gene loci, which are resistant to E2F-mediated transcriptional activation (Narita 
et al., 2003). If this is the case, why then do RUNX1 and RUNX1-ETO not induce 
SAHF and what does this tell us? Perhaps SAHF are not present in RUNX1-ETO 
induced senescent cells because this from of senescence is primarly driven via 
the p53 pathway. RUNX1-ETO has also been demonstrated to constitutively 
activate the Wnt pathway (Muller-Tidow et al 2004; Simon et al 2005) whereas 
the downregulation of Wnt signalling is absolutely required for formation of SAHF 
(Ye et al 2007).  The lack of SAHF in RUNX1 expressing cells could also be related 
to a certain threshold level of p16INK4a that RUNX1 fails to achieve and/or it 
could be due to the inability of RUNX1 to induce PML bodies. Alternatively, 
RUNX1 and RUNX1-ETO induced senescence may represent a form of senescence 
which is reversible upon inactivation of the p53 and/or the p16-pRb pathways 
and therefore SAHF are not apparent. This could be addressed by co-transducing 
cells with RUNX1 or RUNX1-ETO and inducible large T antigen which could be 
switched on when cells enter senescence or by infecting senescent cells with a 
lentiviral vector encoding SV40 large T antigen to abrogate p53 and pRb 
function. Another possibility could be that DNA damage and SAHF accumulation 
are somehow mechanistically linked to each other. It is possible that DNA 
damage foci might trigger SAHF formation cooperatively with p16INK4a, HIRA/ASF1 
and PML bodies and there may be a threshold level of DNA damage above which 
formation of SAHF appears. For example, it has been demonstrated that CHK1 
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can modify chromatin and trancriptionally repress some genes (Shimada et al 
2008). In addition, at sites of DNA damage a number of chromatin modifications 
occur, most of which, however, lead to chromatin relaxation (Murr et al 2006; 
Ziv et al 2006). It could be speculated that SAHF formation is a consequence of 
cellular attempts to counteract DNA damage-induced chromatin relaxation and 
DNA damage responses. Further detailed analysis of kinetics of the formation of 
DNA damage foci and SAHF as well as spatial comparison between those 
structures would help to address the issue of whether DNA damage foci play a 
causative role in SAHF formation. 
 
The RUNX genes share an intriguing and paradoxical dualistic nature. This means 
that depending on the context they can act as oncogenes or tumour suppressors 
(Blyth et al 2005). Given that both RUNX1 and RUNX1-ETO senescent phenotypes 
differ significantly from classical oncogene-induced senescence it is reasonable 
to postulate that RUNX1 and RUNX1-ETO induced senescence reflect failsafe 
rather than oncogenic functions. This hypothesis is supported by the fact that 
RUNX1 and RUNX1-ETO expressing cells undergo growth arrest without a 
preliminary phase of hyper-replication and do not trigger a DNA damage 
response. In this respect they resemble p53 induced senescence where ectopic 
expression of p53 did not result in γ-H2AX foci or SAHF formation (Chapter 5, 
Section 5.8) suggesting that the appearance of SAHF and γ-H2AX foci may 
distinguish oncogene from tumour suppressor induced senescence. It has been 
demonstrated in our laboratory that other RUNX genes when ectopically 
expressed in primary murine embryonic fibroblasts (MEFs) also induce premature 
senescence without an initial hyper-replicative phase (Kilbey et al 2007; Wotton 
et al 2004) suggesting that ectopic RUNX may be activating a downstream 
execution phase of oncogene-induced senescence. This may indicate that, in the 
context of senescence, the RUNX genes act as tumour suppressors rather than 
oncogenes.  In support of this hypothesis, primary fibroblasts lacking RUNX2 fail 
to undergo senescence and are instead transformed by oncogenic H-RASV12 
pointing to an intrinsic role of RUNX genes in this process (Kilbey et al 2007). 
The requirement for RUNX2 may reflect relative abundance of its expression 
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compared to other family members in MEFs rather than a unique RUNX2-specific 
function. Consistent with this idea, it has been shown that RUNX1 is required for 
growth arrest in response to N-RAS in haematopoietic progenitor cells (Motoda et 
al 2007). Taken together, this may indicate that different RUNX proteins play 
similar non-redundant roles in cellular senescence. Interestingly, loss of RUNX2 
has been recently implicated in the bypass of senescence in primary osteoblasts 
and their immortalisation, underpinning the role of RUNX2 as a tumour 
suppressor (Zaidi et al 2007). Furthermore, a RUNX1 tumour suppressive function 
has been recently linked to a number of types of solid cancers. For example, 
RUNX1 has been found to be downregulated in the early stages of hepatocellular 
carcinoma (Miyagawa et al 2006) and gastric cancer (Sakakura et al 2005). 
Interestingly, a novel splice variant of RUNX1 which confers loss of wild-type 
tumour suppressive functions has been identified in ovarian cancer patients 
(Nanjundan et al 2007). 
 
From the observations made in this study a scenario emerges whereby RUNX1 
and RUNX1-ETO induce senescence by different yet to some extent overlapping 
pathways (Figure 7.1). While it is clear that RUNX1 requires p53 in MEFs to 
induce senescence (Wotton et al 2004), p53 has not been found to be essential 
for senescence in human cells where p16INK4a appeared to be more important. 
The role of p21WAF1 in RUNX1 induced senescence requires further investigation 
since it is dramatically induced in human fibroblasts possibly due to direct 
activation of the promoter. It is plausible that both p16INK4a and p21WAF1 
cooperate to achieve pRb activation and establish growth arrest. RUNX1 induced 
senescence partially relies on p38 MAPK signalling and p38 could contribute to 
p16INK4a upregulation in these cells, although there are other mediators also 
likely to be involved in p16INK4a regulation. Slightly elevated ROS levels in RUNX1 
expressing cells could be responsible for the activation of p38 MAPK given that 
these two events correlated well with each other, however other molecules such 
as Gadd45a must also be considered as potential candidates. Finally, the finding 
that RUNX1 induced senescence does not entail DNA damage foci and SAHF 
formation leads to the hypothesis that RUNX1 act as a tumour suppressor rather 
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than an oncogene in the context of senescence. Interestingly several genes 
belonging to the ceramide pathway have been shown to be up- or down-
regulated by RUNX1 in microarray experiment which has been recently 
performed in our laboratory (Wotton et al 2008). Ceramide has been implicated 
in cellular senescence (Mouton and Venable 2000; Venable et al 1995) and even 
RAS induces senescence via ceramide accumulation (Castro et al 2008). It may 
represent another signalling pathway or another interacting factor involved in 
RUNX1 mediated senescence and may warrant further investigation in the 
future. 
 
  
Figure 7.1 Diagram illustrating the potential mechanism of RUNX1 and 
RUNX1-ETO induced senescence 
Increases in ROS levels activate p38 MAPK which in turn regulates the expression 
of p53 and p16. RUNX1 induces p16-dependent senescence whereas RUNX1-ETO 
RUNX1 RUNX1-ETO 
p38 MAPK 
p16 
p21 
p53 
 
No replicative 
stress and DNA 
damage signals 
PML 
Lack of SAHF accumulation 
p21 
     ROS 
p53 
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induces p53-dependent senescence. RUNX1 and RUNX1-ETO differentially induce 
p21, possibly due to exerting direct opposing effects on the p21 promoter. PML 
may play a role in p53 stabilisation in RUNX1-ETO induced senescence. The 
thickness of the arrows reflect the level of upregulation of relevant mediators of 
senescence by RUNX1 or RUNX1-ETO 
 
Physical and functional interactions between STAT5 and RUNX1 have been 
revealed recently (Ogawa et al 2008). This is particularly interesting given that 
STAT5 is also capable of inducing premature senescence when overexpressed in 
primary human fibroblasts and, like RUNX1, does not involve SAHF formation 
(Hemann and Narita 2008) suggesting that they may share some common 
pathway to senescence. On the other hand RUNX1-ETO, in contrast to RUNX1, 
induces p16-independent but p53-dependent senescence. RUNX1-ETO potently 
induces reactive oxygen species and ROS may be responsible for the 
accumulation of phosphorylated p38 MAPK, which is required for the 
development of the senescent phenotype. It seems that p38 MAPK, in turn, 
activates p53, which is also likely to be stabilised by PML. Given that RUNX1-ETO 
seems to have a suppressive effect on p21WAF1, it will be important to see if p21 
is indeed dispensable for RUNX1-ETO to induce senescence. If this proves to be 
the case it will be important to identify the downstream effectors of p53 that 
establish G2/M arrest in RUNX1-ETO expressing cells. The mechanism by which 
p53 regulates the G2/M transition involves regulation of the cyclin dependent 
kinase Cdc2 which is essential for entry into mitosis (Nurse 1990; Taylor and 
Stark 2001b). Binding to cyclin B and phosphorylation by CDK-activating kinase 
(CAK) are required to activate Cdc2 (Pines 1995; Taylor and Stark 2001a). 
Gadd45α and/or 14-3-3 sigma emerge as interesting effectors of p53 that may 
play a role in RUNX1-ETO induced senescence. Both Gadd45α and 14-3-3 sigma 
are direct targets of p53 and are known to inhibit Cdc2 activity. The protein 14-
3-3 sigma binds to Cdc2-Cyclin B complex and sequesters it in the cytoplasm 
(Chan et al 1999; Hermeking et al 1997) whereas Gadd45α inhibits Cdc2 by 
blocking its binding to cyclin B (Jin et al 2000; Zhan et al 1999). Thus, it could 
be that RUNX1-ETO causes G2/M arrest due to p53-dependent activation of 
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Gadd45α and/or 14-3-3 sigma. Given that Gadd45α has been shown to be 
involved in p38 activation in H-RASV12 induced senescence (Bulavin et al 2003) it 
is tempting to speculate that the same p53-Gadd45α -p38 positive feedback loop 
is operative in RUNX1-ETO induced senescence.  
 
 
In conclusion, I have reported that RUNX1 and the RUNX1/CBFβ oncogenic fusion 
derivatives: RUNX1-ETO and CBFβ-MYH11 induce premature senescence when 
ectopically expressed in primary cells revealing a central role for Runx-regulated 
pathways in this tumour suppressive response. While the nature of CBFβ-MYH11 
induced senescence remains to be investigated I have demonstrated that RUNX1 
and RUNX1-ETO induce senescence by distinctive yet partially overlapping 
cellular mechanisms. I have also identified DNA binding and the C-terminal 
domain as an absolute requirement to induce senescence by RUNX1. In addition I 
have found that RUNX1-ETO C-terminal domain containing corepressor binding 
sites of ETO protein is critical for RUNX1-ETO induced senescence. Importantly, I 
have shown that both RUNX1 and RUNX1-ETO induced senescence differ from 
prototypical H-RASV12 induced senescence. This study emphasises the fact that 
cellular senescence represents a heterogeneous process driven by diverse 
pathways depending on the stimuli and the cell type. 
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